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1.	Introduction	
	
1.1.	Analysis	of	protein	structure	and	function	
	
The	 function	 of	 a	 protein	 is	 largely	 a	 consequence	 of	 its	 structure,	 with	 different	
functions	 being	 associated	 with	 particular	 three-dimensional	 folds	 in	 the	 proteins	
performing	 them.	 (Hegyi	 &	 Gerstein	 1999)	 Describing	 the	 three-dimensional	
structure	of	a	protein	from	its	amino	acid	sequence	is	not	trivial,	leading	to	a	number	
of	 techniques	 being	 developed	 over	 the	 years	 to	 obtain	 high-quality	 structural	
information.	 The	 first	 of	 these	 was	 x-ray	 crystallography,	 which	 involves	 the	
production	of	protein	crystals	from	purified	protein	samples:	these	crystals	are	then	
exposed	to	an	x-ray	beam,	and	the	diffraction	patterns	caused	by	the	crystal	used	to	
obtain	information	about	its	structure.	(Lieberman	et	al.	2013)	
	
While	 significant	 improvements	 in	 resolution	 have	 been	 achieved	 since	 the	 first	
protein	 structures	 were	 described,	 x-ray	 crystallography	 is	 not	 without	
disadvantages:	creating	protein	crystals	for	water-insoluble	proteins	(e.g.	membrane	
proteins)	 remains	 a	 considerable	 challenge,	 and	 the	 crystallization	 process	 might	
result	in	a	loss	of	information	regarding	the	native	structure	of	the	protein.	(Yonath	
2011)	 Obtaining	 information	 regarding	 protein-protein	 interactions	 through	 this	
method	requires	the	co-crystallization	of	both	proteins:	while	difficult,	this	feat	has	
shed	light	into	the	arrangement	of	a	number	of	protein	complexes	since	it	was	first	
described.	(Wiesmann	et	al.	1999)	
	
A	second	technique,	nuclear	magnetic	resonance	(NMR),	has	been	particularly	useful	
to	determine	protein	dynamics	since	it	does	not	require	crystallization:	it	is	based	on	
the	effect	of	a	magnetic	field	on	atom	behavior,	which	is	influenced	by	the	presence	
of	other	neighboring	atoms.	(Marion	2013)	Although	normally	restricted	to	proteins	
in	 solution	smaller	 than	30-40	kDa	and	requiring	 large	amounts	of	 soluble	protein,	
NMR	 has	 been	 applied	 with	 great	 success	 to	monitor	 intermolecular	 interactions,	
including	 drug-target	 and	 transient	 protein-protein	 interactions.	 (Pellecchia	 et	 al.	
2008)	(Liu	et	al.	2016)	
	
In	addition,	recent	advances	have	resulted	in	cryo-electron	microscopy	becoming	the	
method	of	choice	to	study	membrane	protein	structures,	as	it	is	able	to	derive	high-
resolution	structural	information	from	two-dimensional	crystals	of	proteins	inserted	
in	 a	 phospholipid	 bilayer.	 (Goldie	 et	 al.	 2014)	 Mass	 spectrometry	 (MS)	 has	 also	
emerged	as	a	powerful	tool	to	characterize	secondary	protein	structures:	techniques	
such	as	ion	mobility	MS	or	hydrogen/deuterium	exchange	MS	are	nowadays	able	to	
detect	 structural	 differences	 or	 probe	 protein-ligand	 interactions.	 (Chalmers	 et	 al.	
2006)	 (Leurs	 et	 al.	 2015)	 The	 increasing	 number	 of	 three-dimensional	 structures	
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described	through	these	means	has	also	resulted	in	more	accurate	protein	structure	
prediction,	using	homology	modeling	to	initiate	structure-based	studies	in	molecules	
for	which	no	experimental	data	is	yet	available.	(Schmidt	et	al.	2014)	
	
The	study	of	protein	function,	on	the	other	hand,	relies	on	molecular	biology	tools:	
site-directed	 mutagenesis	 has	 been	 extensively	 used	 to	 study	 the	 role	 of	 specific	
protein	residues	in	protein	function,	as	the	importance	of	the	mutated	residues	can	
be	 determined	 by	 comparing	 the	 biological	 function	 of	 the	 native	 and	 mutant	
variants.	 (Morrison	 &	Weiss	 2001)	 Domain	 shuffling	 among	 related	 proteins	 with	
differing	 functions	 can	 also	 be	 very	 informative,	 as	 the	 biological	 activities	 of	 the	
chimeric	proteins	thus	created	offer	critical	 insight	into	the	structural	determinants	
influencing	protein	function.	(Lafuse	1991)	In	this	way,	studies	on	protein	structure	
and	 function	 are	 closely	 interrelated:	 the	 availability	 of	 structural	 information	
permits	 restricting	the	design	of	mutant	protein	variants	 to	putative	active	sites	or	
interacting	 regions,	 while	 the	 mutants	 thus	 created	 can	 confirm	 and	 add	 to	 the	
information	offered	by	structural	models.	(Wildhagen	et	al.	2011)	The	application	of	
these	different	methods	has	 resulted	 in	a	deeper	understanding	of	protein-protein	
interactions,	 such	 as	 those	 taking	 place	 between	 ligands	 (e.g.	 cytokines)	 and	 their	
specific	receptors.	(Newell	et	al.	2000)	
	
1.2.	The	interleukin-6	family	of	cytokines	
	
Cytokines	are	a	broad	category	of	small	intercellular	signaling	peptides,	usually	with	
a	molecular	weight	between	8-30	kDa.	(Cannon	2000)	Cytokines	exert	their	actions	
by	binding	to	and	activating	specific	receptors	located	in	the	surface	of	their	target	
cells,	in	a	similar	way	to	classic	protein	hormones.	(Kishimoto	et	al.	1994)	However,	
in	 contrast	 to	 hormones	 cytokines	 are	 mostly	 absent	 in	 the	 circulation	 and	 their	
concentrations	 only	 increase	 drastically	 in	 response	 to	 trauma	 or	 infection;	 in	
addition,	 cytokines	 can	 be	 produced	 by	 virtually	 all	 nucleated	 cells,	 while	 classic	
hormones	 are	 secreted	 from	 discrete	 glands	 such	 as	 the	 adrenal	 gland	 or	 the	
pancreas.	(Cannon	2000)	
	
Cytokines	can	be	subdivided	into	different	groups	based	on	the	presence	of	shared	
structural	 elements	 in	 their	 receptors.	 (Schwartz	 et	 al.	 2016)	 One	 of	 the	 main	
cytokine	 classes	 is	 the	 interleukin-6	 (IL-6)	 family,	 named	 after	 its	 first	 identified	
member,	 IL-6:	 a	 pleiotropic	 cytokine	 acting	 via	 the	 glycoprotein	 130	 (gp130)	
receptor.	(Hirano	et	al.	1985)	(Hirano	et	al.	1986)	(Taga	et	al.	1989)	(Hibi	et	al.	1990)	
In	 the	 following	 years	 other	 cytokines	 have	 been	 added	 to	 the	 IL-6	 class,	 which	
nowadays	 comprises	 ten	 different	members:	 these	 are	 IL-6,	 interleukin-11	 (IL-11),	
interleukin-27	 (IL-27),	 interleukin-31	 (IL-31),	 leukemia	 inhibitory	 factor	 (LIF),	
oncostatin	 M	 (OSM),	 ciliary	 neurotrophic	 factor	 (CNTF),	 cardiotrophin-1	 (CT-1),	
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cardiotrophin-like	cytokine	(CLC)	and	neuropoietin	(NP).	(Ip	et	al.	1992)		(Gearing	et	
al.	1992)	(Yin	et	al.	1993)	(Pennica	et	al.	1995)	(Elson	et	al.	2000)	(Pflanz	et	al.	2004)	
(Derouet	et	al.	2004)	(Dillon	et	al.	2004)	
	
The	 different	 members	 of	 the	 IL-6	 family	 present	 very	 little	 sequence	 homology,	
although	 they	 all	 adopt	 a	 common	 secondary	 structure:	 all	 of	 them	 form	 a	 four-
helical	 bundle	 with	 an	 up-up-down-down	 topology,	 linked	 by	 loops.	 (Bazan	 1990)	
(Robinson	et	al.	1994)	(McDonald	et	al.	1995)	(Somers	et	al.	1997)	(Deller	et	al.	2000)	
Besides	these	similarities	 in	their	secondary	structure,	all	of	these	cytokines	recruit	
gp130	 in	 their	 signaling	 receptor	 complexes:	 the	 only	 exception	 is	 IL-31,	 which	
replaces	gp130	with	the	IL-31	receptor	alpha	(IL-31RA),	a	markedly	similar	receptor	
originally	described	as	a	gp130-like	cytokine	receptor.	(Dreuw	et	al.	2004)	
	
In	 addition	 to	 gp130	 there	 are	 other	 signaling	 receptors	 interacting	 with	 the	 IL-6	
class	 ligands:	 these	 include	 the	 LIF	 receptor	 (LIFR),	 OSM	 receptor	 (OSMR),	 IL-27	
receptor	 subunit	 alpha	 (IL-27RA)	 and	 IL-31RA.	 (Gearing	 et	 al.	 1991)	 (Mosley	 et	 al.	
1996)	(Pflanz	et	al.	2002)	(Diveu	et	al.	2003)	IL-6	family	cytokines	exert	their	actions	
through	signaling	receptor	dimers,	with	IL-6	and	IL-11	activating	a	gp130	homodimer	
and	most	other	members	(LIF,	CNTF,	CLC,	CT-1,	NP	and	OSM)	being	able	to	signal	via	
a	 LIFR/gp130	heterodimer.	 (Murakami	 et	 al.	 1993)	 (Yin	 et	 al.	 1993)	 (Gearing	 et	 al.	
1992)	 (Davis,	 Aldrich,	 Stahl,	 et	 al.	 1993)	 (Pennica	 et	 al.	 1995)	 (Elson	 et	 al.	 2000)	
(Derouet	et	al.	2004)	Additionally,	OSM	has	the	exceptional	ability	within	the	family	
of	being	able	 to	 recruit	 a	 second	 receptor	 complex,	 comprised	of	 an	OSMR/gp130	
heterodimer.		(Mosley	et	al.	1996)	IL-27	activates	an	IL27-RA/gp130	dimer,	while	IL-
31	utilizes	an	OSMR/IL31-RA	complex.	(Pflanz	et	al.	2004)	(Dillon	et	al.	2004)	
	
In	 some	 cases	 the	 activation	 of	 these	 signaling	 receptor	 complexes	 requires	 the	
participation	of	non-signaling	 receptors,	which	 include	 the	 IL-6	 receptor	 (IL-6R)	 for	
IL-6,	 the	 IL-11	 receptor	 alpha	 (IL-11RA)	 for	 IL-11,	 the	 Epstein-Barr	 virus	 induced	 3	
(EBI3)	 for	 IL-27	and	 the	CNTF	 receptor	 (CNTFR)	 for	CNTF,	CLC	and	NP.	 (Taga	et	 al.	
1989)	 (Baumann	et	al.	1996)	 (Devergne	et	al.	1997)	 (Davis,	Aldrich,	 Ip,	et	al.	1993)	
(Elson	et	al.	2000)	(Derouet	et	al.	2004)	Although	not	directly	involved	in	intracellular	
signaling,	 the	 aforementioned	 cytokines	 are	 unable	 to	 efficiently	 recruit	 their	
signaling	receptors	unless	they	are	first	bound	to	their	non-signaling	receptor.	(Davis,	
Aldrich,	 Ip,	 et	 al.	 1993)	 (Stahl	 et	 al.	 1993)	 (Nandurkar	 et	 al.	 1996)	 The	 different	
existing	IL-6	type	ligand-receptor	interactions	have	been	summarized	in	Figure	1.	
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Figure	 1:	 Cytokine-receptor	 interactions	 within	 the	 IL-6	 cytokine	 family.	 IL-6	
cytokines	signal	through	several	different	signaling	receptor	complexes:	IL-6	and	IL-
11	 employ	 a	 gp130/gp130	 homodimer,	 with	 LIF,	 CNTF,	 CLC,	 CT-1,	 NP	 and	 OSM	
binding	to	a	LIFR/gp130	heterodimer.	OSM	can	also	use	the	OSMR/gp130	complex,	
while	IL-27	utilizes	the	IL27-RA/gp130	complex	and	IL-31	binds	to	OSMR/IL-31RA.	In	
some	 cases	 non-signaling	 receptors	 are	 required	 for	 the	 cytokine	 to	 be	 able	 to	
recruit	the	signaling	complex:	these	are	IL-6R	(for	IL-6),	IL-11RA	(for	IL-11),	EBI3	(for	
IL-27)	and	CNTFR	(for	CNTF,	CLC	and	NP).	
	
	
1.3.	Biological	relevance	of	oncostatin	M	
	
OSM	is	the	only	IL-6	type	cytokine	able	to	activate	two	different	signaling	complexes	
with	high	affinity	 (LIFR/gp130	and	OSMR/gp130),	 so	 it	 should	 come	as	no	 surprise	
that	this	cytokine	influences	a	wide	array	of	biological	processes.	(Thoma	et	al.	1994)	
(Hermanns	2015)	 It	 appears	 to	be	of	particular	 importance	 in	 the	 liver,	where	 the	
role	of	OSM	has	been	very	well	characterized:	one	of	its	functions	is	the	regulation	of	
cholesterol	 metabolism	 through	 the	 modulation	 of	 the	 levels	 of	 low-density	
lipoprotein	 (LDL)	 receptors	 in	 liver	 cells.	 (Grove	et	 al.	 1991)	 This	 cytokine	 can	 also	
promote	hepatocyte	proliferation	through	activation	of	the	OSMR,	a	process	that	is	
particularly	 important	 in	 liver	 regeneration	 after	 injury	 and	 in	 the	 expansion	 and	
maintenance	of	primary	hepatocyte	cultures	in	vitro.	(Nakamura	et	al.	2004)	(Levy	et	
al.	2015)	Additionally,	it	is	also	able	to	regulate	the	acute	phase	protein	response	of	
hepatocytes	during	inflammatory	processes.	(Richards	et	al.	1992)	(Wang	et	al.	2000)	
	
OSM	 has	 also	 been	 shown	 to	 be	 an	 important	 modulator	 of	 hematopoiesis,	
stimulating	both	 the	hematopoietic	progenitor	 cells	directly	 as	well	 as	 the	 stromal	
cells	 influencing	the	hematopoietic	microenvironment.	 (Tanaka	et	al.	2003)	Several	
other	 studies	 have	 documented	 the	 influence	 of	 OSM	 in	 other	 physiological	
processes	such	as	cartilage	catabolism,	adipogenesis	inhibition,	bone	remodeling	or	
OSM	
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central	nervous	system	development.	 (de	Hooge	et	al.	2003)	 (Miyaoka	et	al.	2006)	
(Guihard	et	al.	2012)	(Morikawa	et	al.	2004)	
	
However,	 given	 that	 the	main	 sources	 of	 OSM	 in	 the	 organism	 are	 thought	 to	 be	
immune	cells	such	as	monocytes,	macrophages,	dendritic	cells	and	neutrophils,	the	
importance	 of	 this	 cytokine	 appears	 to	 be	 magnified	 in	 the	 context	 of	 different	
pathological	conditions	(Zarling	et	al.	1986)	(Malik	et	al.	1989)	(Grenier	et	al.	1999)	
(Suda	 et	 al.	 2002)	 This	 cytokine	 was	 originally	 described	 as	 an	 inhibitor	 of	
proliferation	 of	 several	 cancer	 cell	 lines,	 but	 this	 antitumorigenic	 effect	 is	 not	
universal:	 the	 opposite	 effect	 has	 been	 reported	 for	 other	 cancer	 cells	 lines,	 and	
most	recently	in	vivo	in	a	murine	model	of	glioblastoma.	(Zarling	et	al.	1986)	(Horn	et	
al.	1990)	(Jahani-Asl	et	al.	2016)	
	
Its	 influence	 in	 inflammatory	 joint	 diseases	 such	 as	 rheumatoid	 arthritis	 has	 been	
studied	in	depth:	the	evidence	collected	so	far	suggests	that	OSM	is	able	to	induce	
maximal	 responses	 to	 other	 inflammatory	 cytokines	 in	 arthritis,	 promoting	 joint	
destruction.	 (Hui	 et	 al.	 2005)	 (Richards	 2013)	 This	 proinflammatory	 effect	 is	 also	
apparent	 in	 other	 chronic	 inflammatory	 diseases,	 such	 as	 allergen-induced	 airway	
inflammation	 in	 the	 lung,	 inflammatory	 skin	 lesions,	 inflammatory	 bowel	 disease,	
atherosclerosis	or	dilated	cardiomyopathy.	(O’Hara	et	al.	2003)	(Boniface	et	al.	2007)	
(Guilloteau	et	al.	2010)	(Hui	et	al.	2005)	(West	et	al.	2017)	(Albasanz-Puig	et	al.	2011)	
(Pöling	et	al.	2014)	
	
Conversely,	activation	of	OSM	signaling	has	been	linked	to	beneficial	effects	in	other	
preclinical	 disease	 models:	 in	 the	 heart	 OSM	 stimulation	 leads	 to	 cardiomyocyte	
dedifferentiation	 and	 functional	 recovery	 after	 myocardial	 infarction,	 while	
OSMR/gp130	activation	 is	 crucial	 for	 the	necessary	 recruitment	of	macrophages	at	
the	site	of	infarction	that	leads	to	cardiac	healing.	(Kubin	et	al.	2011)	(Lörchner	et	al.	
2015)	Activation	of	 the	OSMR/gp130	complex	has	also	been	 linked	with	protective	
effects	 in	 in	 vivo	 models	 of	 ischemic	 stroke,	 spinal	 cord	 injury,	 obesity-induced	
hepatic	insulin	resistance	and	steatosis	(Guo	et	al.	2015)	(Slaets	et	al.	2014)	(Luo	et	
al.	2016)	The	main	biological	actions	of	OSM	are	illustrated	in	Figure	2.	
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Figure	 2:	 Main	 biological	 activities	 of	 OSM.	 OSM	 influences	 a	 wide	 array	 of	
biological	processes	 in	physiological	 conditions,	particularly	 in	 the	 liver,	 the	central	
nervous	 system	 and	 the	 bone	 marrow.	 In	 addition,	 it	 can	 also	 influence	 several	
pathological	 situations,	 such	 as	 different	 chronic	 inflammatory	 diseases,	 acute	
myocardial	 injury	 and	 cancer.	 Detailed	 explanations	 of	 these	 processes	 and	
references	 can	 be	 found	 in	 the	 main	 text.	 All	 images	 were	 obtained	 under	 an	
unlimited	use	license	from	Openclipart	(www.openclipart.org).	
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1.4.	Oncostatin	M	cytokine-receptor	interactions	and	intracellular	signaling	
	
OSM	cytokine-receptor	 interaction	roughly	follows	the	general	paradigm	for	helical	
cytokines	and	the	extracellular	domain	of	its	receptor	complexes,	first	described	for	
growth	hormone	25	years	ago.	 (de	Vos	et	al.	1992)	OSM	has	 two	distinct	 receptor	
binding	sites:	site	II	is	formed	by	the	residues	in	the	middle	of	helices	A	and	C,	while	
site	 III	encompasses	the	N-terminal	parts	of	 the	AB	 loop	and	the	D-helix	as	well	as	
the	BC	loop.	(Deller	et	al.	2000)	Other	members	of	the	IL-6	class	share	this	binding	
site	arrangement,	such	as	LIF,	which	is	the	closest	to	OSM	in	structural	terms.	(Rose	
&	Bruce	1991)	(Hudson	et	al.	1996)	
	
In	order	to	 initiate	signaling	OSM	binds	first	 to	gp130	through	site	 II,	after	which	a	
second	signaling	receptor	(LIFR	or	OSMR)	is	recruited	via	site	III.	(Mosley	et	al.	1996)	
Ligand-receptor	 interaction	 through	site	 III	 in	both	LIF	and	OSM	 is	dependent	on	a	
conserved	FXXK	binding	motif	located	in	the	N-terminal	region	of	the	D-helix	of	the	
cytokines.	 (Hudson	 et	 al.	 1996)	 (Deller	 et	 al.	 2000)	 However,	 the	 key	 features	
enabling	OSM	alone	to	interact	with	the	OSMR/gp130	complex	remain	unknown	so	
far:	 the	 most	 distinctive	 structural	 feature	 of	 OSM	 is	 an	 extended	 loop	 between	
helices	 B	 and	 C,	 but	 a	 previous	 study	 found	 that	 deletions	 in	 this	 region	 did	 not	
impair	OSMR	recruitment.	 (Chollangi	et	al.	2012)	The	 three-dimensional	 structures	
of	both	OSM	and	LIF	are	represented	in	Figure	3.	
	
	
	
LIF	 OSM	
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Figure	3:	Secondary	structure	and	receptor	binding	site	locations	of	OSM	and	LIF.	
The	three-dimensional	structures	of	LIF	(in	orange)	and	OSM	(in	blue)	are	depicted,	
with	 its	receptor	binding	sites	highlighted.	The	common	region	binding	to	gp130	in	
LIF	and	OSM	(site	II),	formed	by	amino	acids	in	helices	A	and	C,	is	shown	in	grey.	The	
binding	site	for	LIFR	in	LIF	and	for	OSMR/LIFR	in	OSM,	comprising	residues	in	the	N-
terminal	AB	loop,	the	BC	loop	and	the	N-terminal	D-helix	regions,	is	marked	in	red.	
	
	
After	 binding	 to	 the	 ligand	 the	 receptors	 within	 the	 signaling	 complex	 undergo	
conformational	 changes,	 causing	 their	 cytoplasmic	 regions	 to	 become	 closer:	 this	
allows	tyrosine	kinases	of	the	Janus	kinase	family	(JAK)	such	as	JAK1,	JAK2	and	TYK2,	
which	 are	 found	 in	 association	 with	 the	 membrane-proximal	 region	 of	 these	
receptors,	to	phosphorylate	each	other	and	initiate	signal	transduction.	(Lütticken	et	
al.	 1994)	 (Stahl	 et	 al.	 1994)	 (Hermanns	 et	 al.	 1999)	 (Radtke	 et	 al.	 2002)	 The	
involvement	of	other	 types	of	kinases,	such	as	Src	and	Tec	 family	kinases,	has	also	
been	reported	in	the	past.	(Heinrich	et	al.	1998)	(Heinrich	et	al.	2003)	
	
Signal	 transducer	 and	 activator	 of	 transcription	 (STAT)	 family	 proteins	 also	 play	 a	
central	 role	 in	 IL-6	 type	 cytokine	 signaling:	 STATs	 are	 recruited	 to	 either	
phosphorylated	receptor	tyrosine	motifs	or	to	the	JAKs	and	become	phosphorylated	
themselves,	leading	to	dimer	formation	and	accumulation	in	the	cell	nucleus,	where	
they	 act	 as	 transcription	 factors	 to	modulate	 gene	 expression.	 (Shuai	 et	 al.	 1993)	
(Shuai	 et	 al.	 1994)	 Phosphorylation	 of	 STAT3	 and	 STAT1	 has	 been	 reported	 after	
receptor	 complex	 binding	 for	 all	 family	 members,	 while	 STAT5	 and	 STAT6	 are	
phosphorylated	 specifically	 by	 activation	 of	 the	 OSMR.	 (Lütticken	 et	 al.	 1994)	
(Sadowski	et	al.	1993)	(Wang	et	al.	2000)	(Fritz	et	al.	2006)	
	
Besides	 the	 JAK/STAT	 signaling	 pathway	 just	 described,	 IL-6	 type	 cytokines	 also	
initiate	other	signaling	cascades,	such	as	the	one	comprised	by	the	Ras-Raf-mitogen-
activated	protein	kinases	 (MAPKs).	 (Schiemann	et	al.	1997)	 (Hermanns	et	al.	2000)	
Among	the	MAPKs	activated	by	the	IL-6	cytokines	are	ERK1/2,	known	to	be	involved	
in	 maintenance	 of	 cell	 survival,	 but	 also	 stress-activated	 members	 of	 the	 MAPK	
family	such	as	p38	or	c-Jun	N-terminal	kinase	(JNK).	(Wang	et	al.	2000)	(Zauberman	
et	al.	1999)	The	third	main	signaling	pathway	activated	by	these	receptor	complexes	
is	 the	 one	 mediated	 by	 the	 proteins	 phosphoinositide	 3-kinase/protein	 kinase	 B	
(PI3K/Akt),	 also	 associated	 with	 cell	 survival.	 (Negoro	 et	 al.	 2001)	 Moreover,	 the	
OSMR	 exhibits	 the	 ability	 to	 signal	 through	 additional	 pathways,	 such	 as	 the	 one	
mediated	 by	 PI3K	 and	 the	 protein	 kinase	 C	 delta,	 that	 drive	 some	 of	 its	 unique	
actions.	 (Smyth	 et	 al.	 2006)	 (Underhill-Day	 &	 Heath	 2006)	 The	 main	 signaling	
components	driving	OSM	responses	are	represented	in	figure	4.	
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Figure	4:	Main	signaling	pathways	activated	by	OSM.	Following	binding	of	OSM,	the	
OSMR	is	able	to	initiate	an	array	of	signaling	events	involving	phosphorylation	(P)	of	
different	signaling	mediators.	The	three	main	cascades	modulating	gene	expression	
in	 response	 to	 OSM	 are	 the	 JAK/STAT,	 Ras/Raf/MAPK	 (including	 ERK1/2,	 JNK	 and	
p38)	and	PI3K/Akt	pathways.	
	
	
Although	all	 these	signaling	cascades	contribute	to	mediate	OSMR	activity,	 in	most	
of	the	biological	functions	reported	so	far	STAT3	phosphorylation	appears	to	play	a	
crucial	role.	As	an	example,	STAT3	is	necessary	for	hematopoiesis,	with	a	dominant	
negative	 form	 of	 STAT3	 suppressing	 this	 process	 during	 mouse	 development.	
(Takizawa	 et	 al.	 2003)	 In	 the	 heart	 STAT3	 is	 required	 for	 cardioprotection	 against	
ischemic	 injury,	 being	 responsible	 for	 the	OSM-regulated	 secretion	 of	 chemokines	
that	leads	to	cardiac	healing	after	myocardial	infarction.	(Hilfiker-Kleiner	et	al.	2004)	
(Lörchner	 et	 al.	 2015)	 Liver	 regeneration	 after	 injury	 is	 also	 dependent	 on	 STAT3	
activation,	 and	 as	 a	 result	 is	 impaired	 in	 mice	 lacking	 the	 OSMR.	 (Li	 et	 al.	 2002)	
(Nakamura	 et	 al.	 2004)	 Moreover,	 STAT3	 is	 also	 involved	 in	 the	 progression	 of	
chronic	 inflammatory	 diseases	mediated	 by	OSM	 such	 as	 atherosclerosis,	which	 is	
alleviated	by	reduced	STAT3	levels.	(Zhang	et	al.	2017)	The	importance	of	STAT3	for	
OSM-derived	 signaling	 is	 further	 reflected	 in	 the	 fact	 that,	 while	 all	 IL-6	 class	
cytokines	lead	to	downstream	STAT3	activation,	OSM	shows	the	strongest	effect	on	
gp130/hOSMR	
OSM	
JAK	
PP
Ras	
STATs	
PSTATs	P
Regula7on	of	gene	expression	
(e.g.	TIMP1,	STAT3)	
ERK	
PP
JNK	
PPp38	
PP
PI3K	
Akt	
P
	 16	
STAT3	in	stimulation	experiments	with	a	variety	of	cell	types.	(Chattopadhyay	et	al.	
2007)	
	
1.5.	Oncostatin	M	species-specific	receptor	activation	profile	
	
A	crucial	particularity	of	OSM	is	the	species-dependent	receptor	activation	ability	it	
displays:	 as	 stated	 before,	 human	 OSM	 (hOSM)	 is	 able	 to	 activate	 both	 human	
LIFR/gp130	(hLIFR)	and	human	OSMR/gp130	(hOSMR).	 (Mosley	et	al.	1996)	On	the	
other	hand	 its	murine	ortholog	appears	to	signal	 through	the	murine	OSMR/gp130	
(mOSMR)	 complex	 almost	 exclusively,	 although	 minor	 mouse	 LIFR/gp130	 (mLIFR)	
activation	has	recently	been	reported	in	the	context	of	bone	remodeling.	(Ichihara	et	
al.	1997)	(Lindberg	et	al.	1998)	(Walker	et	al.	2016)	
	
To	make	matters	more	complex	the	human	cytokine	is	unable	to	bind	to	the	murine	
OSMR/gp130	(mOSMR),	and	 in	turn	mouse	OSM	(mOSM)	cannot	activate	either	of	
the	 human	 receptor	 complexes.	 (Lindberg	 et	 al.	 1998)	 (Drechsler	 et	 al.	 2012)	 The	
species-specific	 receptor	 activation	 abilities	 of	 each	 ortholog	 are	 schematically	
represented	in	Figure	5.	
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Figure	 5:	OSM	displays	 species-specific	 receptor	 activation	 abilities.	 The	 receptor	
activation	abilities	 for	 the	human	and	murine	OSM	orthologs	are	 shown:	mOSM	 is	
specific	to	the	mOSMR,	while	neither	of	the	murine	cytokines	can	bind	to	the	human	
receptors.	On	the	other	hand,	hOSM	is	promiscuous	for	hLIFR	and	hOSMR,	and	both	
human	molecules	are	able	to	activate	the	mLIFR	but	not	the	mOSMR.	
	
	
This	difference	 in	behavior	 is	especially	problematic	given	the	widespread	usage	of	
mouse	models	in	the	investigation	of	OSM	functions:	unlike	rats,	mice	do	not	reflect	
the	 full	 physiological	 response	 that	hOSM	would	have	 in	humans.	 (Drechsler	et	 al.	
2012)	 The	 underlying	 molecular	 mechanisms	 behind	 this	 characteristic,	 however,	
remain	unexplained	to	date.	
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2.	Goals	of	the	Study	
	
Multiple	studies	have	described	the	central	role	of	OSM	in	a	variety	of	physiological	
and	pathological	 situations,	 as	well	 as	 its	 potential	 therapeutic	 applications.	 These	
actions	 are	 a	 consequence	 of	 OSM	 recognizing	 and	 binding	 to	 specific	 surface	
receptor	complexes,	in	particular	the	one	formed	by	OSMR	and	gp130,	which	leads	
to	 the	 initiation	 of	 downstream	 signaling	 events	 and	 subsequent	 changes	 in	 gene	
expression.	
	
However,	 despite	 its	 biological	 relevance,	 very	 little	 detailed	 knowledge	 regarding	
the	 interaction	 between	OSM	and	 its	 receptors	 is	 available	 to	 date.	 In	 contrast	 to	
other	 IL-6	family	cytokines,	no	co-crystal	structures	 involving	OSM	and	either	of	 its	
receptor	 complex	 members	 have	 been	 reported	 so	 far.	 Furthermore,	 only	 OSM	
binding	 to	gp130	has	been	examined	 in	detail	 using	molecular	biology	 techniques:	
consequently,	 the	 structural	 features	 differentiating	 OSM	 from	 other	members	 of	
the	IL-6	family	are	still	unknown.	
	
In	addition,	the	differing	receptor	specificity	between	human	and	mouse	OSM	also	
remains	unexplained:	while	hOSM	can	activate	both	hOSMR	and	hLIFR	 complexes,	
mOSM	 is	 specific	 for	 the	 mOSMR.	 This	 is	 particularly	 concerning	 in	 view	 of	 the	
potential	 therapeutic	 applications	of	OSM,	 since	 as	of	 now	 the	 results	 obtained	 in	
preclinical	murine	models	cannot	be	directly	translated	to	the	human	situation.	
	
In	light	of	these	facts,	this	work	had	two	clearly	defined	goals:	the	first	of	these	was	
to	 investigate	 the	 critical	 features	 in	 hOSM	enabling	 signaling	 through	 the	 specific	
hOSMR	complex,	focusing	on	the	comparison	with	the	closely	related	hLIF	to	identify	
exclusive	hOSM	traits.	This	could	be	done	through	the	expression	and	purification	of	
recombinant	cytokines,	the	identification	of	specific	readout	systems	for	the	hOSMR	
and	hLIFR	and	 the	generation	of	mutant	hOSM	variants.	 The	 second	goal	 involved	
mapping	 the	 molecular	 determinants	 responsible	 for	 the	 existing	 divergence	 in	
receptor	 activation	 profiles	 between	 hOSM	 and	 mOSM	 by	 employing	 the	 same	
techniques,	as	well	as	assessing	the	feasibility	of	modifying	their	receptor	specificity	
to	improve	the	translatability	of	future	studies	in	murine	models.	
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3.	Materials	and	Methods	
	
3.1.	Materials	
	
3.1.1.	Laboratory	equipment	
	
Equipment	 Manufacturer	
Pipetting	equipment	
HandyStep®	electronic	repeating	pipette	 BrandTech®	
Pipet-Aid®	XP	 Drummond	Scientific®	
Pipet-Lite	pipettes	 Rainin®	
Centrifuges	
Galaxy	Mini	centrifuge	 VWR®	
Heraeus™	Fresco™	21	 ThermoFisher	Scientific™	
Heraeus™	Multifuge™	1	L	 ThermoFisher	Scientific™	
Heraeus™	Multifuge™	3S-R	 ThermoFisher	Scientific™	
Heraeus™	Biofuge™	Stratos™	 ThermoFisher	Scientific™	
Sorvall®	 Evolution™	 RC	 superspeed	
centrifuge	
ThermoFisher	Scientific™	
Mammalian	cell	culture	equipment	
MaxQ	2000	CO2	Plus	digital	CO2	resistant	
shaker	
ThermoFisher	Scientific™	
Heracell™	150	CO2	incubator	 ThermoFisher	Scientific™	
Herasafe™	 KS	 (NSF)	 Class	 II,	 Type	 A2	
Biological	Safety	Cabinet	
ThermoFisher	Scientific™	
Leica	DMi1	inverted	microscope	 Leica	Microsystems®	
Neubauer	cell	counting	chamber	 Optik	Labor®	
Molecular	cloning	equipment	
Heraeus™	microbiological	incubator	 ThermoFisher	Scientific™	
Horizontal	electrophoresis	chambers	 Peqlab®	
Labcycler	thermocycler	 Sensoquest®	
NanoDrop	 2000c	 UV-Vis	
spectrophotometer	
ThermoFisher	Scientific™	
New	 Brunswick™	 Innova®	 44	 incubator	
shaker	
Eppendorf®	
UV	transilluminator	 INTAS	Science	Imaging	Instruments®	
Protein	electrophoresis	and	detection	
ChemiDoc™	MP	System	 Bio-Rad®	
Consort	 EV261	 electrophoresis	 power	
supply	
Sigma-Aldrich®	
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FLUOstar®	Galaxy	microplate	reader	 BMG	Labtech®	
Odyssey®	9120	imaging	system	 LI-COR	Biosciences®	
Sonopuls®	 HD	 2070	 ultrasonic	
homogenizer	
Bandelin®	
XCell	SureLock™	Mini-Cells	 Novex™	
XCell	II™	Blot	Modules	 Novex™	
Assorted	laboratory	equipment	
Assistent	RM5	rotating	mixer	 Karl	Hecht®	
BioPhotometer	6131	spectrophotometer	 Eppendorf®	
Borosilicate	flasks	and	bottles	 SCHOTT	DURAN®	
Dewar	Carrying	Flask	 KGW-Isotherm®	
Discovery	DV-215CDM	analytical	balance	 Ohaus®	
Fridge	and	-20ºC	freezers	 Liebherr®	
GFL®-3006	laboratory	shaker	 Gesellschaft	für	Labortechnik®	
HERAfreeze™	HFC	Series	-86°C	Ultra-Low	
Temperature	Chest	Freezer	
ThermoFisher	Scientific™	
IKAMAG™	RCT	hot	plate	magnetic	stirrer	 IKA®	
Milli-Q®	 Integral	 Water	 Purification	
System	
Merck	Millipore®	
pH	211	precision	pH	meter	and	HI	1144	
Tris	buffer	pH	electrode	
Hanna	Instruments®	
R-202	microwave	oven	 Sharp®	
Rocky®	RT-1S	rocking	platform	 Uniequip®	
Scotsman	AF103	ice	flaker	 Scotsman®	Ice	Systems	
Stuart™	SB2	tube	rotator	 Bibby	Scientific®	
Thermomixer	comfort	 Eppendorf®	
Vortex-Genie	2	 Scientific	Industries®	
	
3.1.2.	Consumables	
	
Consumables	 Manufacturer	
Tubes	and	flasks	
1	mL	CryoTube™	vials	 Nunc™	
1.5	and	2	mL	polypropylene	tubes	 Eppendorf®	
12	 mL	 polypropylene	 two-position	 cap	
tubes	
Greiner	Bio-One®	
15	 and	 50	 mL	 Cellstar®	 polypropylene	
tubes	
Greiner	Bio-One®	
PCR	8er	SoftStrips	0.2	mL	 Biozym®	
Polycarbonate	 125	 and	 250	 mL	 Corning®	
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Erlenmeyer	cell	culture	flasks	
Pipettes	and	tips	
Cellstar®	serological	pipettes	 Greiner	Bio-One®	
Combitips®	Plus	electronic	pipette	tips	 Eppendorf®	
Disposable	pipette	tips	 Greiner	Bio-One®	
Fisherbrand™	SureOne™	filter	tips	 ThermoFisher	Scientific™	
Dishes	and	plates	
6-well	 and	 96-well	 Cellstar®	 cell	 culture	
plates	
Greiner	Bio-One®	
10	cm	Cellstar®	cell	culture	dishes	 Greiner	Bio-One®	
10	cm	Petri	dishes	 Greiner	Bio-One®	
96-well	flat	bottom	microplates	 Greiner	Bio-One®	
Others	
1	mL	Omnifix®-R	single-use	syringes	 B.	Braun®	
Cell	scraper	25cm	 Sarstedt®	
Disposable	10	µL	inoculation	loops	 Roth®	
Filtropur	S	0.2	syringe	filter	 Sarstedt®	
Mr.	Frosty™	Freezing	Container	 ThermoFisher	Scientific™	
Parafilm	M®	All-Purpose	laboratory	film	 Bemis®	
Semi-micro	cuvette,	polystyrene	 Sarstedt®	
Surgical	disposable	scalpels	 B.	Braun®	
	
3.1.3.	Chemical	reagents	
	
Reagent	 Catalog	Number	 Manufacturer	
Acetic	acid	 3738	 Roth®	
Ammonium	persulfate	 A3678	 Sigma-Aldrich®	
Ampicillin	sodium	salt	 K029	 Roth®	
Aprotinin	 10820	 Sigma-Aldrich®	
Aqua	B.	Braun	 0082479E	 B.	Braun®	
Benzamidine,	hydrochloride	 199001	 Merck	Millipore®	
Bicine	 B3876	 Sigma-Aldrich®	
Bis-Tris	 A1025	 Applichem®	
Bromophenol	blue	 108122	 Merck	Millipore®	
Calcium	chloride	(CaCl2)	 102382	 Merck	Millipore®	
Chloroform	 6340	 Roth®	
D(+)-glucose	 X997	 Roth®	
DEPC	 K028	 Roth®	
Dimethyl	sulfoxide	(DMSO)	 D4540	 Sigma-Aldrich®	
dNTP	set	(100	mM)	 10297018	 Invitrogen™	
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DTT	(1,4-Dithiothreitol)	 6908	 Roth®	
EDTA	 1610729	 Bio-Rad®	
Ethanol	ROTIPURAN®	≥	
99.8%	purity	
9065	 Roth®	
Ethidium	 bromide	 solution	
1	%	BioChemica	
A1152	 Applichem®	
Glycerin	≥	86%	purity	 7533	 Roth®	
Hydrochloric	 acid	 fuming	
37%	(HCl)	
4625	 Roth®	
Imidazole	 3899	 Roth®	
IPTG	 2316	 Sigma-Aldrich®	
Isopropanol	ROTIPURAN®	≥	
99.8%	purity	
6752	 Roth®	
Kanamycin	sulphate	 T832	 Roth®	
Leupeptin	 L2884	 Sigma-Aldrich®	
Magnesium	chloride	
(MgCl2)	hexahydrate	
2189	 Roth®	
Magnesium	sulfate	(MgSO4)	 105886	 Merck	Millipore®	
Methanol	ROTIPURAN®	≥	
99.9%	purity	
4627	 Roth®	
Phenylmethylsulfonylfluorid	
(PMSF)	
6367	 Roth®	
Polyethylene	 glycol	 6000	
(PEG-6000)	
81260	 Sigma-Aldrich®	
Potassium	acetate	 T874	 Roth®	
Potassium	chloride	(KCl)	 104933	 Merck	Millipore®	
Potassium	phosphate	
monobasic	(KH2PO4)	
104873	 Merck	Millipore®	
Random	Primers	 C1181	 Promega®	
RNasin®	Plus	RNase	
Inhibitor	
N2611	 Promega®	
Rotiphorese®	Gel	40	(29:1	
acrylamide/bisacrylamide)	
A515	 Roth®	
Sodium	 dodecyl	 sulfate	
(SDS)	ultra	pure	≥	99.5%	
2326	 Roth®	
Sodium	chloride	(NaCl)	 3957	 Merck	Millipore®	
Sodium	fluoride	(NaF)	 201154	 Sigma-Aldrich®	
Sodium	hydroxide	(NaOH)	 106498	 Merck	Millipore®	
Sodium	 orthovanadate	
(Na3VO4)	
S6508	 Sigma-Aldrich®	
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Sodium	 phosphate	 dibasic	
(Na2HPO4)	
4984	 Roth®	
TEMED	 2367	 Roth®	
TriFast™	 30-2010	 Peqlab®	
Tris	 5429	 Roth®	
Tween®	20	 9127	 Roth®	
Urea	 U5378	 Sigma-Aldrich®	
	
3.1.4.	Ladders	and	enzymes	
	
Reagent	 Catalog	Number	 Manufacturer	
Ladders	
GeneRuler	1	kb	DNA	ladder	 SM0312	 ThermoFisher	Scientific™	
GeneRuler	 100	 bp	 DNA	
ladder	
SM0241	 ThermoFisher	Scientific™	
Protein	Marker	VI	(10	-	245)	
prestained	
A8889	 AppliChem®	
Enzymes	
AscI	restriction	enzyme	 R0558	 New	England	Biolabs®	
DNAse	I	 10104159001	 Roche®	
DpnI	restriction	enzyme	 R0176	 New	England	Biolabs®	
EcoRI	restriction	enzyme	 EN-114	 Jena	Bioscience®	
HindIII	restriction	enzyme	 EN-116	 Jena	Bioscience®	
Lysozyme	 from	chicken	egg	
white	
62970	 Sigma-Aldrich®	
NdeI	restriction	enzyme	 R0111	 New	England	Biolabs®	
PacI	restriction	enzyme	 R0547	 New	England	Biolabs®	
PfuUltra	 High	 Fidelity	 DNA	
Polymerase	
600380	 Agilent®	
Phusion	 Hot	 Start	 II	 DNA	
Polymerase	(2	U/µL)	
F-549S	 ThermoFisher	Scientific™	
RNAse	A	 10109142001	 Roche®	
RQ1	RNAse-free	DNase	 M6101	 Promega®	
SlaI	restriction	enzyme	 EN-134	 Jena	Bioscience®	
SuperScript®	 II	 Reverse	
Transcriptase	
18064014	 Invitrogen™	
T4	DNA	ligase	 M1804	 Promega®	
XbaI	restriction	enzyme	 EN-143	 Jena	Bioscience®	
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3.1.5.	Cell	lines,	cell	culture	mediums	and	reagents	
	
Reagent	 Catalog	Number	 Manufacturer	
Mammalian	cell	lines	
A375	cell	line	(human	
malignant	melanoma)	
88113005	
European	 Collection	 of	
Authenticated	 Cell	
Cultures	(ECACC)	
FreeStyle™	293-F	(HEK293	
cells	adapted	to	high	
density,	serum-free,	
suspension	growth)	
R79007	 ThermoFisher	Scientific™	
HepG2	cell	line	(human	
hepatocellular	carcinoma)	
-	 Gift	of	Dr.	Sarah	Tonack	
JAR	cell	line	(human	
choriocarcinoma)	
ATCC®	HTB-144™	
American	 Type	 Culture	
Collection	(ATCC®)	
MH-S	cell	line	(murine	
monocyte)	
-	
Gift	 of	 Dr.	 Holger	
Lörchner	
NIH3T3	cell	line	(murine	
fibroblast)	
-	
Gift	 of	 Dr.	 Praveen	
Gajawada	
NIH3T3	cell	line	(murine	
fibroblast)	stably	
transfected	with	empty	
vector	
-	
Gift	 of	 Dr.	
Krishnamoorthy	
Sreenivasan	
NIH3T3	cell	line	(murine	
fibroblast)	stably	
transfected	with	anti-
mouse	LIFR	shRNA	
-	
Gift	 of	 Dr.	
Krishnamoorthy	
Sreenivasan	
Cell	culture	mediums	
Dulbecco's	modified	Eagle	
medium	(DMEM)	with	4500	
mg/L	glucose,	L-glutamine	
and	sodium	bicarbonate	
D5796	 Sigma-Aldrich®	
DMEM	with	high	glucose,	
HEPES	and	no	phenol	red	
21063029	 Gibco™	
DMEM/F-12	with	
GlutaMAX™	supplement	
31331028	 Gibco™	
FreeStyle™	293	expression	
medium	
12338001	 Gibco™	
Opti-MEM®	I	reduced	 31985062	 Gibco™	
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serum	medium	
OptiPRO™	SFM	 12309019	 Gibco™	
Roswell	Park	Memorial	
Institute	(RPMI)	1640	
medium	with	L-glutamine	
21875034	 Gibco™	
Reagents	and	kits	
Anti-clumping	agent	 0010057AE	 Gibco™	
Fetal	bovine	serum	(FBS)	 F7524	 Sigma-Aldrich®	
FreeStyle™	MAX	reagent	 16447100	 Invitrogen™	
Lipofectamine®	RNAiMAX	
transfection	reagent	
13778030	 Invitrogen™	
Penicillin-streptomycin	
solution	
P4333	 Sigma-Aldrich®	
Trypsin-EDTA	solution	10x	
(sterile-filtered)	
59418C	 Sigma-Aldrich®	
Vybrant®	MTT	cell	
proliferation	assay	kit	
V13154	 ThermoFisher	Scientific™	
	
3.1.6.	Antibodies,	recombinant	proteins	and	siRNAs	
	
Reagent	 Catalog	Number	 Manufacturer	
Antibodies	
His-Tag	(monoclonal	mouse	
Penta-His	antibody,	BSA-
free)	
34660	 Qiagen®	
Goat	IgG	Horseradish	
Peroxidase-conjugated	
antibody	
HAF109	 R&D	Systems®	
LIFR	alpha	antibody	
(human)	
AF-249-NA	 R&D	Systems®	
Mouse	IgG	(H+L)	Alexa	
Fluor®	680-conjugated	
A21057	 Invitrogen™	
Mouse	IgG	Horseradish	
Peroxidase-conjugated	
antibody	
HAF007	 R&D	Systems®	
OSMR	beta	antibody	
(human)	
AF4389	 R&D	Systems®	
Pan-Actin	 4968	
Cell	Signaling	
Technology®	
Phospho-ERK1/2	 9101	 Cell	Signaling	
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(Thr202/Tyr204)	 Technology®	
Phospho-SAP/JNK	
(Thr183/Tyr185)	
9251	
Cell	Signaling	
Technology®	
Phospho-STAT1	(Tyr701)	 9171	
Cell	Signaling	
Technology®	
Phospho-STAT3	(Tyr705)	 9131	
Cell	Signaling	
Technology®	
Rabbit	IgG	Horseradish	
Peroxidase-conjugated	
antibody	
HAF008	 R&D	Systems®	
STAT3	(124H6)	mouse	
monoclonal	
9139	
Cell	Signaling	
Technology®	
TIMP1	(D10E6)	rabbit	
monoclonal	
8946	
Cell	Signaling	
Technology®	
TIMP1	(mouse)	 MAB9801	 R&D	Systems®	
Recombinant	proteins	
LIF	Protein	(human)	 7734-LF/CF	 R&D	Systems®	
Oncostatin	M	(OSM)	
Protein	(human)	
295-OM-010/CF	 R&D	Systems®	
Oncostatin	M	(OSM)	
Protein	(mouse)	
495-MO-025/CF	 R&D	Systems®	
siRNAs	
5x	siRNA	Buffer	 B-002000-UB-100	 Dharmacon®	
ON-TARGETplus	Non-
targeting	Control	Pool	
D-001810-10-05	 Dharmacon®	
SMARTpool:	ON-
TARGETplus	LIFR	siRNA	
L-008017-01-0005	 Dharmacon®	
SMARTpool:	ON-
TARGETplus	OSMR	siRNA	
L-008050-00-0005	 Dharmacon®	
	
3.1.7.	Protein	Electrophoresis	and	Detection	
	
Reagent	 Catalog	Number	 Manufacturer	
Protein	Electrophoresis	
Amersham™	Protran™	0.45	
µm	NC	nitrocellulose	
blotting	membranes	
10600002	
GE	Healthcare	Life	
Sciences®	
Bovine	Serum	Albumin	
solution	
A7284	 Sigma-Aldrich®	
DC™	Protein	Assay	 5000112	 Bio-Rad®	
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Empty	Gel	Cassettes,	mini,	
1.0	mm	
NC2010	 Novex™	
NuPAGE™	4-12%	Bis-Tris	
Protein	Gels,	1.0	mm,	17-
well	
NP0329BOX	 Novex™	
NuPAGE®	20xMES	SDS	
Running	Buffer	
NP0002	 Novex™	
Protein	standard	for	protein	
quantification	
P0834	 Sigma-Aldrich®	
RedAlert™	10x	Western	
Blot	Stain	
71078	 Merck	Millipore®	
Rotilabo®-Blotting	Papers,	
Thickness	0.35	mm	
CL66	 Roth®	
Skim	milk	powder	 70166	 Sigma-Aldrich®	
Protein	Detection	
SuperSignal™	West	Femto	
Maximum	Sensitivity	
Substrate	
34095	 ThermoFisher	Scientific™	
InstantBlue™	Coomassie®	
stain	
ISB1L	
Expedeon	Protein	
Solutions®	
SilverQuest™	Silver	Staining	
Kit	
LC6070	 Novex™	
	
3.1.8.	Molecular	cloning,	recombinant	protein	expression	and	purification	
	
Reagent	 Catalog	Number	 Manufacturer	
Molecular	cloning	
Human	Oncostatin	M	
template	vector	
-	
Gift	of	Dr.	Heike	
Hermanns	
LB	Broth	(Lennox)	 X964	 Roth®	
LB	Agar	(Lennox)	 X965	 Roth®	
LE	agarose	 840004	 Biozym®	
MGC	Human	LIF	Sequence-
Verified	cDNA	(CloneId:	
7939578),	glycerol	stock	
MHS6278-202857165	 ThermoFisher	Scientific™	
NucleoBond®	Xtra	Maxi	kit	 740414	 Macherey-Nagel®	
NucleoSpin®	Gel	and	PCR	
clean-up	kit	
740609	 Macherey-Nagel®	
pCAGGS	vector	with	PacI	
and	AscI	restriction	sites	
-	
Gift	of	Dr.	André	
Schneider	
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pcDNA™	3.1(+)	vector	 -	
Gift	of	Dr.	Natalie	Al-
Furoukh	
pET-26b(+)	vector	 -	
Gift	of	Dr.	Natalie	Al-
Furoukh	
pFLAG-CMV-3	vector	 E6783	 Sigma-Aldrich®	
XL-1	Blue	competent	E.	coli	 -	
Gift	of	Dr.	Natalie	Al-
Furoukh	
Recombinant	protein	expression	and	purification	
Amicon	Ultra-4	10	kDa	
centrifugal	filters	
UFC801024	 Merck	Millipore®	
BL21	(DE3)	competent	E.	
coli	
-	
Gift	of	Dr.	Natalie	Al-
Furoukh	
HIS-Select®	HF	nickel	
affinity	gel	
H0537	 Sigma-Aldrich®	
Polypropylene	columns	(5	
ml)	
34964	 QIAGEN®	
Protein	Deglycosylation	Mix	 P6039S	 New	England	Biolabs®	
SHuffle®	T7	Express	
competent	E.	coli	
C3029H	 New	England	Biolabs®	
	
3.1.9.	Primers	
	
All	primers	were	purchased	from	Sigma-Aldrich®	
Primer	Name	 Sequence	(5'	->	3')	
Cytokine	cloning	in	pET-26b(+)	vector	
NdeI	hOSM	fw	 AAAGGGAAACATATGGCGGCTATAGGCAGCTGCTCGA	
hOSM	SlaI	rev	 TTTCCCTTTCTCGAGCCGGCTCCGGTTCGGGCTCTCC	
NdeI	hLIF	fw	 AAAGGGAAACATATGAGCCCCCTCCCCATCACCCCTG	
hLIF	SlaI	rev	 TTTCCCTTTCTCGAGGAAGGCCTGGGCCAACACGGCG	
NdeI	mOSM	fw	 AAAGGGAAACATATGAATCGTGGCTGCTCCAACTCT	
mOSM	SlaI	rev	 TTTCCCTTTCTCGAGTCTCCGGCTGCGTGTGGAGCCA	
Cytokine	cloning	in	pcDNA	3.1(+)	vector	
EcoRI	NatSP	hOSM	
fw	
AAAGGGAAAGAATTCGCACGGGCACCCAGCATGGGGGTACTGCTC
ACACAGAGGACG	
EcoRI	NativeSP	
hLIF	fw	
AAAGGGAAAGAATTCGAAGTGCAGCCCATAATGAAGGTCTTGGCG
GCAGGAGTTGTG	
EcoRI	NativeSP	
mOSM	fw	
AAAGGGAAAGAATTCGTACCAGGACCCAGTATGCAGACACGGCTT
CTAAGAACACTG	
NdeI-EcoRI-Koz-
PPT	fw	
AAAGGGAAACATATGGAATTCGCCACCATGTCTGCACTTCTGATCC
T	
	 29	
PPT+hOSM	fw	 GGAGCTGCAGTTGCTGCGGCTATAGGCAGC	
PPT+hOSM	rev	 GCTGCCTATAGCCGCAGCAACTGCAGCTCC	
PPT+hLIF	fw	 GAGCTGCAGTTGCTAGCCCCCTCCCCATCA	
PPT+hLIF	rev	 TGATGGGGAGGGGGCTAGCAACTGCAGCTC	
PPT+mOSM	fw	 GGAGCTGCAGTTGCTAATCGTGGCTGCTCC	
PPT+mOSM	rev	 GGAGCAGCCACGATTAGCAACTGCAGCTCC	
Cytokine	cloning	in	pFLAG-CMV-3	vector	
HindIII	hOSM	fw	 AAAGGGAAAAAGCTTCCGGCTCCGGTTCGGGCTCTCCCCCCA	
HindIII	mOSM	fw	 AAAGGGAAAAAGCTTAATCGTGGCTGCTCCAACTCTTCCTCT	
HindIII	hLIF	fw	 AAAGGGAAAAAGCTTAGCCCCCTCCCCATCACCCCTGTCAAC	
HisTag	XbaI	rev	 TTTCCCTTTTCTAGAGTCTCAGTGGTGGTGGTGGTGGTGCTCGAG	
Cytokine	cloning	in	pCAGGS	vector	
PacI	hOSM	fw	
AAAGGGAAATTAATTAAGCTAGCGCATCGCCACCATGGGGGTACT
GCTCACACAGAGGACG	
SP+hOSM	fw	 CAAGCATGGCGAGCATGGCGGCTATAGGCAGCTG	
SP+hOSM	rev	 CAGCTGCCTATAGCCGCCATGCTCGCCATGCTTG	
PacI	mOSM	fw	
AAAGGGAAATTAATTAAGCTAGCGCATCGCCACCATGCAGACACG
GCTTCTAAGAACACTG	
PacI	hLIF	fw	 AAAGGGAAATTAATTAAGCTAGCGCATCGCCACCATGAAGGTCTT
GGCGGCAGGAGTTGTG	
SP+hLIF	fw	 GGAAACATGGGGCGGGGAGCCCCCTCCCCATCAC	
SP+hLIF	rev	 GTGATGGGGAGGGGGCTCCCCGCCCCATGTTTCC	
AscI	HisTag	rev	 TTTCCCTTTGGCGCGCCGCGGCCGCTATCAGTGGTGGTGGTGGTG
GTGCTCGAG	
Human	OSM	-	LIF	chimeras	
hLIF	AB	Start	fw	 AATGCCCTCTTTATTCCCTATATACGTATC	
hLIF	AB	Start	rev	 GATACGTATATAGGGAATAAAGAGGGCATT	
hLIF	AB	End	fw	 CTGAGAGAGCACTGCGGCCCCAACGTGACG	
hLIF	AB	End	rev	 CGTCACGTTGGGGCCGCAGTGCTCTCTCAG	
hLIF	AB2	fw	 TTTATTCTCTATTACCGTATCCAAGGCCTG	
hLIF	AB2	rev	 CAGGCCTTGGATACGGTAATAGAGAATAAA	
hLIF	AB3	fw	 CTCTATTACACAGCCCAAGGCCTGGATGTT	
hLIF	AB3	rev	 AACATCCAGGCCTTGGGCTGTGTAATAGAG	
hLIF	BC	Start	fw	 AACATCACCCGGGACTTAGAGCAGCGCCTC	
hLIF	BC	Start	rev	 GAGGCGCTGCTCTAAGTCCCGGGTGATGTT	
hLIF	BC	End	fw	 GACTTGGAGAAGCTGAACGCCACCGCCGAC	
hLIF	BC	End	rev	 GTCGGCGGTGGCGTTCAGCTTCTCCAAGTC	
hLIF	Dhelix	rev	 GCCCAGCTTCTTCTTCTGGAAGACATCCTTACCCGAGGTGGGGGTG
GGCGG	
hLIF	Dhelix	fw	 TCGGGTAAGGATGTCTTCCAGAAGAAGAAGCTGGGCTGCAGGTTC
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CTGCAT	
hOSM	AB	Start	fw	 AGCAGACTCCTGGACCTCTATTACACAGCC	
hOSM	AB	Start	rev	 GGCTGTGTAATAGAGGTCCAGGAGTCTGCT	
hOSM	AB	End	fw	 CTGGACAAGCTATGTAGGGAGCGCCCCGGG	
hOSM	AB	End	rev	 CCCGGGGCGCTCCCTACATAGCTTGTCCAG	
hOSM	BC	Start	fw	 CACAGACTGGCCGACCAGAAGATCCTCAAC	
hOSM	BC	Start	rev	 GTTGAGGATCTTCTGGTCGGCCAGTCTGTG	
hOSM	BC	End	fw	 CTCCACAGCAAGCTCCAGATGGCGAGGCCG	
hOSM	BC	End	rev	 CGGCCTCGCCATCTGGAGCTTGCTGTGGAG	
hOSM	Dhelix	rev	 GCCCTCCAGCTTGCGCTGAAAAGCATCCGAGGCAGGGGTGTCAGG
GCCGTA	
hOSM	Dhelix	fw	 CCTGCCTCGGATGCTTTTCAGCGCAAGCTGGAGGGCTGTCAACTCC
TGGGG	
Human	OSM	point	mutants	-	AB	loop	
hOSM	P33A	fw	 CAGCAGACTCCTGGACGCCTATATACGTATCCA	
hOSM	P33A	rev	 TGGATACGTATATAGGCGTCCAGGAGTCTGCTG	
hOSM	Y34A	fw	 CTCCTGGACCCCGCTATACGTATCCAAGGCCTGGATG	
hOSM	Y34A	rev	 CATCCAGGCCTTGGATACGTATAGCGGGGTCCAGGAG	
hOSM	I35A	fw	 GACTCCTGGACCCCTATGCACGTATCCAAGGCCTGG	
hOSM	I35A	rev	 CCAGGCCTTGGATACGTGCATAGGGGTCCAGGAGTC	
hOSM	R36A	fw	 TCCTGGACCCCTATATAGCTATCCAAGGCCTGGATG	
hOSM	R36A	rev	 CATCCAGGCCTTGGATAGCTATATAGGGGTCCAGGA	
hOSM	I37A	fw	 CTGGACCCCTATATACGTGCCCAAGGCCTGGATGTTCC	
hOSM	I37A	rev	 GGAACATCCAGGCCTTGGGCACGTATATAGGGGTCCAG	
hOSM	Q38A	fw	 GGACCCCTATATACGTATCGCAGGCCTGGATGTTCCTAAA	
hOSM	Q38A	rev	 TTTAGGAACATCCAGGCCTGCGATACGTATATAGGGGTCC	
hOSM	G39A	fw	 CCTATATACGTATCCAAGCCCTGGATGTTCCTAAACT	
hOSM	G39A	rev	 AGTTTAGGAACATCCAGGGCTTGGATACGTATATAGG	
hOSM	L40A	fw	 CCTATATACGTATCCAAGGCGCGGATGTTCCTAAACTGAGAG	
hOSM	L40A	rev	 CTCTCAGTTTAGGAACATCCGCGCCTTGGATACGTATATAGG	
hOSM	D41A	fw	 CCAAGGCCTGGCTGTTCCTAAACTGAGAGAGCA	
hOSM	D41A	rev	 TGCTCTCTCAGTTTAGGAACAGCCAGGCCTTGG	
hOSM	V42A	fw	 TATCCAAGGCCTGGATGCTCCTAAACTGAGAGAGC	
hOSM	V42A	rev	 GCTCTCTCAGTTTAGGAGCATCCAGGCCTTGGATA	
hOSM	P43A	fw	 CCAAGGCCTGGATGTTGCTAAACTGAGAGAGCA	
hOSM	P43A	rev	 TGCTCTCTCAGTTTAGCAACATCCAGGCCTTGG	
hOSM	K44A	fw	 CTGGATGTTCCTGCACTGAGAGAGCACTGCAGGGAGC	
hOSM	K44A	rev	 GCTCCCTGCAGTGCTCTCTCAGTGCAGGAACATCCAG	
hOSM	L45A	fw	 GCCTGGATGTTCCTAAAGCGAGAGAGCACTGCAGGG	
hOSM	L45A	rev	 CCCTGCAGTGCTCTCTCGCTTTAGGAACATCCAGGC	
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hOSM	R46A	fw	 CTGGATGTTCCTAAACTGGCAGAGCACTGCAGGGAGC	
hOSM	R46A	rev	 GCTCCCTGCAGTGCTCTGCCAGTTTAGGAACATCCAG	
hOSM	E47A	fw	 GTTCCTAAACTGAGAGCGCACTGCAGGGAGCG	
hOSM	E47A	rev	 CGCTCCCTGCAGTGCGCTCTCAGTTTAGGAAC	
hOSM	H48A	fw	 CCTAAACTGAGAGAGGCCTGCAGGGAGCGCC	
hOSM	H48A	rev	 GGCGCTCCCTGCAGGCCTCTCTCAGTTTAGG	
hOSM	C49A	fw	 AACTGAGAGAGCACGCCAGGGAGCGCCCC	
hOSM	C49A	rev	 GGGGCGCTCCCTGGCGTGCTCTCTCAGTT	
Human	OSM	point	mutants	-	D	helix	
hOSM	P153A	fw	 GCCGCCCACCGCCACCCCTGC	
hOSM	P153A	rev	 GCAGGGGTGGCGGTGGGCGGC	
hOSM	T154A	fw	 CGCCCACCCCCGCCCCTGCCTCG	
hOSM	T154A	rev	 CGAGGCAGGGGCGGGGGTGGGCG	
hOSM	P155A	fw	 CCACCCCCACCGCTGCCTCGGAT	
hOSM	P155A	rev	 ATCCGAGGCAGCGGTGGGGGTGG	
hOSM	S157A	fw	 CCCCACCCCTGCCGCGGATGCTTTTCA	
hOSM	S157A	rev	 TGAAAAGCATCCGCGGCAGGGGTGGGG	
hOSM	D158A	fw	 CCTGCCTCGGCTGCTTTTCAGCGCAAGCTG	
hOSM	D158A	rev	 CAGCTTGCGCTGAAAAGCAGCCGAGGCAGG	
hOSM	F160A	fw	 CTCGGATGCTGCTCAGCGCAAGCTGGAGGGC	
hOSM	F160A	rev	 GCCCTCCAGCTTGCGCTGAGCAGCATCCGAG	
hOSM	Q161A	fw	 GCCTCGGATGCTTTTGCGCGCAAGCTGGAGGG	
hOSM	Q161A	rev	 CCCTCCAGCTTGCGCGCAAAAGCATCCGAGGC	
hOSM	R162A	fw	 CAGCCCTCCAGCTTGGCCTGAAAAGCATCCGA	
hOSM	R162A	rev	 TCGGATGCTTTTCAGGCCAAGCTGGAGGGCTG	
hOSM	K163A	fw	 GATGCTTTTCAGCGCGCGCTGGAGGGCTGCAG	
hOSM	K163A	rev	 CTGCAGCCCTCCAGCGCGCGCTGAAAAGCATC	
hOSM	L164A	fw	 GCTTTTCAGCGCAAGGCGGAGGGCTGCAGGTT	
hOSM	L164A	rev	 AACCTGCAGCCCTCCGCCTTGCGCTGAAAAGC	
hOSM	E165A	fw	 CAGCGCAAGCTGGCGGGCTGCAGGTTC	
hOSM	E165A	rev	 GAACCTGCAGCCCGCCAGCTTGCGCTG	
hOSM	G166A	fw	 CGCAAGCTGGAGGCCTGCAGGTTCCTG	
hOSM	G166A	rev	 CAGGAACCTGCAGGCCTCCAGCTTGCG	
Mouse	OSM	sequence	optimization	and	mouse/human	chimeras	
mOSM	SeqOpt	
PacI	fw	
AAAGGGAAATTAATTAAGCTAGCGCATCGCCACCATGCAGACGAG
ATTGCTGCGCACCCTG	
mOSM	SeqOpt	
AscI	rev	
TTTCCCTTTGGCGCGCCGCGGCCGCTATCAATGATGATGGTGGTGA
TGCTCCAGCCT	
mOSM	Dlong	fw	 CAGCCGCCCACCCCCACCCCTGCAAGCGACGCTTTTCAAAG	
mOSM	Dlong	rev	 AGGGGTGGGGGTGGGCGGCTGGCTCGCGCCACTGTCGGTTT	
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mOSM	WT	1	 ATGCAGACGAGATTGCTGCGC	
mOSM	WT	2	 GTCAGGCTCAGCAGGGTGCGCAGCAATCTCGTCTG	
mOSM	WT	3	 ACCCTGCTGAGCCTGACCCTGTCACTGCTTATCCTTTCT	
mOSM	WT	4	 CGATTGGCAAGGGCCATAGAAAGGATAAGCAGTGACAGG	
mOSM	WT	5	 ATGGCCCTTGCCAATCGCGGGTGCAGCAACAGC	
mOSM	WT	6	 GCTCAACAGTTGGCTGCTGCTGTTGCTGCACCCG	
mOSM	WT	7	 AGCAGCCAACTGTTGAGCCAGCTTCAAAACCAGGCCA	
mOSM	WT	8	 GGTGTTGCCGGTCAGGTTGGCCTGGTTTTGAAGCTG	
mOSM	WT	9	 ACCTGACCGGCAACACCGAGAGCCTTCTTGAGCCCT	
mOSM	WT	10	 GGTTTTGCAGGCGGATGTAGGGCTCAAGAAGGCTCTC	
mOSM	WT	11	 ACATCCGCCTGCAAAACCTCAACACCCCCGACCTT	
mOSM	WT	12	 GTGCACGCAGCGCGAAGGTCGGGGGTGTTGA	
mOSM	WT	13	 CGCGCTGCGTGCACCCAGCACAGCGTGGCT	
mOSM	WT	14	 GGTGTCCTCGCTAGGGAAAGCCACGCTGTGCTGG	
mOSM	WT	15	 TTCCCTAGCGAGGACACCCTGAGGCAGTTGAGCAAGC	
mOSM	WT	16	 CGGTGGACAGGAAGTGTGGCTTGCTCAACTGCCTCAG	
mOSM	WT	17	 CACACTTCCTGTCCACCGTCTACACCACCCTGGACC	
mOSM	WT	18	 TCGAGCTGGTACAGCACTCGGTCCAGGGTGGTGTAGA	
mOSM	WT	19	 GAGTGCTGTACCAGCTCGACGCGCTCCGGCAGAA	
mOSM	WT	20	 GCGGGGGTCTTCAGAAACTTCTGCCGGAGCGCG	
mOSM	WT	21	 GTTTCTGAAGACCCCCGCATTCCCCAAGTTGGACAGC	
mOSM	WT	22	 CAGGATGTTGTGCCTGGCGCTGTCCAACTTGGGGAAT	
mOSM	WT	23	 GCCAGGCACAACATCCTGGGCATCAGGAACAACGTCT	
mOSM	WT	24	 AGAAGCCTAGCCATGCAGAAGACGTTGTTCCTGATGCC	
mOSM	WT	25	 TCTGCATGGCTAGGCTTCTGAACCACAGCCTTGAGATCC	
mOSM	WT	26	 GGTTTGCGTGGGTTCGGGGATCTCAAGGCTGTGGTTC	
mOSM	WT	27	 CCGAACCCACGCAAACCGACAGTGGCGCGAGCA	
mOSM	WT	28	 CGGGCGTAGTGGTAGACCTGCTCGCGCCACTGTC	
mOSM	WT	29	 GGTCTACCACTACGCCCGACGTGTTTAATACCAAGATAGGC	
mOSM	WT	30	 CCACAGAAAGCCGCAAGAGCCTATCTTGGTATTAAACACGT	
mOSM	WT	31	 TCTTGCGGCTTTCTGTGGGGTTACCATCGGTTCATGGG	
mOSM	WT	32	 ACACTCTCCCGACGCTGCCCATGAACCGATGGTAACC	
mOSM	WT	33	 CAGCGTCGGGAGAGTGTTCAGGGAGTGGGACGATG	
mOSM	WT	34	 CCTGCTCCTCGTGGAGCCATCGTCCCACTCCCTGA	
mOSM	WT	35	 GCTCCACGAGGAGCAGGAGGCTGGAGCATCACCA	
mOSM	WT	36	 ATGATGATGGTGGTGATGCTCCAGCCT	
mOSM	AB	10	 GTCCTTGGATGCGGATGTAGGGCTCAAGAAGGCTCTC	
mOSM	AB	11	 ACATCCGCATCCAAGGACTCGATGTGCCCAAGCTT	
mOSM	ABshort	12	 GTGCAATGTTCGCGAAGCTTGGGCACATCGA	
mOSM	ABshort	13	 CGCGAACATTGCACCCAGCACAGCGTGGCT	
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mOSM	ABlong	12	 CGGCAGTGTTCGCGAAGCTTGGGCACATCGA	
mOSM	ABlong	13	 CGCGAACACTGCCGGGAACGGCCTGGAGCT	
mOSM	ABlong	14	 GGTGTCCTCGCTAGGGAAAGCTCCAGGCCGTTCC	
mOSM	D	28	 CGCTTGCAGTGGTAGACCTGCTCGCGCCACTGTC	
mOSM	D	29	 GGTCTACCACTGCAAGCGACGCTTTTCAAAGAAAGCTCGAA	
mOSM	D	30	 CCACAGAAAGCCGCATCCTTCGAGCTTTCTTTGAAAAGCGT	
mOSM	D	31	 GGATGCGGCTTTCTGTGGGGTTACCATCGGTTCATGGG	
Mouse	OSM	point	mutants	-	AB	loop	
mOSM	L35I	10	 GGTTTTGGATGCGGATGTAGGGCTCAAGAAGGCTCTC	
mOSM	L35I	11	 ACATCCGCATCCAAAACCTCAACACCCCCGACCTT	
mOSM	N37G	10	 GTCCTTGCAGGCGGATGTAGGGCTCAAGAAGGCTCTC	
mOSM	N37G	11	 ACATCCGCCTGCAAGGACTCAACACCCCCGACCTT	
mOSM	N39D	11	 ACATCCGCCTGCAAAACCTCGACACCCCCGACCTT	
mOSM	N39D	12	 GTGCACGCAGCGCGAAGGTCGGGGGTGTCGA	
mOSM	T40V	11	 ACATCCGCCTGCAAAACCTCAACGTGCCCGACCTT	
mOSM	T40V	12	 GTGCACGCAGCGCGAAGGTCGGGCACGTTGA	
mOSM	D42K	11	 ACATCCGCCTGCAAAACCTCAACACCCCCAAACTT	
mOSM	D42K	12	 GTGCACGCAGCGCGAAGTTTGGGGGTGTTGA	
mOSM	35+37	10	 GTCCTTGGATGCGGATGTAGGGCTCAAGAAGGCTCTC	
mOSM	35+37	11	 ACATCCGCATCCAAGGACTCAACACCCCCGACCTT	
mOSM	35+39	11	 ACATCCGCATCCAAAACCTCGACACCCCCGACCTT	
mOSM	35+40	11	 ACATCCGCATCCAAAACCTCAACGTGCCCGACCTT	
mOSM	35+42	11	 ACATCCGCATCCAAAACCTCAACACCCCCAAACTT	
mOSM	37+39	11	 ACATCCGCCTGCAAGGACTCGACACCCCCGACCTT	
mOSM	37+40	11	 ACATCCGCCTGCAAGGACTCAACGTGCCCGACCTT	
mOSM	37+42	11	 ACATCCGCCTGCAAGGACTCAACACCCCCAAACTT	
mOSM	39+40	11	 ACATCCGCCTGCAAAACCTCGACGTTCCCGACCTT	
mOSM	39+40	12	 GTGCACGCAGCGCGAAGGTCGGGAACGTCGA	
mOSM	39+42	11	 ACATCCGCCTGCAAAACCTCGACACCCCCAAACTT	
mOSM	39+42	12	 GTGCACGCAGCGCGAAGTTTGGGGGTGTCGA	
mOSM	40+42	11	 ACATCCGCCTGCAAAACCTCAACGTGCCCAAGCTT	
mOSM	40+42	12	 GTGCACGCAGCGCGAAGCTTGGGCACGTTGA	
mOSM	35+37+39	
11	
ACATCCGCATCCAAGGACTCGACACCCCCGACCTT	
mOSM	35+37+40	
11	
ACATCCGCATCCAAGGACTCAACGTGCCCGACCTT	
mOSM	35+37+42	
11	
ACATCCGCATCCAAGGACTCAACACCCCCAAACTT	
mOSM	35+39+40	
11	
ACATCCGCATCCAAAACCTCGACGTTCCCGACCTT	
	 34	
mOSM	35+39+42	
11	
ACATCCGCATCCAAAACCTCGACACCCCCAAACTT	
mOSM	35+40+42	
11	
ACATCCGCATCCAAAACCTCAACGTGCCCAAGCTT	
mOSM	37+39+40	
11	
ACATCCGCCTGCAAGGACTCGACGTTCCCGACCTT	
mOSM	37+39+42	
11	
ACATCCGCCTGCAAGGACTCGACACCCCCAAACTT	
mOSM	37+40+42	
11	
ACATCCGCCTGCAAGGACTCAACGTGCCCAAGCTT	
mOSM	39+40+42	
11	
ACATCCGCCTGCAAAACCTCGATGTGCCCAAGCTT	
mOSM	39+40+42	
12	
GTGCACGCAGCGCGAAGCTTGGGCACATCGA	
mOSM	
35+37+39+40	11	
ACATCCGCATCCAAGGACTCGACGTTCCCGACCTT	
mOSM	
35+37+39+42	11	
ACATCCGCATCCAAGGACTCGACACCCCCAAACTT	
mOSM	
35+37+40+42	11	
ACATCCGCATCCAAGGACTCAACGTGCCCAAGCTT	
mOSM	
35+39+40+42	11	
ACATCCGCATCCAAAACCTCGATGTGCCCAAGCTT	
mOSM	
37+39+40+42	
ACATCCGCCTGCAAGGACTCGATGTGCCCAAGCTT	
mOSM	5M	 ACATCCGCATCCAAGGACTCGATGTGCCCAAGCTT	
Human	OSM	mutants	-	mouse	AB	loop	
hOSM	AB	mO	fw	 GACTCCTGGACCCCTATATACGTCTGCAAAACCTCAACACCCCCGA
CCTTCGCGCTGCG	
hOSM	AB	mO	rev	 AAGGCCCCGGGGCGCTCCCTGCACGCAGCGCGAAGGTCGGGGGT
GTTGAGGTTTTGCAG	
hOSM	G39N	fw	 ATATACGTATCCAAAACCTGGATGTTCC	
hOSM	G39N	rev	 GGAACATCCAGGTTTTGGATACGTATAT	
hOSM	V42T	fw	 TCCAAGGCCTGGATACTCCTAAACTGAGAG	
hOSM	V42T	rev	 CTCTCAGTTTAGGAGTATCCAGGCCTTGGA	
hOSM	K44D	fw	 GCCTGGATGTTCCTGATCTGAGAGAGCACT	
hOSM	K44D	rev	 AGTGCTCTCTCAGATCAGGAACATCCAGGC	
hOSM	39+42	fw	 AACCTGGATACTCCTAAACTGAGAGAGCACTGCA	
hOSM	39+42	rev	 GTATCCAGGTTTTGGATACGTATATAGGGGTCCA	
hOSM	39+44	fw	 AACCTGGATGTTCCTGATCTGAGAGAGCACTGCAGGGAGCG	
hOSM	39+44	rev	 ATCAGGAACATCCAGGTTTTGGATACGTATATAGGGGTCCA	
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hOSM	42+44	fw	 ACTCCTGATCTGAGAGAGCACTGCAGGGAGCG	
hOSM	42+44	rev	 ATCAGGAGTATCCAGGCCTTGGATACGTATAT	
hOSM	39+42+44	
fw	
AACCTGGATACTCCTGATCTGAGAGAGCACTGCAGGGAGCG	
hOSM	39+42+44	
rev	
ATCAGGAGTATCCAGGTTTTGGATACGTATATAGGGGTCCA	
Sequencing	primers	
T7	seq	fw	 TAATACGACTCACTATAGGG	
pCAGGS	seq	fw	 GCCTCTGCTAACCATGTTCATGC	
pCAGGS	seq	rev	 TCGATACCGTCGATCTCAGTGGTA	
pFLAG	seq	fw	 ACGCAAATGGGCGGTAGGCGTGT	
	
3.1.10.	Buffers	
	
Bis-Tris	buffer	(3.5x)	
1.25	M	bis-Tris,	pH	6.4	
	
DNA	loading	buffer	(6x)	
20mM	Tris,	pH	7.8	
20mM	acetic	acid	
1mM	EDTA	
50%	glycerol	
	
His-Tag	purification	binding	buffer	
50	mM	sodium	phosphate,	pH	7.4	
500	mM	NaCl	
10	mM	imidazole	
	
His-Tag	purification	elution	buffer	
50	mM	sodium	phosphate,	pH	7.4	
500	mM	NaCl	
250	mM	imidazole	
	
His-Tag	purification	wash	buffer	
50	mM	sodium	phosphate,	pH	7.4	
500	mM	NaCl	
20	mM	imidazole	
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Miniprep	solution	A	
25	mM	Tris,	pH	8.0	
10	mM	EDTA	
50	mM	D(+)-Glucose	
10	µg/mL	RNase	A	
	
Miniprep	solution	B	
0.2	N	NaOH	
1%	SDS	
	
Miniprep	solution	C	
3	M	potassium	acetate	
8.9%	acetic	acid	
	
KCM	buffer	(5x)	
0.5	M	KCl	
150	mM	CaCl2	
250	mM	MgCl2	
	
Phosphate-buffered	saline	(PBS)	
10	mM	Na2HPO4	
1.5	mM	KH2PO4	
137	mM	NaCl	
2.7	mM	KCl	
pH	adjusted	to	7.4	with	HCl	
	
Protease/phosphatase	inhibitor	mix	
500	μg/ml	benzamidin	
2	μg/ml	aprotinin	
2	μg/ml	leupeptin	
2	mM	PMSF	
1	mM	sodium	orthovanadate	
20	mM	sodium	fluoride	
	
Protein	extraction	buffer	
100	mM	Tris,	pH	8.8	
10	mM	EDTA	
40	mM	DTT	
10	%	SDS	
pH	adjusted	to	8.0	with	HCl	
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Protein	loading	buffer	(5x)	
66.7	mM	Tris,	pH	6.8	
2.2%	SDS	
27%	glycerol	
	
Protein	transfer	buffer	
25	mM	bis-Tris	
25	mM	bicine	
1	mM	EDTA	
20%	methanol	
	
Tris-Acetate-EDTA	(TAE)	buffer	
40mM	Tris,	pH	7.8	
40mM	acetic	acid	
2mM	EDTA	
	
Tris-buffered	saline	+	Tween-20	(TBS-T)	buffer	
20	mM	Tris	
136.9	mM	NaCl	
0.01%	Tween®	20	
pH	adjusted	to	7.6	with	HCl	
	
Tris-EDTA	(TE)	buffer	
10	mM	Tris,	pH	7.4	
1	mM	EDTA	
	
TSB	buffer	
5%	DMSO	
10	mM	MgCl2	
10	mM	MgSO4	
10%	polyethylene	glycol	6000	
dissolved	in	2xLB	broth	
	
Sonication	buffer	
50	mM	Tris,	pH	8.0	
500	mM	NaCl	
10	mM	imidazole	
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3.1.11.	Software	
	
Software	 Version	 Manufacturer	
ApE	-	A	plasmid	Editor	 2.0.47	 M.	Wayne	Davis	
Clustal	Omega	 1.2.2	
European	Molecular	
Biology	Laboratory	-	
European	Bioinformatics	
Institute	(EMBL-EBI)	
DNAWorks	 3.2.3	
National	Institutes	of	
Health	(NIH)	
Image	Lab	 5.0	build	18	 Bio-Rad®	
Image	Studio	 4.0.21	 LI-COR	Biosciences®	
MacPyMOL	 1.7.2.1	 Schrödinger	LLC®	
MetaPIGA	 3.100	
Đorđe	Grbić,	Michel	C.	
Milinkovitch	and	Raphaël	
Helaers	
QuikChange®	Primer	Design	
Program	
-	 Agilent®	
R	 3.0.3	
The	R	Foundation	for	
Statistical	Computing	
RStudio	 0.98.1062	 RStudio®	
SWISS-MODEL	 -	
Swiss	Institute	of	
Bioinformatics	
	
3.2.	Methods	
	
3.2.1.	Cell	line	culture	conditions	
	
Cell	 lines	 were	 cultured	 under	 37ºC	 and	 8%	 CO2	 in	 the	 recommended	 medium	
supplemented	with	10%	FBS:	A375	and	NIH3T3	cells	were	grown	in	DMEM	medium,	
HepG2	cells	in	DMEM/F12	medium,	JAR	cells	in	RPMI	1640	medium	and	FreeStyle™	
293-F	 cells	 in	 FreeStyle™	 293	 Expression	 Medium.	 DMEM,	 DMEM/F12	 and	 RPMI	
1640	mediums	were	additionally	supplemented	with	penicillin/streptomycin.	
	
Adherent	cell	lines	(A375,	NIH3T3,	HepG2	and	JAR)	were	grown	in	10	cm	cell	culture	
dishes	 and	 passaged	 at	 80-90%	 confluence.	 First	 the	 medium	 was	 aspirated,	 the	
plate	 was	 washed	 once	 with	 5	 mL	 of	 PBS	 buffer	 and	 5	 mL	 of	 a	 2xTrypsin-EDTA	
solution	diluted	in	PBS	was	added.	The	plate	was	incubated	for	5-10	minutes	at	37ºC	
until	 the	 cell	 layer	was	dispersed,	after	which	addition	of	5	mL	of	growth	medium	
stopped	 trypsin	digestion.	Cells	were	subsequently	pelleted	by	centrifugation	 for	5	
minutes	at	200	g,	followed	by	aspiration	of	the	supernatant,	resuspension	of	the	cell	
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pellet	in	fresh	growth	medium	and	plating	in	new	cell	culture	dishes/plates	at	a	1:4	
to	1:10	ratio.	
	
Cryopreservation	of	adherent	 lines	was	achieved	by	 resuspension	of	 the	cell	pellet	
after	trypsinization	in	FBS,	to	which	an	equal	volume	of	medium	supplemented	with	
20%	DMSO	was	slowly	added.	The	resulting	cell	solution	was	aliquoted	in	CryoTube™	
vials,	and	cooled	down	in	the	-80ºC	freezer	inside	a	Mr.	Frosty™	freezing	container.	
	
The	 suspension	 cell	 line	 FreeStyle™	293-F	was	 grown	 in	125	or	250	mL	disposable	
cell	culture	Erlenmeyer	flasks,	employing	a	CO2-resistant	incubator	at	150-160	rpm.	
Passage	of	these	cells	was	performed	upon	reaching	a	density	of	1	to	3x106	cells/mL,	
by	 dilution	 of	 the	 cells	 to	 0.1-0.2x106	 cells/mL	 in	 in	 fresh	medium	 pre-warmed	 to	
37ºC.	Anti-clumping	agent	was	added	to	the	medium	during	the	 first	 few	passages	
after	initially	thawing	the	cryostocks	to	prevent	clump	formation.	
	
Cryopreservation	of	the	FreeStyle™	293-F	was	achieved	in	cultures	at	1x106	cells/mL	
by	centrifugation	for	5	minutes	at	350	g.	The	supernatant	was	aspirated	and	the	cell	
pellet	resuspended	at	a	density	of	107	cells/mL	in	ice-cold	sterile-filtered	FreeStyle™	
293	Expression	Medium	supplemented	with	10%	DMSO.	1	mL	aliquots	were	placed	
into	CryoTube™	vials,	and	a	Mr.	Frosty™	freezing	container	was	used	to	slowly	cool	
down	the	cells	inside	the	-80ºC	freezer.	
	
3.2.2.	Cell	stimulation	assays	
	
Cell	 stimulation	was	performed	 in	6-well	 cell	 culture	plates	with	80-90%	confluent	
cells	 for	 10-minute	 stimulation	 assays,	 and	 50-60%	 confluent	 cells	 for	 24-hour	
stimulation	assays.	25	ng/mL	of	the	desired	cytokine	was	added	into	each	well,	after	
which	the	plate	was	incubated	at	37ºC	and	8%	CO2	for	the	specified	amount	of	time.	
	
The	medium	was	removed	after	stimulation,	wells	were	washed	once	with	PBS	and	
proteins	were	harvested	by	addition	of	100	µL	of	a	3:2	solution	of	protein	extraction	
buffer	 and	 protein	 loading	 buffer	 (5x)	 supplemented	 with	 protease/phosphatase	
inhibitors.	After	a	brief	sonication	(6-7	pulses	of	0.5	seconds	at	20%	power	using	a	
Sonopuls®	 HD	 2070	 ultrasonic	 homogenizer),	 2-5	 µL	 of	 the	 sample	 were	 used	 to	
measure	protein	concentration	with	the	DC™	Protein	Assay	and	a	FLUOstar®	Galaxy	
microplate	reader	following	the	manufacturer's	instructions.	
	
To	prepare	the	remainder	of	the	sample	for	protein	electrophoresis	DTT	was	added	
to	a	 final	concentration	of	0.04	M,	samples	were	boiled	at	99ºC	for	2	minutes	and	
diluted	to	a	concentration	of	1	µg/µL.	
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3.2.3.	Protein	electrophoresis	
	
Protein	electrophoresis	was	carried	out	with	either	10%	polyacrylamide	bis-Tris	gels	
polymerized	with	ammonium	persulfate	and	TEMED	or	17-well	NuPAGE™	4-12%	Bis-
Tris	 Protein	 Gels.	 SDS-polyacrylamide	 gel	 electrophoresis	 (SDS-PAGE)	 was	 then	
performed	in	XCell	SureLock™	Mini-Cells	with	NuPAGE™	MES	buffer.	2	µL	of	Protein	
Marker	VI	 or	 10	µg	of	 sample	protein	were	 loaded	 into	 the	wells,	 after	which	 the	
Mini-Cells	were	put	in	ice	and	connected	to	an	electrophoresis	power	supply.	
	
Protein	electrophoresis	was	performed	at	75V	for	the	initial	10	minutes,	after	which	
the	 voltage	 was	 increased	 to	 165V	 until	 reaching	 the	 desired	 separation.	 Once	
protein	electrophoresis	was	completed,	the	cassette	encasing	the	SDS-PAGE	gel	was	
removed	and	protein	detection	was	performed	through	western	blotting,	Coomassie	
blue	staining	or	silver	staining.	
	
3.2.4.	Western	blotting	
	
XCell	 II™	 Blot	Modules	were	 used	 to	 transfer	 the	 proteins	 from	 SDS-PAGE	 gels	 to	
Amersham™	Protran™	0.45	µm	NC	nitrocellulose	blotting	membranes.	The	gel	was	
placed	 in	 direct	 contact	 with	 a	 nitrocellulose	 membrane	 pre-soaked	 in	 protein	
transfer	buffer,	and	gel	and	membrane	were	sandwiched	by	pre-soaked	filter	paper	
and	blotting	sponges	inside	the	blotting	module.	
	
The	module	was	 inserted	into	an	XCell	SureLock™	Mini-Cell,	protein	transfer	buffer	
was	 added	 to	 the	 mini-cell's	 inside	 chamber	 and	 cold	 tap	 water	 to	 the	 outer	
chamber.	The	mini-cell	was	then	connected	to	an	electrophoresis	power	supply,	and	
protein	transfer	was	carried	out	for	2	hours	at	30V.	
	
After	 the	2	hours	had	passed,	membranes	were	 taken	out	of	 the	blotting	modules	
and	incubated	with	RedAlert™	Western	Blot	Stain	to	verify	the	protein	transfer	had	
been	 successful.	 In	 the	 cases	 in	 which	multiplexing	 was	 necessary	 the	membrane	
was	cut	 into	different	sections,	 in	accordance	to	 the	expected	molecular	weight	of	
the	proteins	 to	be	detected.	RedAlert™	 stain	was	 subsequently	 removed	by	a	 first	
incubation	with	distilled	water	followed	by	incubation	in	TBS-T	buffer;	these	and	all	
subsequent	steps	were	performed	under	gentle	shaking.	
	
Membranes	were	 then	 transferred	 to	 a	 solution	 of	 5%	 skim	milk	 powder	 in	 TBS-T	
and	 incubated	at	room	temperature	(RT)	 for	1	hour,	 in	order	to	prevent	unspecific	
protein	binding	 to	 the	membrane.	Afterwards	membranes	were	washed	 five	 times	
with	 TBS-T,	waiting	 for	 5	minutes	 at	 RT	 between	 each	wash.	 The	 desired	 primary	
antibody	 was	 diluted	 following	 the	 manufacturer's	 instructions	 into	 a	 solution	 of	
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either	 3%	 skim	 milk	 powder	 or	 3%	 BSA	 in	 TBS-T,	 added	 to	 the	 membrane	 and	
incubated	overnight	at	4ºC.	
	
On	the	following	day	the	antibody	solution	was	removed	and	the	membranes	were	
washed	 5	 times	 with	 TBS-T,	 followed	 by	 a	 1-hour	 incubation	 at	 RT	 with	 the	
corresponding	 secondary	 antibody	 in	 a	 solution	 of	 3%	 skim	milk	 powder	 in	 TBS-T.	
Removal	 of	 the	 secondary	 antibody	was	 followed	 by	 an	 additional	 5	 washes	with	
TBS-T.	Detection	was	performed	with	an	Odyssey®	9120	imaging	system	in	the	case	
of	 fluorescently	 labeled	 secondary	 antibodies,	 while	 horseradish	 peroxidase-
conjugated	secondary	antibody	detection	was	performed	using	SuperSignal™	West	
Femto	substrate	and	a	ChemiDoc™	MP	System.	
	
3.2.5.	Coomassie	blue	and	silver	staining	
	
Coomassie	blue	staining	to	visualize	total	protein	in	an	SDS-PAGE	gel	was	carried	out	
using	 InstantBlue™	 Coomassie®	 stain.	 After	 protein	 separation	 by	 electrophoresis	
the	gel	cassette	was	removed,	the	gel	was	transferred	to	the	InstantBlue™	solution	
and	 kept	 shaking	 for	 1	 hour	 at	 RT.	 Removal	 of	 the	 InstantBlue™	 solution	 was	
followed	by	3-5	washes	with	distilled	water,	after	which	the	gel	was	scanned	using	
the	ChemiDoc™	MP	System.	
	
Silver	staining	was	performed	with	the	SilverQuest™	Silver	Staining	Kit.	After	cassette	
removal	gels	were	incubated	in	the	kit's	fixing	solution	for	a	minimum	of	1	hour	in	a	
rocking	platform,	then	transferred	first	to	the	sensitizing	solution	for	30	minutes	and	
washed	3	times	with	distilled	water.	The	silver	solution	was	added	and	incubated	for	
20	minutes,	after	which	the	gel	was	washed	briefly	and	 incubated	with	developing	
solution.	Once	the	bands	reached	the	desired	intensity	the	gel	was	transferred	to	the	
stopping	 solution	 and	 kept	 shaking	 for	 10	 minutes,	 after	 which	 it	 was	 washed	 3	
additional	times	with	distilled	water	and	scanned	with	the	ChemiDoc™	MP	System.	
	
3.2.6.	Cell	proliferation	assays	
	
Cell	proliferation	assays	were	performed	in	96-well	cell	culture	plates,	in	which	A375	
cells	were	seeded	at	a	density	of	5000	cells/well	 in	DMEM	medium	without	phenol	
red,	stimulated	with	10	ng/mL	of	the	desired	cytokine	and	grown	for	5	days	before	
performing	an	MTT	proliferation	assay	following	the	manufacturer's	instructions.	
	
Briefly,	the	medium	was	changed	and	MTT	reagent	was	added	to	the	wells.	After	an	
incubation	of	4	hours	at	37ºC	degrees,	a	10%	SDS	solution	in	0.01	M	HCl	was	added	
and	 incubated	overnight	 at	 37ºC	and	8%	CO2,	 after	which	 the	absorbance	of	 each	
sample	at	570	nm	was	measured	by	a	FLUOstar®	Galaxy	microplate	reader.	
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3.2.7.	DNA	electrophoresis	
	
To	 cast	 an	 agarose	 gel	 for	 DNA	 electrophoresis,	 1%	 agarose	 was	 added	 into	 TAE	
buffer	 and	 the	 mixture	 was	 heated	 in	 a	 microwave	 oven	 until	 the	 agarose	 was	
completely	dissolved.	Once	it	had	cooled	down	to	55ºC	a	small	amount	(4	µL	per	100	
mL	of	solution)	of	1%	ethidium	bromide	was	mixed	in,	and	the	resulting	solution	was	
poured	 into	a	horizontal	electrophoresis	 chamber	with	appropriate	 combs	 to	 form	
the	desired	wells.	
	
After	solidification	of	the	solution	into	a	gel	the	combs	were	removed,	the	chamber	
was	 filled	with	 TAE	 buffer	 and	 the	 DNA	was	 loaded	 into	 the	wells	 along	with	 the	
appropriate	 GeneRuler	 DNA	 ladder.	 The	 chamber	 was	 then	 connected	 to	 an	
electrophoresis	power	supply,	and	electrophoresis	was	carried	out	for	20-30	minutes	
at	 100-160V	 depending	 on	 the	 size	 of	 the	 gel	 and	 of	 the	 DNA	 bands	 of	 interest.	
Afterwards	DNA	bands	were	visualized	employing	an	UV	transilluminator.	
	
3.2.8.	Standard	molecular	cloning	
	
Genes	 selected	 for	 recombinant	 protein	 expression	 in	E.	 coli	were	 cloned	 into	 the	
pET-26b(+)	 vector,	 while	 expression	 in	 mammalian	 cells	 was	 achieved	 via	 the	
pCAGGS	vector.	Primers	complementary	to	the	5'	and	3'	ends	of	 the	gene's	coding	
region	and	including	specific	restriction	enzyme	sites	were	designed	and	purchased	
from	Sigma-Aldrich®.	
	
Amplification	 of	 the	 gene	 of	 interest	 by	 polymerase	 chain	 reaction	 (PCR)	 was	
performed	by	following	the	manufacturer's	instructions:	for	a	25	µL	reaction	mixture	
Phusion	HF	buffer	was	supplemented	with	0.5	µM	of	 the	desired	primers,	200	µM	
dNTPs,	3%	DMSO,	0.5	units	of	Phusion	Hot	Start	II	DNA	Polymerase	and	either	1-5	ng	
of	plasmid	DNA	or	2.5	µL	of	cDNA	as	template.	
	
After	carefully	mixing	the	different	reagents	 in	 ice,	the	tubes	were	transferred	to	a	
thermocycler	in	which	the	PCR	reaction	was	performed.	An	initial	denaturation	step	
(98ºC,	30	seconds)	was	followed	by	23-25	cycles	of	denaturation	(98ºC,	10	seconds),	
annealing	(68ºC,	25	seconds)	and	extension	(72ºC,	30	seconds/kilobase),	after	which	
a	final	extension	step	(72ºC,	5	minutes)	concluded	the	amplification.	
	
The	resulting	PCR	product	was	supplemented	with	5	µL	of	DNA	 loading	buffer	and	
subjected	to	DNA	electrophoresis,	after	which	the	band	corresponding	to	the	gene	
of	interest	was	excised	using	a	disposable	scalpel	and	purified	using	the	NucleoSpin®	
Gel	and	PCR	clean-up	kit	according	to	the	manufacturer's	instructions.	
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After	 purification	 the	 PCR	 products	 were	 eluted	 in	 30	 µL	 of	 distilled	 water	 and	
subjected	to	restriction	enzyme	digestion.	1	µL	of	the	selected	restriction	enzymes,	
able	to	recognize	and	cut	restriction	sites	in	the	sequence	of	the	employed	primers,	
was	mixed	with	their	recommended	buffer	and	the	purified	DNA	in	a	total	volume	of	
50	µL,	and	incubated	for	4	hours	at	37ºC.	In	parallel,	1	µg	of	the	desired	plasmid	was	
subjected	to	restriction	enzyme	digestion	with	identical	enzymes	and	conditions.	
	
After	4	hours,	10	µL	of	DNA	loading	buffer	was	added	to	the	digestion	mixture	and	
DNA	electrophoresis	was	performed.	The	bands	corresponding	to	the	vector	and	the	
gene	of	interest	were	excised	and	purified	using	the	NucleoSpin®	Gel	and	PCR	clean-
up	kit,	and	eluted	in	20-30	µL	of	distilled	water.	DNA	concentration	of	these	samples	
was	 measured	 by	 a	 NanoDrop	 2000c	 UV-Vis	 spectrophotometer,	 and	 ligation	
reactions	were	performed	with	a	3:1	molar	 ratio	between	 the	gene	 to	be	 inserted	
and	the	vector.	
	
For	 the	 ligation,	 40	 ng	 of	 vector	 and	 the	 corresponding	 amount	 of	 insert	 were	
diluted	in	distilled	water,	and	2	µL	of	T4	DNA	ligase	and	ligase	buffer	were	added	for	
a	total	volume	of	20	µL.	This	ligation	mixture	was	then	incubated	overnight	at	16ºC	
before	being	transformed	into	chemically	competent	XL-1	Blue	E.	coli.	
	
3.2.9.	Molecular	cloning	by	gene	synthesis	
	
Codon-optimization	of	the	amino	acid	sequence	of	the	genes	to	be	cloned	and	the	
design	 of	 the	 overlapping	 oligonucleotides	 covering	 the	 optimized	 gene	 sequence	
was	done	with	DNAWorks.	 (Hoover	&	 Lubkowski	 2002)	Default	 options	were	used	
except	 in	 two	 cases:	 the	 first	 concerned	 the	 selection	 of	 the	 option	 'no	 gaps	 in	
assembly',	which	 facilitates	 the	generation	of	 subsequent	mutants	 reusing	most	of	
the	original	set	of	oligonucleotides.	Additionally,	 the	planned	restriction	sites	to	be	
used	in	the	cloning	procedure	were	excluded	from	the	protein-coding	region	of	the	
synthetic	gene.	Oligonucleotides	were	acquired	from	Sigma-Aldrich®.	
	
Assembly	of	the	synthetic	genes	required	a	nested	PCR	protocol.	(Varadarajan	et	al.	
2009)	 In	 the	 first	 PCR	 amplification	 procedure,	 50	 µL	 of	 Phusion	 HF	 buffer	 was	
supplemented	with	2	pM	of	each	of	 the	designed	oligonucleotides,	200	µM	dNTPs	
and	 1	 unit	 of	 Phusion	 Hot	 Start	 II	 DNA	 Polymerase.	 The	 oligonucleotides	 were	
assembled	 in	 a	 thermocycler	 by	 means	 of	 an	 initial	 denaturation	 step	 (95ºC,	 2	
minutes)	followed	by	40	cycles	of	denaturation	(95ºC,	30	seconds),	annealing	(52ºC,	
30	seconds)	and	extension	(72ºC,	30	seconds).	
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The	product	of	this	first	reaction	was	directly	used	as	DNA	template	in	a	second	PCR	
amplification	step,	in	which	1	µM	of	the	outermost	forward	and	reverse	primers,	200	
µM	dNTPs	and	1	unit	of	Phusion	Hot	Start	II	DNA	Polymerase	was	added	to	50	µL	of	
Phusion	HF	buffer.	 The	PCR	 conditions	were	 similar	 to	 the	 first,	 but	 the	 annealing	
temperature	was	increased	to	58ºC,	the	number	of	cycles	was	reduced	to	30	and	a	
final	extension	step	(72ºC,	5	minutes)	was	included.	
	
The	result	of	the	second	PCR	amplification	was	a	single	band	that	could	be	separated	
by	DNA	electrophoresis,	purified,	digested	with	restriction	enzymes	and	ligated	into	
a	vector	by	following	the	procedure	detailed	in	section	3.2.8.	
	
3.2.10.	Molecular	cloning	by	overlap	extension	PCR	
	
Chimeric	cytokines	were	generated	by	overlap	extension	PCR,	employing	 the	same	
general	procedures	detailed	in	section	3.2.8.	In	a	first	PCR	amplification	step,	primers	
complementary	to	the	sequences	to	be	joined	were	designed	so	that	the	amplified	
fragments	would	have	an	overlapping	30	base	pair	sequence	covering	the	chimeric	
region.	
	
These	PCR	products	were	purified	and	used	together	as	DNA	templates	in	a	second	
PCR	reaction,	along	with	the	primers	corresponding	to	the	5'	and	3'	ends	of	the	full	
cytokine	 sequence.	 The	 resulting	 full-length	 product	 was	 purified,	 subjected	 to	
restriction	enzyme	digestion	and	ligated	into	the	vector	of	interest.	
	
3.2.11.	Site-directed	mutagenesis	
	
Point	mutants	were	 created	by	different	 procedures,	 including	 gene	 synthesis	 and	
overlap	extension	PCR,	but	most	of	the	variants	used	in	this	work	were	generated	by	
site-directed	mutagenesis.	 Overlapping	 forward	 and	 reverse	 primers	 including	 the	
desired	mutation	were	generated	with	the	QuikChange®	Primer	Design	Program	and	
used	to	amplify	a	template	vector	containing	the	gene	to	be	mutated.	
	
Full-length	 plasmid	 amplification	 was	 achieved	 by	 PCR	 reaction,	 using	 a	 25	 µL	
mixture	 containing	 PfuUltra	 buffer,	 0.25	 µM	 of	 each	 primer,	 200	 µM	 dNTPs,	 1.25	
units	of	PfuUltra	High	Fidelity	DNA	Polymerase	and	20	ng	of	template	plasmid	DNA.	
The	reaction	conditions	involved	a	first	denaturation	step	(95ºC,	1	minute)	followed	
by	30	cycles	of	denaturation	 (95ºC,	30	 seconds),	annealing	 (68ºC,	30	 seconds)	and	
extension	 (72ºC,	 1	 minute/kilobase),	 as	 well	 as	 a	 final	 extension	 step	 (72ºC,	 10	
minutes).	
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The	resulting	PCR	product	was	purified	by	addition	of	400	µL	 isopropanol,	80	µL	of	
distilled	water	and	100	µL	of	ammonium	acetate	4M	to	20	µL	of	 the	PCR	mixture.	
After	a	15-minute	 incubation	at	RT	 the	 solution	was	centrifuged	 for	15	minutes	at	
21000	g	and	the	supernatant	was	discarded.	The	pellet	was	washed	with	500	µL	of	
70%	 ethanol	 and	 centrifuged	 again	 (10	 minutes,	 21000	 g),	 the	 supernatant	 was	
discarded	 and	 the	 pellet	 was	 allowed	 to	 dry	 for	 10-15	 minutes	 to	 remove	 any	
residual	ethanol.	
	
The	pellet	was	then	resuspended	in	water	and	digested	with	DpnI	for	4	hours	at	37ºC	
in	 order	 to	 remove	 the	original	 plasmid	 employed	 as	DNA	 template.	 Since	DpnI	 is	
only	 able	 to	 cut	methylated	DNA	 the	 template	 vector	 isolated	 from	E.	 coli	will	 be	
degraded,	while	 the	unmethylated	PCR	product	will	not	be	affected.	After	4	hours	
the	digestion	mixture	can	be	directly	used	to	transform	chemically	competent	XL-1	
Blue	 E.	 coli,	 since	 the	 PCR	 product	 generated	 is	 able	 to	 re-circularize	 and	 form	 a	
doubly	nicked	plasmid	that	can	be	transformed	into	the	bacteria.	
	
3.2.12.	Generation	of	chemically	competent	E.	coli	
	
In	order	to	generate	chemically	competent	bacteria	 for	 transformation,	1	mL	of	LB	
broth	without	 antibiotics	was	 first	 inoculated	with	 10	µL	 of	 XL1	Blue	E.	 coli	 under	
sterile	conditions.	After	incubation	for	1	hour	at	37ºC	and	700-800	rpm,	50-100	µL	of	
the	 solution	 was	 plated	 into	 an	 LB-Agar	 plate	 without	 antibiotics	 and	 allowed	 to	
grow	overnight	in	a	bacterial	incubator	at	37ºC.	
	
The	 following	 day	 5	mL	 of	 LB	 broth	were	 inoculated	with	 a	 single	 clone	 from	 the	
plate	 under	 sterile	 conditions,	 and	 kept	 overnight	 in	 a	 bacterial	 incubator	 at	 37ºC	
shaking	at	180-200	rpm.	This	starter	culture	was	then	used	to	inoculate	100	mL	of	LB	
broth,	which	was	incubated	shaking	at	37ºC	until	its	optical	density	measurement	at	
600	nm	(OD600)	reached	a	value	of	0.5-0.6.	
	
The	culture	was	harvested	by	centrifugation	for	15	minutes	at	2500	g	and	4ºC	and	
the	supernatant	was	discarded.	The	bacterial	pellet	was	immediately	resuspended	in	
7.5	mL	of	TSB	buffer	and	incubated	for	1	hour	on	ice,	after	which	the	cell	suspension	
was	aliquoted,	frozen	in	liquid	nitrogen	and	stored	at	-80ºC.	
	
3.2.13.	Chemical	Transformation	of	competent	E.	coli	
	
50	µL	of	transformation	mixture	was	made	up	with	5	µL	of	the	ligation	product	from	
the	molecular	cloning	protocol	in	KCM	buffer,	or	20-100	ng	of	purified	DNA	plasmid.	
An	aliquot	of	chemically	competent	XL1	Blue	E.	coli	was	allowed	to	thaw	in	ice,	50	µL	
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were	added	to	the	transformation	mixture	and	the	resulting	solution	was	incubated	
on	ice	for	10	minutes,	followed	by	a	20-minute	incubation	at	RT.	
	
Afterwards	1	mL	of	LB	broth	without	antibiotics	pre-warmed	to	37ºC	was	added,	and	
the	 sample	 was	 incubated	 for	 60-90	minutes	 at	 37ºC	 and	 700-800	 rpm.	 Bacterial	
cells	were	pelleted	by	centrifugation	for	1	minute	at	2000	g,	1	mL	of	supernatant	was	
discarded	and	the	pellet	was	resuspended	in	the	remaining	solution.	Samples	were	
then	 plated	 on	 LB-Agar	 plates	 supplemented	 with	 appropriate	 antibiotics,	 and	
incubated	overnight	at	37ºC.	
	
3.2.14.	Plasmid	DNA	isolation	and	purification	
	
Plasmid	 DNA	was	 amplified	 in	 transformed	 XL1	 Blue	 E.	 coli.	 For	 the	 isolation	 of	 a	
small	amount	of	plasmid	DNA	after	molecular	cloning	(miniprep),	3	mL	of	LB	broth	
with	 the	 adequate	 selection	 antibiotic	was	 inoculated	with	 a	 single	 colony	 from	 a	
plate	of	transformed	E.	coli	and	incubated	overnight	at	37ºC	and	180-220	rpm.	
	
On	 the	 following	 day,	 bacteria	 were	 pelleted	 by	 centrifugation	 of	 2	 mL	 of	 the	
overnight	culture	for	5	minutes	at	21000	g.	The	supernatant	was	discarded	and	the	
pellet	resuspended	in	150	µL	of	miniprep	solution	A,	after	which	200	µL	of	miniprep	
solution	B	was	added	to	lysate	the	bacteria	for	10	minutes	at	RT.	The	lysis	reaction	
was	stopped	and	the	proteins	and	genomic	DNA	were	precipitated	by	adding	175	µL	
of	miniprep	solution	C	and	incubating	for	10	minutes	on	ice.	
	
This	step	was	followed	by	centrifugation	at	21000	g	and	4ºC	for	15	minutes	to	pellet	
the	 genomic	 DNA.	 The	 supernatant	 containing	 plasmid	 DNA	 was	 transferred	 to	
another	 tube	 containing	 500	 µL	 of	 isopropanol	 and	 subsequently	 precipitated	 by	
centrifugation	at	21000	g	and	4ºC	for	20	minutes.	After	washing	the	pellet	with	500	
µL	 of	 70%	 ethanol	 by	 centrifugation	 at	 21000	 g	 and	 4ºC	 for	 10	 minutes,	 the	
supernatant	was	decanted	and	 the	pellet	was	allowed	 to	dry	 for	10-15	minutes	 to	
remove	 residual	 ethanol.	 Finally,	 the	 pellet	was	 resuspended	 in	 TE	 buffer	 and	 the	
plasmid	 DNA	 was	 verified	 by	 DNA	 sequencing	 (performed	 by	 Seqlab	 Sequence	
Laboratories	Göttingen)	and/or	restriction	enzyme	digestion.	
	
For	 the	 isolation	 of	 large	 amounts	 of	 plasmid	 DNA	 after	 plasmid	 verification,	 the	
NucleoBond®	Xtra	Maxi	kit	was	used	according	to	the	manufacturer's	instructions.	A	
starter	culture	of	3	mL	of	LB	broth	supplemented	with	the	selection	antibiotic	was	
inoculated	with	 a	 single	 colony	 and	 grown	 for	 8	 hours	 at	 37ºC	 and	 180-220	 rpm,	
after	 which	 a	 larger	 culture	 of	 300	mL	 of	 LB	 broth	with	 antibiotic	 was	 inoculated	
1:1000	with	the	starter	culture	and	grown	overnight	at	37ºC	and	180-220	rpm.	
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On	the	following	day	the	bacteria	were	pelleted	by	centrifugation	at	5000	g	and	4ºC	
for	10	minutes,	resuspended	in	the	kit's	re-suspension	buffer	and	lysed	for	5	minutes	
by	addition	of	lysis	buffer.	Protein	and	chromosomal	DNA	was	precipitated	with	the	
neutralization	buffer,	after	which	the	lysate	was	loaded	into	previously	equilibrated	
NucleoBond®	Xtra	Maxi	columns	with	filters.	
	
The	columns	were	then	washed	first	with	the	kit's	equilibration	buffer,	the	filter	was	
removed	and	a	second	wash	was	performed	with	wash	buffer,	followed	by	elution	of	
plasmid	 DNA	with	 elution	 buffer.	 Isopropanol	 was	 added	 at	 RT	 to	 precipitate	 the	
eluted	plasmid	DNA,	which	was	then	pelleted	by	centrifugation	at	10000	g	and	4ºC	
for	30	minutes.	The	supernatant	was	discarded	and	the	pellet	washed	with	RT	70%	
ethanol	and	centrifuged	at	5000	g	for	5	minutes.	
	
Finally	 the	 ethanol	 was	 discarded	 and	 the	 pellet	 was	 allowed	 to	 dry	 at	 room	
temperature	 for	 15	minutes,	 before	 re-suspension	 in	 300	µL	 of	 TE	 buffer.	 Plasmid	
DNA	 concentration	 was	 measured	 with	 a	 NanoDrop	 2000c	 UV-Vis	
spectrophotometer	and	verified	by	DNA	sequencing	(Seqlab	Sequence	Laboratories	
Göttingen).	
	
3.2.15.	RNA	isolation	and	purification	
	
3	 mL	 of	 TriFast™	 was	 added	 to	 a	 10	 cm	 cell	 culture	 dish	 of	 80-90%	 confluent	
monolayer	cells,	the	cells	were	harvested	with	the	help	of	a	pipette	and	incubated	at	
RT	 for	 5	 minutes.	 The	 solution	 was	 supplemented	 with	 600	 µL	 of	 chloroform,	
vortexed	for	15	seconds,	 incubated	at	RT	for	3	minutes	and	centrifuged	at	12000	g	
and	4ºC	for	20	minutes.	
	
The	upper	aqueous	fresh	was	recovered	after	centrifugation,	500	µL	of	isopropanol	
was	 added	 and	 incubated	 at	 RT	 for	 10	minutes,	 after	which	 it	was	 centrifuged	 at	
12000	g	and	4ºC	for	15	minutes	to	enable	RNA	precipitation.	The	supernatant	was	
discarded	 and	 the	 pellet	 washed	 twice	 with	 1	 mL	 of	 75%	 ethanol	 (in	 0.1%	 DEPC	
water)	by	centrifugation	at	7500	g	and	4	ºC	for	5	minutes.	
	
Finally,	the	supernatant	was	discarded	and	the	pellet	allowed	to	dry	for	5-10	minutes	
before	re-suspension	in	RNAse-free	water	(Aqua	B.	Braun).	Optimal	re-suspension	of	
the	RNA	was	ensured	by	an	 incubation	at	56ºC	and	850	 rpm	 for	10	minutes,	after	
which	 the	 RNA	 concentration	 was	 measured	 with	 a	 NanoDrop	 2000c	 UV-Vis	
spectrophotometer.	
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3.2.16.	Reverse	Transcription	PCR	
	
Purified	RNA	was	employed	for	complementary	DNA	(cDNA)	synthesis	using	random	
primers:	1	µg	of	the	RNA	to	be	retro-transcribed,	along	with	1	µL	of	RQ1	DNase	and	
0.1	µL	of	RNasin	plus	in	10	µL	of	RQ1	DNase	reaction	buffer,	were	incubated	at	37ºC	
for	30	minutes	to	degrade	any	DNA	remnants.	
	
1	µL	of	25	mM	EDTA	was	then	added,	the	sample	was	heated	to	65ºC	and	incubated	
for	10	minutes	before	addition	of	0.5	µL	random	primers	and	1	µL	of	10	mM	dNTPs.	
After	5	more	minutes	of	incubation	at	65ºC	the	solution	was	cooled	down	on	ice,	4	
µL	of	Superscript®	II	buffer	and	2	µL	of	0.1M	DTT	were	supplemented	and	a	2-minute	
incubation	at	25ºC	was	performed.	
	
Immediately	after	 this	step	1	µL	of	Superscript®	 II	 reverse	transcriptase	was	added	
and	the	mixture	was	incubated	at	25ºC	for	an	additional	10	minutes,	followed	by	an	
incubation	at	42ºC	for	50	minutes	and	a	final	 incubation	at	70ºC	for	15	minutes	to	
inactivate	 the	 reverse	 transcriptase.	 Distilled	 water	 was	 added	 to	 make	 the	 final	
volume	50	µL,	in	order	to	obtain	a	20	ng/µL	cDNA	solution.	
	
3.2.17.	Soluble	recombinant	protein	expression	in	a	prokaryotic	system	
	
A	pET-26b(+)	plasmid	containing	the	gene	to	be	expressed	followed	by	a	C-terminal	
hexahistidine	tag	(His-tag)	was	transformed	in	SHuffle®	T7	Express	competent	E.	coli	
following	 the	 general	 protocol	 detailed	 in	 section	 3.2.13,	 except	 for	 the	 final	
incubation	being	performed	at	30ºC	instead	of	37ºC,	plated	in	LB-agar	plates	with	50	
µg/mL	of	kanamycin	and	incubated	overnight	at	30ºC.	
	
A	single	colony	from	the	plate	was	then	used	to	inoculate	a	starter	culture	of	3	mL	of	
LB	broth	with	kanamycin,	which	was	grown	overnight	at	30ºC	and	180-220	rpm.	On	
the	 following	 day	 the	 starter	 culture	 was	 diluted	 into	 200	 mL	 of	 LB	 broth	 with	
kanamycin,	 and	 the	 resulting	 solution	 incubated	 at	 30ºC	 and	 180-220	 rpm	 until	
reaching	an	OD600	value	of	0.5-0.7.	
	
At	 this	 point	 the	 culture	 was	 supplemented	 with	 0.1	 mM	 of	 IPTG	 to	 induce	
recombinant	 protein	 expression	 and	 allowed	 to	 grow	 for	 an	 additional	 4-6	 hours.	
Finally,	the	bacterial	cells	were	harvested	by	centrifugation	at	5000	g	and	4ºC	for	10-
15	minutes,	 at	which	 point	 the	 pellets	 could	 either	 be	 stored	 at	 -20ºC	 for	 several	
days	or	immediately	processed.	
	
In	order	to	release	the	produced	recombinant	protein	from	the	bacterial	cytoplasm,	
cell	pellets	were	resuspended	in	9	mL	of	cold	sonication	buffer	and	a	first	lysis	step	
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was	performed	by	incubation	for	30	minutes	on	ice	with	1	mg/mL	of	lysozyme	along	
with	a	protease	inhibitor	(1	mM	PMSF).	
	
Afterwards	 the	 bacterial	 cell	 wall	 was	 thoroughly	 ruptured	 by	 10	 rounds	 of	 30	
seconds	of	sonication	on	ice,	interspersed	with	30	second	breaks	to	avoid	excessive	
heating	of	the	samples.	1	mM	MgCl2	and	0.1	mg/mL	DNase	I	were	then	added	to	the	
sample	to	degrade	bacterial	and	plasmid	DNA,	and	the	solution	was	centrifuged	at	
21000	 g	 and	 4ºC	 for	 30-40	 minutes	 to	 separate	 the	 insoluble	 fraction.	 The	
supernatant	 containing	 the	 soluble	 recombinant	 protein	 of	 interest	 was	 then	
collected	and	purified	by	using	the	protocol	detailed	in	section	3.2.20.	
	
3.2.18.	Soluble	recombinant	protein	expression	in	a	mammalian	system	
	
A	 pcDNA	 3.1(+),	 pFLAG-CMV-3	 or	 pCAGGS	 plasmid	 containing	 the	 gene	 to	 be	
expressed	followed	by	a	C-terminal	hexahistidine	tag	(His-tag)	was	transfected	 into	
FreeStyle™	293-F	cells	at	a	density	of	106	cells/mL	according	to	the	manufacturer's	
instructions.	First,	purified	plasmids	were	diluted	to	a	concentration	of	1	µg/mL	and	
filter-sterilized	with	a	0.22	µm	filter.	
	
To	transfect	a	30	mL	flask	of	293-F	cells,	37.5	µL	of	plasmid	per	mL	was	diluted	into	
0.6	mL	 of	OptiPro™	 SFM	kept	 at	 RT	 in	 a	 sterile	 tube	 and	mixed	 by	 inversion.	 In	 a	
second	 tube	 37.5	 µL	 of	 FreeStyle™	 MAX	 Reagent	 was	 also	 diluted	 in	 0.6	 mL	 of	
OptiPro™	SFM	at	RT	and	mixed	by	inversion.	
	
Immediately	 afterwards	 the	 OptiPro™	 SFM	 medium	 with	 the	 MAX	 reagent	 was	
added	 to	 the	 medium	 with	 the	 plasmid,	 mixed	 by	 inversion	 15-20	 times	 and	
incubated	for	10-20	minutes	at	RT.	Finally,	the	medium	was	added	dropwise	to	the	
cell	culture	flask	while	gently	swirling	the	flask,	and	the	cells	were	allowed	to	grow	
under	normal	culturing	conditions	for	an	additional	3	to	7	days.	
	
After	the	desired	amount	of	time,	the	cell	solutions	were	centrifuged	at	4000	g	and	
4ºC	 for	15	minutes	 to	pellet	cells	and	 insoluble	debris.	The	supernatant	containing	
the	 soluble	 recombinant	 protein	 was	 collected,	 supplemented	with	 300	mM	NaCl	
and	10	mM	imidazole	and	used	for	his-tagged	protein	purification	according	to	the	
procedure	in	section	3.2.20.	
	
3.2.19.	His-tagged	protein	purification	
	
All	 purification	 steps	 were	 performed	 at	 4ºC.	 0.75-1	 mL	 of	 HIS-Select®	 HF	 nickel	
affinity	gel	slurry,	containing	nickel-nitrilotriacetic	acid	(Ni-NTA)	chelate	groups	able	
to	bind	 to	histidine	 residues,	was	 transferred	 to	a	5	mL	polypropylene	column.	An	
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initial	wash	by	gravity	flow	with	2	column	volumes	of	distilled	water	was	performed	
to	remove	the	ethanol	in	which	the	gel	is	preserved,	followed	by	3	column	volumes	
of	His-tag	purification	binding	buffer	to	equilibrate	the	affinity	gel.	
	
The	 column	 was	 then	 capped	 and	 supernatant	 containing	 C-terminal	 his-tagged	
recombinant	 proteins	 added.	 An	 incubation	 step	 at	 4ºC	 in	 an	 end-over-end	 tube	
rotator	for	20-30	minutes	was	carried	out	in	order	to	allow	the	recombinant	protein	
to	bind	to	the	affinity	gel,	after	which	the	column	was	placed	vertically	and	the	gel	
became	packed	again	at	the	bottom.	
	
The	next	step	comprised	uncapping	the	column	and	discarding	the	flow	through	by	
gravity	 flow,	 followed	 by	 washing	 with	 10	 column	 volumes	 of	 His-tag	 purification	
wash	buffer.	To	elute	the	recombinant	protein	from	the	affinity	gel,	the	column	was	
capped	 and	 1	 mL	 of	 His-tag	 purification	 elution	 buffer	 added.	 After	 a	 10-minute	
incubation	 the	 cap	was	 removed,	 the	 buffer	 collected	 and	 the	 elution	 repeated	 3	
additional	times.	
	
Finally,	 the	 eluted	 product	 was	 concentrated	 in	 centrifugal	 filters	 with	 a	 10	 kDa	
molecular	 weight	 cutoff	 by	 centrifugation	 at	 4000g	 and	 4ºC	 for	 30	 minutes,	 and	
collected	in	PBS	buffer	before	measuring	protein	concentration	and	assessing	purity.	
	
3.2.20.	siRNA	transfection	
	
A	 reverse	 transfection	 protocol	 was	 employed	 according	 to	 the	 manufacturer's	
instructions.	500	µL	of	OptiMEM®	medium	was	added	to	each	well	of	a	6-well	 cell	
culture	plate,	supplemented	with	7.5	µL	of	the	desired	siRNA	20	µM	stock	and	7.5	µL	
of	Lipofectamine®	RNAiMAX	and	incubated	for	10-20	minutes	at	RT.	
	
Immediately	 after	 this	 step,	 2.5x105	 cells	 resuspended	 in	 2.5	mL	 of	 antibiotic-free	
growth	medium	supplemented	with	10%	FCS	were	added	to	each	well	and	incubated	
overnight	under	37ºC	and	5-8%	CO2	 conditions.	On	 the	 following	day	 the	medium	
was	exchanged	to	growth	medium	with	antibiotics	and	FCS,	and	cells	were	allowed	
to	 grow	 for	 an	 additional	 24-48	 hours	 before	 performing	 the	 desired	 stimulation	
assays.	
	
3.2.21.	Deglycosylation	assay	
	
Deglycosylation	 assays	 were	 performed	 using	 the	 Protein	 Deglycosylation	 Mix	 kit	
under	 denaturing	 reaction	 conditions.	 18	 µL	 of	 recombinant	 protein	 in	 PBS	 was	
supplemented	with	2	µL	of	 the	glycoprotein	denaturing	buffer	provided	 in	 the	 kit,	
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denatured	by	heating	at	100ºC	for	10	minutes,	chilled	on	ice	and	centrifuged	for	10	
seconds.	
	
5	 µL	 of	 glycobuffer	 2,	 5	 µL	 of	 10%	 NP-40	 and	 15	 µL	 of	 distilled	 water	 were	 then	
added	 to	 the	 solution,	 followed	 by	 5	 µL	 of	 deglycosylation	 enzyme	 cocktail.	 The	
reaction	was	incubated	at	37ºC	overnight,	and	samples	were	subjected	to	SDS-PAGE	
and	western	blotting.	
	
3.2.22.	Statistical	analysis	
	
Statistical	analysis	was	performed	and	graphical	 representations	were	created	 in	R	
and	Rstudio.	The	existence	of	statistically	significant	differences	between	groups	was	
assessed	through	a	two-tailed	Welch's	T-test,	considering	p-values	below	0.05	to	be	
significant.	 Welch's	 T-test	 is	 a	 variant	 of	 Student's	 T-test	 recommended	 for	 small	
sample	 sizes	 and/or	 unequal	 group	 variances;	 as	 is	 the	 case	 for	 other	 parametric	
tests,	 it	 is	 relatively	 insensitive	 to	 deviations	 from	 normality.	 (McDonald	 2014)	
Graphical	representation	of	the	data	is	based	on	the	mean	value	of	the	group,	with	
error	bars	corresponding	to	the	standard	error	of	the	mean	(s.e.m.).	
	
3.2.23.	Structural	modeling	and	visualization	
	
Visualization	 of	 protein	 structures	 was	 carried	 out	 with	 MacPyMOL.	 Structures	
derived	from	crystallization	data	were	employed	for	human	OSM	(Protein	Data	Bank	
ID:	1EVS)	and	human	LIF	(Protein	Data	Bank	ID:	2Q7N).	(Deller	et	al.	2000)	(Huyton	et	
al.	2007)	A	homology	model	for	mouse	OSM	based	on	the	available	human	structure	
was	generated	with	SWISS-MODEL.	(Biasini	et	al.	2014)	
	
3.2.24.	Phylogeny	inference	
	
Protein	sequences	were	retrieved	 from	the	Reference	Sequence	 (RefSeq)	database	
of	NCBI	and	aligned	by	Clustal	Omega.	(Maglott	et	al.	2000)	(Sievers	et	al.	2011)	The	
aligned	 protein	 sequences	 were	 then	 used	 to	 construct	 a	 phylogenetic	 tree	 by	
stochastic	 heuristics,	 applying	 the	 metapopulation	 genetic	 algorithm	 (metaGA)	
implemented	 in	MetaPIGA.	 (Lemmon	&	Milinkovitch	2002)	 (Helaers	&	Milinkovitch	
2010)	
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4.	Results	
	
4.1.	Structural	determinants	of	human	Oncostatin	M	activity	
	
4.1.1.	Readout	systems	to	assess	human	receptor	complex	activation	
	
The	 first	 step	 in	 order	 to	 study	 receptor	 complex	 activation	 required	 establishing	
reliable	systems	to	monitor	this	event.	Unfortunately,	there	are	no	tools	available	to	
track	 activation	 of	 these	 receptors	 directly,	 such	 as	 antibodies	 specifically	 raised	
against	the	phosphorylated	forms	of	OSMR	and	LIFR.	
	
As	a	result,	studies	on	OSM	signaling	have	had	to	rely	on	indirect	measurements	of	
receptor	 activation.	 One	 of	 the	 most	 common	 approaches	 is	 to	 monitor	 the	
phosphorylation	of	downstream	signaling	mediators	after	cytokine	stimulation:	 the	
most	common	target	has	been	STAT3,	which	is	tyrosine	phosphorylated	in	response	
to	IL-6	family	cytokines.	(Akira	et	al.	1994)	
	
Different	 human	 cell	 lines	 have	 been	 identified	 that	 exclusively	 express	 either	 the	
OSMR/gp130	complex	(A375	human	melanoma	cell	 line,	Fig.	6A)	or	the	LIFR/gp130	
complex	 (JAR	 human	 choriocarcinoma	 cell	 line,	 Fig.	 6C).	 (Auguste	 et	 al.	 1997)	 By	
performing	cytokine	stimulations	 in	parallel	 in	 two	such	cell	 lines,	 it	becomes	 then	
possible	to	assess	the	activation	of	each	of	the	receptors	through	the	comparison	of	
the	 STAT3	 phosphorylation	 pattern	 10	 minutes	 after	 stimulation.	 (Chollangi	 et	 al.	
2012)	
	
To	 further	 validate	 this	 readout	 system,	 siRNA	 experiments	 were	 performed	 to	
confirm	 that	 the	 observed	 STAT3	 phosphorylation	 in	 A375	 and	 JAR	 cell	 lines	 is	 a	
product	 of	 the	 activation	 of	 their	 respective	 specific	 receptors.	 As	 expected,	 only	
siRNA-mediated	knockdown	of	the	hOSMR	affected	STAT3	phosphorylation	in	A375	
cells	(Fig.	6B).	In	a	similar	fashion,	only	siRNA	directed	against	hLIFR	impaired	STAT3	
phosphorylation	in	JAR	cells	(Fig.	6D).	
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Figure	6:	STAT3	phosphorylation	reflects	hOSMR	activation	in	A375	cells,	and	hLIFR	
activation	 in	 JAR	 cells.	 (A)	STAT3	phosphorylation	pattern	 in	A375	cells	stimulated	
for	10	minutes	with	hLIF	and	hOSM.	(B)	STAT3	phosphorylation	pattern	in	A375	cells	
treated	for	72	hours	with	the	indicated	siRNAs,	and	stimulated	for	10	minutes	before	
sample	 harvesting.	 (C)	 STAT3	 phosphorylation	 in	 JAR	 cells	 after	 a	 10-minute	
stimulation	with	hLIF	and	hOSM.	 (D)	 STAT3	phosphorylation	 in	 JAR	cells	 incubated	
for	 72	 hours	 after	 siRNA	 transfection	 and	 subjected	 to	 10-minute	 cytokine	
stimulation	prior	to	harvesting.	
	
	
To	 corroborate	 that	 the	 variations	 potentially	 observed	 in	 STAT3	 phosphorylation	
are	not	 just	due	 to	a	delay	 in	 signaling,	but	a	consequence	of	differential	 receptor	
activation	 properties,	 a	 second	 readout	 system	 based	 on	 longer-term	 (24	 hour)	
stimulation	 experiments	 was	 established.	 Tissue	 inhibitor	 of	 metalloproteinase	 1	
(TIMP1)	 upregulation	 is	 a	 well-known	 target	 of	 OSMR	 activation	 in	 different	 cell	
types,	including	hepatic	cells,	so	the	HepG2	human	hepatoma	cell	line	was	selected	
to	monitor	 hOSMR	 activation	 through	 TIMP1	 expression	 (Fig.	 7A).	 (Richards	 et	 al.	
1993)	 (Bugno	 et	 al.	 1995)	 Additionally,	 since	 STAT3	 levels	 after	 24	 hours	 are	
markedly	increased	in	response	to	its	activation	via	phosphorylation,	long-term	hLIFR	
activation	was	assessed	through	measurement	of	STAT3	expression	levels	in	the	JAR	
human	choriocarcinoma	cell	line	(Fig.	7C).	(Bugno	et	al.	1995)		
	
Once	 again	 siRNA-mediated	 knockdown	 experiments	 were	 performed	 to	 confirm	
that	TIMP1	expression	in	HepG2	cells	is	exclusively	due	to	hOSMR	signaling	(Fig.	7B),	
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while	STAT3	upregulation	in	JAR	cells	upon	stimulation	is	mediated	by	the	hLIFR	(Fig.	
7D).	
	
	
	
Figure	 7:	 TIMP1	 expression	 after	 24	 hours	 reflects	 hOSMR	 activation	 in	 HepG2	
cells,	while	 STAT3	upregulation	 is	 a	 consequence	of	hLIFR	activation	 in	 JAR	 cells.	
(A)	 TIMP1	 expression	 levels	 in	 HepG2	 cells	 stimulated	 for	 24	 hours	with	 hLIF	 and	
hOSM.	 (B)	TIMP1	expression	in	HepG2	cells	treated	for	48	hours	with	the	indicated	
siRNAs,	 and	 subsequently	 stimulated	 for	 an	 additional	 24	 hours	 before	 sample	
harvesting.	 (C)	Total	STAT3	 levels	 in	 JAR	cells	after	a	24-hour	stimulation	with	hLIF	
and	hOSM.	(D)	Total	STAT3	expression	levels	in	JAR	cells	incubated	for	48	hours	after	
siRNA	 transfection	 before	 being	 subjected	 to	 an	 additional	 24-hour	 cytokine	
stimulation	treatment	prior	to	harvesting.	
	
	
In	 addition,	 a	 non-Western	 blot	 based	 assay	 system	was	 implemented	 to	 confirm	
long-term	biological	activity	caused	by	hOSMR	activation.	OSM	was	first	described	as	
a	 growth	 regulator	 of	 human	 tumor	 cells,	 inhibiting	 the	 proliferation	 of	 A375	
melanoma	 cells	 as	well	 as	 other	 tumor-derived	 cell	 lines.	 (Zarling	 et	 al.	 1986)	 This	
ability	was	 apparent	 after	 seeding	A375	 cells	 at	 low	density	 and	 stimulating	 them	
with	either	hOSM	or	hLIF:	after	5	days,	only	hOSM	proved	capable	of	inhibiting	cell	
growth	(Fig.	8A).	
	
One	of	the	most	popular	methods	to	easily	monitor	cellular	growth	is	the	MTT	assay,	
a	 colorimetric	assay	employed	 to	detect	 living	cells.	 (Mosmann	1983)	By	means	of	
this	 method	 the	 effect	 of	 different	 treatments	 on	 cell	 proliferation	 could	 be	
quantified,	evidencing	the	growth	inhibition	caused	by	hOSM	(Fig.	8B).	
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Figure	 8:	 A375	 cell	 line	 proliferation	 reflects	 hOSMR	 activation	 after	 5	 days.	 (A)	
Proliferation	of	A375	cells	after	5	days	 is	 inhibited	by	stimulation	with	10	ng/mL	of	
hOSM,	but	unaffected	by	treatment	with	equal	amounts	of	hLIF.	(B)	Quantification	
of	A375	cell	proliferation	via	MTT	assay,	5	days	after	plating	and	stimulation	with	the	
indicated	concentrations	of	either	hOSM	or	hLIF	(n=3	for	each	group).	
	
4.1.2.	Production	of	recombinant	human	Oncostatin	M	
	
Initially,	the	nucleotide	sequence	of	hOSM	flanked	by	NdeI	and	SlaI	restriction	sites	
was	amplified	by	PCR	and	 cloned	 in	 a	pET-26b(+)	 vector.	 This	 vector	 contains	 a	C-
terminal	His-tag	and	a	T7	promoter,	which	enables	recombinant	protein	expression	
upon	 IPTG	 induction	 in	 Escherichia	 coli	 (E.	 coli).	 The	 resulting	 plasmid	 was	 then	
transformed	in	the	BL21	(DE3)	E.	coli	strain,	commonly	used	for	recombinant	protein	
production	due	to	its	high	protein	yield.	
	
However,	when	expressed	in	BL21	(DE3)	hOSM	tended	to	misfold	and	aggregate	into	
insoluble	inclusion	bodies:	while	expression	in	the	insoluble	fraction	was	very	robust,	
little	 soluble	protein	 could	be	detected	2	hours	after	 IPTG	 induction	 (Fig.	9A).	This	
particularity	had	 forced	past	 studies	on	OSM	and	mutant	OSM	variants	 to	 apply	 a	
variety	of	strategies	to	obtain	these	recombinant	proteins	in	soluble	form.	Successful	
OSM	purification	methods	 include	 its	 recovery	and	 refolding	 from	 inclusion	bodies	
(Sporeno	et	al.	1994),	its	fusion	and	subsequent	cleavage	to	a	solubility	tag	such	as	
GST	(Deller	et	al.	2000)	(Chollangi	et	al.	2012)	or	its	expression	in	eukaryotic	systems	
such	as	Picchia	pastoris	(Kong	et	al.	2009)	or	Chinese	hamster	ovary	cells.	(Kallestad	
et	al.	1991)	
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Since	most	of	 these	approaches	require	additional	 time-consuming	steps,	an	effort	
to	 establish	 a	 protocol	 for	 production	 of	 soluble	 hOSM	 in	 E.	 coli	 was	 made	 to	
facilitate	the	generation	of	the	cytokine	variants	to	be	studied	in	this	project.	Given	
that	 disulfide	 bonds	 had	 been	 shown	 to	 be	 critical	 for	 proper	 OSM	 folding	 and	
function,	(Kallestad	et	al.	1991)	it	appeared	likely	that	OSM	aggregation	might	be	a	
consequence	 of	 the	 reducing	 redox	 state	 of	 the	 prokaryotic	 cytoplasm	 preventing	
disulfide	bond	formation.	(Baneyx	&	Mujacic	2004)	
	
In	 order	 to	 test	 this	 hypothesis,	 the	 same	 hOSM	 plasmid	 was	 transformed	 into	
SHuffle®	T7	Express	competent	E.	coli.	This	is	a	modified	BL21	(DE3)	strain	expressing	
DsbC,	a	chaperone/disulfide	bond	isomerase	that	catalyzes	disulfide	bond	formation	
and	promotes	proper	folding	of	disulfide	bond-containing	proteins.	(de	Marco	2009)	
When	expressed	in	this	strain	hOSM	was	detected	in	the	soluble	fraction	as	early	as	
2	hours	after	induction	(Fig.	9B).	
	
	
	
Figure	 9:	 The	 presence	 of	 DsbC,	 a	 chaperone/disulfide	 bond	 isomerase,	 enables	
soluble	 recombinant	 hOSM	 expression	 in	 E.	 coli.	 Western	 blots	 using	 penta-His	
antibody	 to	 detect	 recombinant	 His-tagged	 hOSM	 production	 are	 shown.	 (A)	
Expression	of	hOSM	in	BL21	(DE3)	E.	coli	2	hours	after	induction	with	0.5	mM	IPTG	at	
different	 temperatures	and	densities,	 as	measured	by	OD600.	 The	 soluble	 (Sol)	 and	
insoluble	 (Pell)	 protein	 fractions	 are	 compared,	 with	 very	 little	 soluble	 OSM	 in	
evidence.	 (B)	 Expression	 of	 hOSM	 in	 SHuffle®	 T7	 Express	 E.	 coli	 at	 30ºC	 after	
induction	 at	 an	 OD600	 of	 0.5-0.7.	 Comparing	 soluble	 (Sol)	 and	 total	 (Tot)	 protein	
fractions,	the	majority	of	OSM	produced	by	this	strain	appears	to	be	soluble.	
	
	
Having	achieved	soluble	hOSM	expression,	the	next	step	was	to	establish	a	protocol	
for	 purification	 of	 the	 recombinant	 protein	 out	 of	 the	 bacterial	 cell	 lysate.	 The	
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inclusion	 of	 a	 C-terminal	 His-tag	 greatly	 facilitated	 this	 task,	 enabling	most	 of	 the	
bacterial	 contaminants	 to	 be	washed	 away	out	 of	 a	Ni-NTA	 affinity	 gel	 column	by	
gravity	 flow	 before	 eluting	 the	 recombinant	 protein	 with	 increasing	 amounts	 of	
imidazole	(Fig.	10).	
	
	
	
Figure	 10:	 Effective	 recovery	 of	 recombinant	 His-tagged	 hOSM	 by	 Ni-NTA	
purification.	(A)	Silver	staining	reveals	most	of	the	bacterial	proteins	 in	the	soluble	
fraction	 are	 eliminated	 during	 the	 purification	 procedure.	 Strong	 bands	 at	
approximately	 24	 kDa	 in	 the	 first	 three	 elution	 steps	 correspond	 to	 the	 eluted	
recombinant	 hOSM.	 (B)	 Western	 blotting	 of	 the	 same	 samples	 using	 penta-His	
antibody	 to	 detect	 recombinant	 His-tagged	 hOSM	 indicates	 that	 the	 protein	 is	
retained	 in	the	affinity	gel	during	the	washing	steps,	and	efficiently	eluted	through	
increasing	imidazole	concentrations.	
	
	
The	eluted	recombinant	hOSM	was	concentrated	by	using	a	centrifugal	filter	with	a	
molecular	weight	cutoff	of	10	kDa,	which	also	enabled	the	removal	of	imidazole	from	
the	 solution.	 This	 led	 to	 a	 recombinant	 protein	 solution	 comparable	 to	 the	
commercially	 available	 cytokine	 in	 terms	 of	 purity,	 as	 assessed	 by	 silver	 staining:	
83.2%	purity	was	estimated	for	 the	commercial	 recombinant	hOSM,	and	74.6%	for	
the	His-tagged	recombinant	hOSM	(Fig.	11).	
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Figure	11:	Recovered	recombinant	His-tagged	hOSM	 is	highly	pure.	Silver	staining	
of	 increasing	 concentrations	 of	 commercial	 hOSM	 and	 His-tagged	 recombinant	
hOSM	is	shown,	proving	both	preparations	to	be	similarly	devoid	of	bacterial-derived	
contaminating	proteins.	
	
	
Finally,	biological	activity	of	soluble	hOSM	produced	in	this	manner	was	compared	to	
commercially	available	human	LIF	(hLIF)	and	hOSM	by	stimulation	of	HepG2	cells	for	
15	minutes	 (Fig.	 12A)	 and	 24	 hours	 (Fig.	 12B).	 Phosphorylation	 patterns	 of	 known	
downstream	mediators	of	OSMR	activation	after	10	minutes	were	identical	for	both	
preparations.	 The	 same	 trend	 was	 observed	 when	 examining	 the	 upregulation	 of	
hOSM	targets	genes	after	24	hours,	confirming	the	validity	of	the	method	for	soluble	
active	hOSM	production	in	E.	coli.	
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Figure	12:	Recombinant	His-tagged	hOSM	displays	biological	activity	comparable	to	
the	 commercially	 available	 cytokine.	 (A)	 Western	 blots	 of	 HepG2	 cell	 samples	
harvested	 after	 a	 10-minute	 stimulation	 with	 20	 ng/mL	 of	 the	 cytokines	 show	
comparable	phosphorylation	patterns	for	commercial	and	His-tag	purified	hOSM.	(B)	
Western	 blots	 of	 HepG2	 cells	 harvested	 after	 a	 24-hour	 stimulation	 with	 the	
indicated	cytokines	evidence	similar	upregulation	of	hOSMR	and	TIMP1	expression	
for	commercial	and	His-tag	purified	hOSM.	
	
	
However,	 not	 all	 the	modified	 protein	 variants	 described	 in	 the	 following	 sections	
could	be	successfully	expressed	in	a	prokaryotic	system	(data	not	shown).	To	address	
this	 issue	a	mammalian-based	expression	system	had	to	be	established,	employing	
human	FreeStyle™	293-F	cells	adapted	to	suspension	growth	in	serum-free	medium.	
In	the	first	place,	the	nucleotide	sequences	for	wild-type	(WT)	hOSM	and	hLIF	were	
cloned	 into	 three	different	mammalian	expression	vectors	 (pcDNA™	3.1(+),	pFLAG-
CMV-3	 and	 pCAGGS),	 preceded	 by	 a	 Kozak	 consensus	 sequence	 and	 either	 their	
native	 signal	 peptide	 or	 the	 signal	 peptide	 from	 pre-pro-trypsin	 (PPT)	 to	 ensure	
secretion	of	the	recombinant	cytokines	into	the	medium.	
	
FreeStyle™	293-F	cells	were	then	transfected	with	the	different	plasmids	according	
to	 the	 manufacturer's	 instructions.	 A	 comparison	 of	 the	 expression	 levels	 3	 days	
after	 transfection	 showed	 robust	 secretion	 of	 recombinant	 hOSM	 in	 the	
supernatant,	but	much	lower	production	of	human	LIF	(Fig.	13A).	Since	the	pCAGGS	
plasmid	 with	 native	 signal	 peptide	 evidenced	 the	 highest	 level	 of	 expression	 for	
hOSM,	constructs	using	this	plasmid	were	employed	for	all	further	experiments.	
	
A	 deglycosylation	 test	 confirmed	 that	 the	 apparent	 smearing	 and	 differences	 in	
molecular	 weight	 in	 comparison	 to	 the	 bacterial-derived	 cytokines	 are	 caused	 by	
glycosylation,	 a	 post-translational	 modification	 exclusive	 of	 eukaryotic	 cells	 (Fig.	
13B).	These	initial	tests	were	followed	by	the	assessment	of	the	expression	over	time	
for	 both	 cytokines,	 in	 order	 to	 determine	 the	 optimal	 incubation	 time	 after	
transfection.	 While	 hOSM	 expression	 reached	 maximum	 levels	 as	 little	 as	 3	 days	
after	 transfection	 and	 plateaued	 afterwards,	 hLIF	 expression	 markedly	 increased	
during	the	first	week	and	did	not	peak	until	days	7-8	(Fig.	13C).	
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Figure	13:	Optimization	of	recombinant	protein	expression	in	mammalian	cells.	(A)	
Western	 blot	 of	 FreeStyle™	 293-F	 cell	 medium	 3	 days	 after	 transfection	 with	 the	
indicated	 vectors,	 using	 penta-His	 antibody	 to	 detect	 recombinant	 protein	
expression,	 reveals	 strong	expression	of	hOSM	cloned	 into	 the	PCAGGS	vector.	 (B)	
Western	 blot	 of	 untreated	 (-)	 and	 deglycosylated	 (+)	mammalian-derived	 hLIF	 and	
hOSM	 after	 purification	 demonstrates	 the	 occurrence	 of	 post-translational	
modifications.	 (C)	Western	 blot	 of	 FreeStyle™	 293-F	 cell	medium	 collected	 3	 to	 9	
days	 after	 transfection	 with	 either	 hOSM	 or	 hLIF	 in	 the	 pCAGGS	 vector	 indicates	
different	peak	production	times	for	each	cytokine.	
	
Despite	 the	 additional	 post-translational	modifications,	 cytokines	 produced	 in	 this	
way	 evidenced	 equivalent	 biological	 activity	 when	 compared	 to	 commercial	
bacterial-derived	 proteins	 (Fig.	 14A-B).	 Importantly,	 both	 hOSM-based	 and	 hLIF-
based	variant	cytokines	could	be	efficiently	expressed	by	the	FreeStyle™	293-F	cells	
and	recovered	by	His-tag	purification	(Fig.	14C),	permitting	a	detailed	examination	of	
the	interaction	between	hOSM	and	its	receptors.	
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Figure	 14:	 Recombinant	 protein	 expression	 in	 mammalian	 cells	 results	 in	 highly	
pure,	 active	 cytokines.	 (A)	Western	blot	of	A375	cell	 samples	collected	after	a	10-
minute	 stimulation	with	 hOSM	 shows	 similar	 biological	 activity	 between	 bacterial-
derived	(commercial)	and	mammalian-derived	cytokines.	(B)	Western	blot	of	JAR	cell	
samples	 subjected	 to	 a	 10-minute	 stimulation	 with	 hLIF	 evidences	 comparable	
biological	 activity	 for	 bacterial-derived	 (commercial)	 and	 mammalian-derived	
cytokines.	 (C)	 Silver	 staining	 of	 purified	 hOSM-based	 and	 hLIF-based	 chimeric	
cytokines.	
	
	
4.1.3.	 Human	 Oncostatin	 M-based	 chimeric	 proteins	 identify	 a	 critical	 binding	
region	for	human	receptor	complex	activation	
	
Despite	 the	 fact	 that	 binding	 site	 III	 of	 hOSM	 is	 a	 relatively	 large	 region	 of	 the	
cytokine,	composed	by	 the	N-terminal	part	of	 the	AB	 loop,	 the	whole	BC	 loop	and	
the	N-terminal	part	of	helix	D	(Fig.	15A-B),	very	few	details	about	its	interaction	with	
both	OSMR	and	LIFR	are	known	so	far.	 It	has	been	proved	that	the	presence	of	an	
FXXK	motif	in	the	N-terminal	D-helix,	which	is	conserved	in	all	LIFR-binding	cytokines	
and	 corresponds	 to	 phenylalanine	 160	 (F160)	 and	 lysine	 163	 (K163)	 in	 hOSM,	 is	
critical	 for	both	LIFR	and	OSMR	activation.	(Hudson	et	al.	1996)	(Deller	et	al.	2000)	
Additionally,	 it	was	 recently	 shown	 that	 shortening	 the	 length	 of	 the	 BC	 loop	 had	
positive	effects	on	receptor	affinity.	(Chollangi	et	al.	2012)	
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Given	the	scarcity	of	 information	available,	one	of	the	starting	goals	of	this	project	
was	to	explore	whether	any	of	the	regions	in	binding	site	III	could	explain	the	unique	
ability	 of	 hOSM	 to	 activate	 the	 hOSMR/gp130	 complex.	 To	 this	 end	 chimeric	
cytokines	 combining	different	 regions	of	 hOSM	and	hLIF	were	designed	 (Fig.	 15C),	
created	 by	 overlap	 extension	 PCR	 and	 cloned	 into	 the	 pCAGGS	 mammalian	
expression	vector	through	PacI	and	AscI	restriction	sites.	
	
	
	
Figure	 15:	 Design	 of	 human	 OSM/LIF	 chimeric	 cytokines.	 (A)	 Three-dimensional	
model	of	human	OSM.	The	N-terminal	AB	loop	region	is	shown	in	yellow,	the	BC	loop	
in	 purple	 and	 the	 N-terminal	 D-helix	 in	 green.	 (B)	 Alignment	 of	 mature	 hLIF	 and	
hOSM	amino	acid	sequences	with	Clustal	Omega.	Residues	forming	binding	site	III	of	
hOSM,	corresponding	to	the	N-terminal	AB	loop,	the	BC	loop	and	the	N-terminal	part	
of	helix	D,	 are	highlighted.	Asterisks	 (*)	denote	 fully	 conserved	 residues,	 colons	 (:)	
indicate	groups	with	strongly	similar	properties	and	periods	 (.)	are	used	for	groups	
with	 weakly	 similar	 properties.	 (C)	 Schematic	 representation	 of	 the	 constructed	
chimeric	 cytokines	 for	 hOSM,	 in	 which	 different	 parts	 of	 binding	 site	 III	 were	
replaced	by	the	equivalent	amino	acid	sequences	from	hLIF.	
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Replacements	of	three	different	lengths	were	made	for	the	AB	loop:	the	longest	one,	
termed	 AB1,	 involved	 the	 substitution	 of	 the	 region	 between	 residues	 proline	 33	
(P33)	to	histidine	48	(H48)	of	hOSM	by	residues	leucine	43	(L43)	to	leucine	59	(L59)	
of	hLIF,	or	vice	versa.	For	the	shorter	AB2	chimeras	the	replaced	region	started	with	
arginine	36	 (R36)	 in	hOSM	and	 threonine	46	 (T46)	 in	hLIF,	while	 the	AB3	chimeras	
started	 at	 leucine	 40	 (L40)	 of	 hOSM	and	 the	 glutamic	 acid	 at	 position	 50	 (E50)	 of	
hLIF.	
	
A	 single	 replacement	 length	was	 chosen	 for	 both	 the	BC	 loop	 chimera	 and	 the	N-
terminal	 D-helix	 chimera.	 The	 BC	 loop	 substitution	 involved	 the	 region	 between	
leucine	88	(L88)	and	glutamic	acid	109	(E109)	in	hOSM	and	between	glutamine	122	
(Q122)	and	serine	134	(S134)	in	hLIF.	Finally,	the	D-helix	chimera	replaced	the	amino	
acids	from	proline	155	(P155)	to	glutamic	acid	165	(E165)	of	hOSM	with	serine	151	
(S151)	to	leucine	161	(L161)	of	hLIF.	
	
After	 expression	 and	 purification	 of	 these	 variants	 in	 a	 mammalian	 expression	
system,	 the	 impact	 of	 the	 different	 binding	 site	 III	 regions	 in	 receptor	 activation	
ability	 was	 investigated	 through	 cell	 stimulation	 assays	 with	 the	 purified	 hOSM-
based	chimeric	cytokines.	
	
Receptor	activation	was	 first	monitored	 indirectly	after	a	10-minute	stimulation	by	
measuring	the	phosphorylation	levels	of	STAT3,	as	previously	detailed.	In	A375	cells,	
which	lack	hLIFR	expression,	it	became	clear	that	replacements	of	any	length	in	the	
AB	loop	of	hOSM	abrogated	OSMR	activation	(Fig.	16A).	Substituting	the	N-terminal	
region	of	the	D	helix	led	to	a	decrease	in	receptor	activation,	while	a	BC	loop	had	no	
measurable	effect.	
	
Conversely,	 stimulation	 of	 the	 hOSMR-deficient	 JAR	 cells	 showed	 normal	 STAT3	
phosphorylation	 patterns	 for	 every	 variant	 except	 for	 the	 AB1	 chimera,	 indicating	
that	 the	secondary	 structure	of	 the	chimeras	 remains	 stable.	This	observation	also	
suggests	 that	 the	 differences	 in	 amino	 acid	 composition	 between	 the	 AB	 loops	 of	
hOSM	and	hLIF	only	appear	to	be	critical	for	hOSMR	activation	(Fig.	16B-C).	
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Figure	16:	Short-term	receptor	activation	ability	of	hOSM-based	chimeric	cytokines	
identifies	the	AB	loop	as	critical	for	hOSMR	activation.	(A)	Western	blot	of	A375	cell	
samples	after	a	10-minute	stimulation	with	25	ng/mL	of	WT	hOSM,	WT	hLIF	and	the	
different	 hOSM-based	 chimeric	 cytokines	 created.	 STAT3	 phosphorylation	 reflects	
hOSMR	 activation,	 while	 total	 STAT3	 and	 pan-Actin	 serve	 as	 loading	 controls.	 (B)	
Western	blot	of	JAR	cell	samples	after	a	10-minute	stimulation	with	25	ng/mL	of	the	
indicated	 cytokines.	 STAT3	 phosphorylation	 reflects	 hLIFR	 activation,	 while	 total	
STAT3	and	pan-Actin	 serve	as	 loading	controls.	 (C)	Quantitative	analysis	of	hOSMR	
and	 hLIFR	 activation	 levels	 after	 a	 10-minute	 stimulation	 treatment	 with	 the	
indicated	 chimeric	 cytokines,	 relative	 to	 the	 observed	 activation	 for	 WT	 hOSM.	
Values	were	normalized	against	 total	STAT3	 levels	and	presented	as	mean	±	s.e.m.	
(n=5).	Statistical	significance	was	determined	by	Welch's	T-test,	with	(**)	indicating	
p-values	<	0.01.	
	
	
A	 second	 set	of	24-hour	 cell	 stimulation	experiments	 confirmed	 that	 replacing	 the	
AB	loop	of	hOSM	leads	to	a	complete	loss	of	hOSMR	activation,	as	reflected	by	the	
expression	levels	of	TIMP1	in	HepG2	cells	(Fig.	17A).	In	comparison,	the	upregulation	
of	total	STAT3	in	JAR	cells	is	consistent	with	normal	hLIFR	activation	by	either	hOSM	
or	hLIF	 (Fig.	17B-C).	The	differing	biological	activity	of	 the	AB	 loop	hOSM	chimeras	
was	further	proved	by	a	5-day	proliferation	assay.	While	WT	hOSM	and	the	BC	loop	
and	N-terminal	D-helix	chimeras	proved	able	to	activate	the	hOSMR	and	thus	inhibit	
cell	proliferation	of	A375	cells,	none	of	 the	AB	 loop	chimeras	or	WT	hLIF	 impaired	
cell	growth	(Fig.	17D).	
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Figure	17:	Long-term	receptor	activation	ability	of	hOSM-based	chimeric	cytokines	
confirms	the	 importance	of	the	AB	loop	in	hOSMR	activation.	(A)	Western	blot	of	
HepG2	 cell	 samples	 after	 a	 24-hour	 stimulation	 with	 25	 ng/mL	 of	 the	 specified	
cytokines.	TIMP1	expression	reflects	hOSMR	activation,	while	pan-Actin	levels	serve	
as	 loading	control.	(B)	Western	blot	of	JAR	cell	samples	after	a	24-hour	stimulation	
with	 25	 ng/mL	 of	 WT	 hOSM,	 WT	 hLIF	 and	 the	 different	 hOSM-based	 chimeric	
cytokines	created.	Total	STAT3	levels	reflect	hLIFR	activation,	while	pan-Actin	serves	
as	 loading	 control.	 (C)	Quantitative	 analysis	 of	 hOSMR	 and	 hLIFR	 activation	 levels	
after	 a	 10-minute	 stimulation	 treatment	 with	 the	 indicated	 chimeric	 cytokines,	
relative	 to	 the	 observed	 activation	 for	WT	 hOSM.	Values	were	 normalized	 against	
pan-Actin	levels	and	presented	as	mean	±	s.e.m.	(n=5).	(D)	A375	proliferation	levels	
after	 a	 5-day	 stimulation	 treatment	 with	 10	 ng/mL	 of	 the	 indicated	 chimeric	
cytokines,	relative	to	the	proliferation	of	the	control	group.	Values	are	given	as	mean	
±	 s.e.m.	 (n=3).	 Statistical	 significance	was	 determined	 by	Welch's	 T-test,	with	 (**)	
indicating	p-values	<	0.01.	
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4.1.4.	 Leukemia	 Inhibitory	 Factor-based	 chimeric	 proteins	 acquire	 the	 ability	 to	
activate	the	human	Oncostatin	M	Receptor	
	
These	 experiments	 indicate	 that	 the	 amino	 acid	 sequence	 of	 the	 AB	 loop	 within	
binding	site	III	of	hOSM	is	key	to	explain	its	unique	receptor	activation	profile	within	
the	 IL-6	 cytokine	 family.	 However,	 they	 did	 not	 rule	 out	 the	 existence	 of	 other	
differentiating	 features	 outside	 site	 III	 that	 may	 also	 be	 required	 for	 hOSMR	
activation.	To	address	this	question	a	number	of	hLIF-based	chimeric	cytokines	with	
different	regions	of	site	III	replaced	by	their	hOSM	equivalents	were	created:	these	
include	 the	 individual	 replacements	 of	 the	 N-terminal	 AB	 loop,	 BC	 loop	 and	 N-
terminal	helix	D	regions,	as	well	as	the	combined	substitution	of	the	two	regions	(AB	
loop	and	helix	D)	influencing	hOSM-hOSMR	binding	(Fig.	18).	
	
	
	
Figure	18:	Design	of	human	LIF/OSM	chimeric	cytokines.	Schematic	representation	
of	 the	 hLIF-based	 chimeric	 cytokines	 created,	 with	 different	 regions	 in	 the	 N-
terminal	AB	loop,	the	BC	loop	and	the	N-terminal	part	of	helix	D	substituted	by	their	
hOSM	counterparts.	
	
	
Mirroring	 in	the	previous	set	of	experiments,	receptor	activation	was	first	assessed	
through	 the	 comparison	 of	 STAT3	 phosphorylation	 levels	 after	 a	 10-minute	
stimulation.	All	the	chimeras	were	still	able	to	signal	through	the	hLIFR,	but	replacing	
the	 N-terminal	 region	 of	 the	 AB	 loop	 alone	 was	 not	 enough	 for	 the	 hLIF-based	
chimera	 to	activate	 the	hOSMR.	On	 the	other	hand,	 the	combined	 replacement	of	
the	 N-terminal	 AB	 loop	 and	 helix	 D	 regions	 was	 sufficient	 to	 achieve	 hOSMR	
stimulation,	albeit	always	at	lower	levels	than	WT	hOSM	(Fig	19A-C).	
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Figure	19:	Short-term	 receptor	activation	ability	of	hLIF-based	chimeric	 cytokines	
indicates	the	importance	of	site	III	regions	in	receptor	interaction.	(A)	Western	blot	
of	10-minute	stimulation	of	A375	cells	with	25	ng/mL	of	WT	hOSM,	WT	hLIF	and	the	
different	 hLIF-based	 chimeric	 cytokines.	 STAT3	 phosphorylation	 reflects	 hOSMR	
activation,	with	 total	STAT3	and	pan-Actin	serving	as	 loading	controls.	 (B)	Western	
blot	of	JAR	cell	samples	stimulated	for	10	minutes	with	25	ng/mL	of	WT	hOSM,	WT	
hLIF	and	the	indicated	hLIF-based	chimeras.	STAT3	phosphorylation	is	an	indication	
of	 hLIFR	 activation,	while	 total	 STAT3	 and	 pan-Actin	 serve	 as	 loading	 controls.	 (C)	
Quantitative	 analysis	 of	 hOSMR	 and	 hLIFR	 activation	 levels	 for	 the	 different	
cytokines	tested,	relative	to	WT	hOSM.	Values	were	normalized	against	total	STAT3	
levels	and	presented	as	mean	±	s.e.m.	(n=5).	Statistical	significance	was	determined	
by	Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
24-hour	stimulation	experiments	confirmed	these	findings,	with	all	cytokines	tested	
again	 activating	 the	 hLIFR	 but	 only	 the	 combined	 AB	 loop	 +	 D-helix	 hLIF-based	
chimera	being	able	to	stimulate	hOSMR-dependent	TIMP1	expression	in	HepG2	(Fig	
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20A-C).	 Additional	 evidence	 that	 the	 differential	 structural	 features	 leading	 to	
hOSMR	 specificity	 are	 contained	 within	 site	 III	 of	 hOSM	 could	 be	 provided	 by	 a	
longer-term	 biological	 assay	 based	 on	 A375	 cell	 proliferation.	 After	 5	 days	 of	
stimulation,	only	WT	hOSM	and	the	AB1	+	D	hLIF-based	chimera	were	able	to	inhibit	
cell	growth	(Fig.	20D).	
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Figure	 20:	 Long-term	 receptor	 activation	 ability	 of	 hLIF-based	 chimeric	 cytokines	
confirms	 the	 importance	 of	 binding	 site	 III	 region	 for	 hOSMR	 interaction.	 (A)	
Western	 blot	 of	 HepG2	 cell	 samples	 collected	 after	 a	 24-hour	 stimulation	with	 25	
ng/mL	of	the	indicated	cytokines.	TIMP1	expression	reflects	hOSMR	activation,	with	
pan-Actin	serving	as	loading	control.	(B)	Western	blot	of	JAR	cell	samples	stimulated	
with	25	ng/mL	of	WT	hOSM,	WT	hLIF	and	the	indicated	hLIF-based	chimeras	for	24	
hours.	Total	STAT3	expression	is	an	indication	of	hLIFR	activation,	while	pan-Actin	is	
used	as	a	 loading	control.	 (C)	Quantitative	analysis	of	hOSMR	and	hLIFR	activation	
levels	 for	 the	 different	 cytokines	 tested,	 relative	 to	 WT	 hOSM.	 Values	 were	
normalized	against	pan-Actin	levels	and	presented	as	mean	±	s.e.m.	(n=5).	(D)	A375	
proliferation	 levels	 after	 stimulation	 for	 5	 days	 with	 10	 ng/mL	 of	 the	 indicated	
chimeric	 cytokines,	 relative	 to	 the	 proliferation	 observed	 for	 the	 control	 group.	
Values	are	presented	as	mean	±	s.e.m.	(n=3).	Statistical	significance	was	determined	
by	Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
4.1.5.	 Alanine	 scanning	 of	 human	 Oncostatin	 M	 highlights	 specific	 residues	
involved	in	human	receptor	complex	activation	
	
To	assess	the	relative	importance	of	each	residue	composing	the	N-terminal	AB	loop	
and	 the	N-terminal	 helix	 D	 regions	 of	 hOSM	 in	 receptor	 activation,	 point	mutants	
were	 created	 by	 site-directed	 mutagenesis,	 transformed	 into	 SHuffle®	 T7	 Express	
competent	E.	coli,	expressed	and	His-tag	purified	as	previously	detailed.	
	
For	each	mutant	a	single	amino	acid	within	the	region	was	replaced	by	alanine,	thus	
removing	all	side	chain	atoms	past	the	β-carbon.	The	biological	function	of	each	of	
these	mutants	gives	 then	an	 indication	of	 the	 importance	of	 its	original	 side	 chain	
functional	group:	mutations	in	functional	epitopes	should	lead	to	a	 loss	of	function	
for	the	variant	protein,	while	mutations	in	residues	that	hinder	binding	will	result	in	
increased	function	instead.	(Cunningham	&	Wells	1989)	
	
In	the	first	place,	alanine	mutants	for	the	AB	loop	region	between	proline	33	(P33)	
and	 cysteine	 49	 (C49)	were	 assessed	 for	 their	 short-term	 hOSMR/hLIFR	 activation	
ability	(Fig	21A-B).	Several	of	these	residues	specifically	abrogated	hOSMR	activation,	
including	 glutamine	 38	 (Q38),	 glycine	 39	 (G39),	 leucine	 45	 (L45)	 and	 to	 a	 lesser	
extent	 tyrosine	 34	 (Y34)	 and	 valine	 42	 (V42),	 while	 mutations	 of	 leucine	 40	 and	
cysteine	49	also	had	a	large	impact	on	the	activation	of	the	hLIFR	(Fig	21C).	
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Figure	21:	Short-term	receptor	activation	ability	of	hOSM	AB	 loop	point	mutants	
identifies	critical	amino	acids	for	receptor	activation.	(A)	Western	blot	of	10-minute	
stimulation	 of	 A375	 cells	 with	 25	 ng/mL	 of	 WT	 hOSM	 and	 the	 indicated	 point	
mutants.	STAT3	phosphorylation	was	used	to	monitor	hOSMR	activation,	with	total	
STAT3	and	pan-Actin	serving	as	loading	controls.	(B)	Western	blot	of	JAR	cell	samples	
stimulated	 for	 10	minutes	with	 25	 ng/mL	 of	WT	 hOSM	 and	 the	 different	 AB	 loop	
point	mutants	shown.	STAT3	phosphorylation	measures	hLIFR	activation,	while	total	
STAT3	 and	 pan-Actin	 are	 included	 as	 loading	 controls.	 (C)	Quantitative	 analysis	 of	
hOSMR	and	hLIFR	activation	levels	for	the	different	point	mutants	tested,	relative	to	
WT	 hOSM.	 Values	 were	 normalized	 against	 total	 STAT3	 levels	 and	 presented	 as	
mean	±	s.e.m.	(n=5).	Statistical	significance	was	determined	by	Welch's	T-test,	with	
(**)	indicating	p-values	<	0.01.	
	
	
The	crucial	 role	of	 these	 residues	 in	 receptor	activation	was	confirmed	by	24-hour	
stimulation	 experiments	 (Fig.	 22A-C),	 with	 the	 detailed	 amino	 acid	 replacements	
displaying	the	same	effects	observed	after	10	minutes	except	for	V42.	These	results	
were	 further	 reinforced	 by	 a	 5-day	 cell	 proliferation	 assay	 on	 A375	 cells.	 In	
accordance	 with	 the	 shorter-term	 stimulation	 experiments,	 all	 of	 the	 mutants	
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identified	 as	 playing	 an	 important	 role	 in	 the	 interaction	 between	 hOSM	 and	 the	
hOSMR	 showed	 impaired	 inhibition	 of	 cell	 growth	 when	 compared	 to	 the	 WT	
cytokine	(Fig.	22D).	
	
	
	
Figure	 22:	 Long-term	 receptor	 activation	 ability	 of	 human	 OSM	 AB	 loop	 point	
mutants	validates	critical	cytokine	residues.	(A)	Western	blot	of	HepG2	cell	samples	
stimulated	 for	 24	hours	with	25	ng/mL	of	WT	human	OSM	and	 the	detailed	point	
mutants.	TIMP1	expression	reflects	human	OSMR	activation,	with	pan-Actin	serving	
as	 loading	 control.	 (B)	Western	blot	 of	 JAR	 cell	 samples	harvested	 after	 a	 24-hour	
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stimulation	 with	 25	 ng/mL	 of	 WT	 human	 OSM	 and	 the	 different	 AB	 loop	 point	
mutants	 indicated.	 STAT3	 phosphorylation	 measures	 human	 LIFR	 activation,	 with	
pan-Actin	 included	 as	 loading	 control.	 (C)	Quantitative	 analysis	 of	 OSMR	 and	 LIFR	
activation	levels	for	the	different	point	mutants	tested,	relative	to	WT	hOSM.	Values	
were	normalized	against	pan-Actin	levels	and	presented	as	mean	±	s.e.m.	(n=5).	(D)	
A375	proliferation	was	measured	by	an	MTT	assay	after	stimulation	for	5	days	with	
10	ng/mL	of	 the	 indicated	point	mutants,	 relative	to	the	proliferation	observed	for	
the	 control	 group.	 Values	 are	 presented	 as	 mean	 ±	 s.e.m.	 (n=3).	 Statistical	
significance	was	determined	by	Welch's	T-test,	with	(*)	corresponding	to	p-values	<	
0.05	and	(**)	indicating	p-values	<	0.01.	
	
	
Interestingly,	most	of	these	residues	appear	to	be	conserved	among	OSM	orthologs	
from	several	 different	 species,	 hinting	at	 the	existence	of	 a	 shared	mechanism	 for	
OSMR	activation	among	mammalians	(Fig.	23).	
	
	
	
Figure	23:	Critical	AB	 loop	residues	are	conserved	 in	mammalians.	The	equivalent	
residues	 to	 Y34,	 Q38,	 G39,	 L40	 and	 L45	 in	 human	 OSM	 are	 present	 in	 most	
mammalian	OSM	orthologs	compared,	with	the	exception	of	G39	in	mouse	and	rat	
OSM.	 Sequence	 alignment	 was	 performed	 with	 Clustal	 Omega,	 with	 amino	 acid	
sequence	numbers	corresponding	to	the	precursor	proteins	in	all	species	studied.	
	
	
Since	the	replacement	of	the	N-terminal	region	of	helix	D,	in	addition	to	the	AB	loop,	
was	 necessary	 before	 the	 hLIF-based	 chimera	 was	 able	 to	 activate	 the	 hOSMR,	
alanine	 scanning	 of	 this	 region	 was	 also	 performed.	 As	 expected	 the	 two	 critical	
residues	forming	the	conserved	FXXK	motif,	phenylalanine	160	(F160)	and	lysine	163	
(K163),	 proved	 to	 be	 crucial	 for	 activating	 both	 hOSMR	 and	 hLIFR	 in	 a	 10-minute	
stimulation	 assay.	 Additionally,	 substitution	 of	 the	 proline	 at	 the	 start	 of	 the	 helix	
(P153)	specifically	impaired	hOSMR	activation	(Fig.	24A-C).	
	
Mus.musculus     54   PYIRLQNLNTPDLRAAC   70
Rattus.norvegicus 55   PYILHQNLNTLTLRAAC   71
Homo.sapiens     57   PYIRIQGLDVPKLREHC   73
Pan.troglodytes 57   PYIRIQGLDVPKLREHC   73
Gorilla.gorilla  57   PYIRIQGLDVPKLREHC   73
Macaca.mulatta       57   PYIRIQGLDIPKLREHC   73
Bos.taurus       54   PYIHLQGLHSPVLQEHC   70
Capra.hircus     54   PYIRFQGLESPKLQEHC   70
Ovis.aries       54   PYIRFQGLESPKLQEHC   70
Sus.scrofa       54   PYIRMQGLDTPGLKEHC   70
Canis.lupus      54   LYIRSQGLDKNGLKEHC   70
Felis.catus      54   PYISIQGLDKDGLKEHC   70
                     **  *.*.       *
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Figure	24:	Short-term	receptor	activation	ability	of	hOSM	N-terminal	helix	D	point	
mutants	 assesses	 individual	 residue	 involvement.	 (A)	Western	 blot	 of	 A375	 cell	
samples	collected	after	a	10-minute	stimulation	with	25	ng/mL	of	WT	hOSM	and	the	
different	 helix	 D	 point	 mutants.	 STAT3	 phosphorylation	 is	 a	 sign	 of	 hOSMR	
activation,	with	 total	STAT3	and	pan-Actin	serving	as	 loading	controls.	 (B)	Western	
blot	of	JAR	cell	samples	harvested	after	stimulation	for	10	minutes	with	25	ng/mL	of	
WT	hOSM	and	 the	helix	D	point	mutants	 shown.	STAT3	phosphorylation	measures	
hLIFR	activation,	while	 total	 STAT3	and	pan-Actin	 are	 included	as	 loading	 controls.	
(C)	 Quantitative	 analysis	 of	 hOSMR	 and	 hLIFR	 activation	 levels	 for	 the	 mutants	
tested,	relative	to	WT	hOSM.	Values	were	normalized	against	total	STAT3	levels	and	
presented	as	mean	±	s.e.m.	(n=5).	Statistical	significance	was	determined	by	Welch's	
T-test,	with	(**)	indicating	p-values	<	0.01.	
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24-hour	 stimulation	 experiments	 confirmed	 the	 specific	 importance	 of	 P154	 for	
hOSMR	 activation,	 with	 the	 alanine	 mutant	 showing	 normal	 hLIFR	 activation	 but	
impaired	hOSMR-dependent	activity	 (Fig.	25A-C).	Final	proof	of	the	requirement	of	
proline	 154	 for	 hOSMR	 activation	was	 given	 by	 a	 5-day	 cell	 proliferation	 assay,	 in	
which	the	P154	point	mutant	is	shown	to	lack	the	growth	inhibition	activity	derived	
from	hOSMR	activation	in	A375	cells	(Fig.	25D).	
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Figure	25:	Long-term	receptor	activation	ability	of	hOSM	N-terminal	helix	D	point	
mutants	 confirms	 critical	 amino	 acids	 in	 the	 region.	 (A)	Western	blot	 samples	of	
HepG2	cells	subjected	to	a	24-hour	stimulation	with	25	ng/mL	of	WT	hOSM	and	the	
helix	D	point	mutants	shown.	TIMP1	expression	derives	from	hOSMR	activation,	with	
pan-Actin	serving	as	loading	control.	(B)	Western	blot	of	JAR	cell	samples	harvested	
after	 a	 24-hour	 stimulation	 with	 25	 ng/mL	 of	 WT	 hOSM	 and	 the	 D-helix	 point	
mutants	 indicated.	 Increased	 STAT3	 levels	 are	 a	 consequence	 of	 hLIFR	 activation,	
while	pan-Actin	is	used	as	a	loading	control.	(C)	Quantitative	analysis	of	hOSMR	and	
hLIFR	 activation	 levels	 relative	 to	WT	hOSM.	Values	were	 normalized	 against	 pan-
Actin	levels	and	presented	as	mean	±	s.e.m.	(n=5).	(D)	A375	proliferation	levels	were	
assessed	 by	 an	MTT	 assay	 after	 5-day	 stimulation	with	 10	 ng/mL	 of	 the	 indicated	
cytokines,	relative	to	the	proliferation	observed	for	the	unstimulated	control	group.	
Values	are	presented	as	mean	±	s.e.m.	(n=3).	Statistical	significance	was	determined	
by	Welch's	 T-test,	with	 (*)	 corresponding	 to	p-values	 <	 0.05	 and	 (**)	 indicating	p-
values	<	0.01.	
	
	
4.2.	 Structural	 basis	 for	 the	 species-dependent	 receptor	 complex	 activation	
properties	of	human	and	murine	Oncostatin	M	
	
4.2.1.	Design	and	production	of	chimeric	mouse/human	Oncostatin	M	cytokines	
	
Besides	 the	unique	OSMR/gp130	activation	ability	explored	 in	 the	 first	part	of	 this	
work,	 perhaps	 the	 most	 intriguing	 characteristic	 of	 OSM	 is	 the	 widely	 divergent	
receptor	activation	abilities	of	the	human	and	mouse	cytokines.	This	difference	may	
be	reflecting	the	natural	evolutionary	process	of	new	cytokines,	as	will	be	discussed	
in	more	detail	in	section	5.4:	phylogenetic	analyses	reveal	both	mOSM	and	mOSMR	
to	 be	more	 distant	 from	 their	 common	 ancestor	 proteins,	 in	 comparison	 to	 other	
mammalian	orthologs	(Fig.	26A-C).	
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Figure	26:	Murine	OSM	and	OSMR	orthologs	are	more	evolutionarily	distant	from	
the	ancestral	state.	(A)	Phylogenetic	analysis	of	9	selected	OSM	orthologs	evidences	
a	higher	degree	of	deviation	from	the	common	ancestor	for	the	murine	protein.	(B)	
Phylogenetic	distances	of	the	OSMR	follow	the	same	pattern	detected	for	its	ligand	
among	9	selected	mammal	species.	(C)	Unbiased	phylogenetic	analysis	of	every	OSM	
protein	 sequence	 contained	 in	 the	 RefSeq	 database	 confirms	 the	 evolutionary	
divergence	 of	 the	 murine	 ortholog.	 Phylogenetic	 analyses	 were	 performed	 by	
stochastic	heuristics	in	MetaPIGA.	(Helaers	&	Milinkovitch	2010)	
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Perhaps	 as	 a	 result	 of	 this	 evolutionary	 process,	 the	 murine	 protein	 is	 unable	 to	
activate	 any	 of	 the	 human	 receptor	 complexes	 and	 appears	 to	 act	 specifically	
through	 mOSMR/gp130,	 while	 hOSM	 cannot	 activate	 mOSMR	 and	 only	 signals	
through	the	mLIFR/gp130	complex	in	murine	cells.	(Ichihara	et	al.	1997)	(Lindberg	et	
al.	1998)	
	
Despite	 this	marked	difference	 in	 their	 receptor	activation	abilities,	both	cytokines	
are	 surprisingly	 similar	 in	 terms	 of	 amino	 acid	 composition:	 when	 the	 mature	
sequences	of	hOSM	and	mOSM	were	aligned,	48.89%	of	their	residues	turned	out	to	
be	 completely	 conserved	and	an	additional	 17.78%	had	 strongly	 similar	 properties	
(Fig.	27B).	In	contrast	hLIF	and	hOSM,	despite	sharing	a	common	receptor,	only	show	
24.39%	identity	when	the	same	comparison	is	made	(Fig.	15B).	
	
This	 fact	 suggests	 that	 the	 differing	 specificity	 between	 human	 and	 mouse	 OSM	
might	 be	 explained	 by	 just	 a	 small	 number	 of	 variations,	 possibly	 in	 the	 regions	
required	for	hOSMR	interaction	identified	in	the	first	section	of	this	work.	In	order	to	
test	this	hypothesis,	chimeric	proteins	based	on	mOSM	were	designed	in	which	the	
two	main	 regions	 influencing	OSMR	binding	within	 site	 III,	 the	AB	 loop	and	 the	N-
terminal	D-helix,	had	been	replaced	by	their	hOSM	counterparts	(Fig.	27A-C).	
	
In	 this	 occasion	 two	 different	 replacement	 lengths	 were	 selected	 for	 both	 the	 N-
terminal	 AB	 loop	 and	 the	 N-terminal	 helix	 D	 constructs.	 In	 the	 shortest	 AB	 loop	
chimera,	 termed	 AB1,	 the	 fragment	 from	 leucine	 35	 (L35)	 to	 alanine	 46	 (A46)	 of	
mOSM	was	replaced	by	residues	isoleucine	37	(I37)	to	histidine	48	(H48)	of	hOSM.	In	
the	AB2	chimera	the	region	replaced	was	extended	to	valine	52	(V52)	of	mOSM	and	
glycine	54	(G54)	of	hOSM,	respectively.	
	
For	 the	 N-terminal	 helix	 D	 chimeras,	 the	 shortest	 modification	 (chimera	 D1)	
consisted	 of	 residues	 threonine	 142	 (T142)	 to	 serine	 152	 (S152)	 of	 mOSM	 being	
replaced	 by	 residues	 alanine	 156	 (A156)	 to	 glycine	 166	 (G166)	 of	 hOSM.	 In	 the	
longest	 version	 the	 replacement	 started	 with	 arginine	 138	 (R138)	 of	 the	 murine	
cytokine	instead,	while	the	hOSM	fragment	being	inserted	commenced	in	glutamine	
149	(Q149).	
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Figure	27:	Design	of	human/mouse	OSM	chimeric	cytokines.	(A)	Three-dimensional	
model	of	mouse	OSM.	The	N-terminal	AB	loop	region	is	depicted	in	yellow,	and	the	
N-terminal	 D-helix	 is	 shown	 in	 green.	 (B)	Alignment	 of	mature	mouse	 and	 human	
OSM	amino	acid	sequences	with	Clustal	Omega.	Residues	forming	binding	site	III	of	
OSM,	corresponding	 to	 the	N-terminal	AB	 loop	and	 the	N-terminal	part	of	helix	D,	
are	 highlighted.	 Asterisks	 (*)	 denote	 fully	 conserved	 residues,	 colons	 (:)	 indicate	
groups	 with	 strongly	 similar	 properties	 and	 periods	 (.)	 are	 used	 for	 groups	 with	
weakly	similar	properties.	(C)	Schematic	representation	of	the	constructed	chimeric	
cytokines	based	on	mOSM,	in	which	different	lengths	of	the	N-terminal	AB	loop	and	
the	N-terminal	helix	D	were	replaced	by	the	equivalent	amino	acid	sequences	from	
hOSM.	
	
	
Considering	the	difficulties	faced	in	expressing	the	previous	hOSM/hLIF	chimeras	in	a	
prokaryotic	system,	a	mammalian	expression	system	was	selected	from	the	start	for	
the	production	of	mOSM	variants.	Accordingly,	the	WT	mOSM	sequence	was	cloned	
from	 NIH3T3	 cDNA	 into	 pcDNA™	 3.1(+),	 pFLAG-CMV-3	 and	 pCAGGS	 mammalian	
expression	vectors	with	a	Kozak	consensus	 sequence	and	either	 the	 signal	peptide	
from	pre-pro-trypsin	(PPT)	or	its	native	signal	peptide.	
	
mOSM WT 
mOSM AB1 
mOSM AB2 
mOSM D1 
mOSM D2 
hOSM WT 
Helix A AB loop Helix B BC loop Helix C Helix D CD loop C	
A
mOSM      --NRGCSNSSSQLLSQLQNQANLTGNTESLLEPYIRLQNLNTPDL
hOSM      AAIGSCSKEYRVLLGQLQKQTDLMQDTSRLLDPYIRIQGLDVPKL
              .**:.   **.***:*::*  :*. **:****:* *:.*.*
mOSM      RAACTQHSVAFPSEDTLRQLSKPHFLSTVYTTLDRVLYQLDALRQ
hOSM      REHCRERPGAFPSEETLRGLGRRGFLQTLNATLGCVLHRLADLEQ
          *  * ::  *****:*** *.:  **.*: :**  **::*  *.*
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After	transfection	of	the	different	constructs	into	FreeStyle™	293-F	cells,	expression	
and	secretion	of	the	cytokine	was	assessed	after	three	days	(Fig.	28A).	Both	pFLAG	
and	pCAGGS	vectors	led	to	robust	expression,	but	due	to	the	presence	of	additional	
modifications	 in	 the	 pFLAG	 construct	 (an	 N-terminal	 FLAG	 tag	 and	 PPT	 signal	
peptide)	the	pCAGGS	construct	was	employed	for	all	subsequent	experiments.	
	
Recombinant	mOSM	produced	after	transfection	was	then	purified	and	subjected	to	
a	deglycosylation	assay,	which	confirmed	that	the	observed	smearing	of	the	purified	
protein	after	SDS-PAGE	separation	is	due	to	post-translational	glycosylation	and	not	
degradation	 (Fig.	 28B).	 A	 time-course	 experiment	monitoring	 recombinant	 protein	
expression	 in	 FreeStyle™	 293-F	 cells	 showed	 peak	 levels	 of	mOSM	production	 4-5	
days	 after	 transfection,	 so	 all	mOSM-derived	 proteins	were	 harvested	 at	 this	 time	
point	(Fig.	28C).	
	
	
	
Figure	28:	Expression	of	recombinant	mOSM	in	a	mammalian	system.	(A)	Western	
blot	 of	 FreeStyle™	 293-F	 cell	medium	 3	 days	 after	 transfection	with	 the	 indicated	
vectors	containing	the	mature	mOSM	sequence,	using	penta-His	antibody	to	detect	
recombinant	protein	expression.	 (B)	Western	blot	of	FreeStyle™	293-F	cell	medium	
samples	collected	3	 to	9	days	after	 transfection	with	mOSM	 in	 the	pCAGGS	vector	
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indicates	a	peak	production	time	after	4-5	days.	(C)	Western	blot	of	untreated	(-)	and	
deglycosylated	 (+)	 mammalian-derived	 mOSM	 after	 purification	 indicates	 the	
presence	of	post-translational	modifications.	
	
	
The	biological	activity	of	the	purified	mOSM	was	also	tested,	and	proved	comparable	
to	a	commercial	bacterial-derived	cytokine	in	a	short-term	NIH3T3	murine	fibroblast	
cell	 stimulation	 assay	 (Fig.	 29A).	 In	 light	 of	 these	 results	 the	 different	 chimeric	
proteins,	along	with	the	WT	mOSM	version,	were	sequence-optimized	for	expression	
in	 mammalian	 cells	 and	 constructed	 from	 overlapping	 nucleotides	 designed	 with	
DNAWorks.	 (Hoover	 &	 Lubkowski	 2002)	 The	 different	 synthetic	 genes	 were	
assembled	through	PCR	and	cloned	into	the	pCAGGS	mammalian	expression	vector	
via	PacI	and	AscI	restriction	enzyme	sites	inserted	at	the	5'	and	3'	ends,	respectively.	
After	verification	of	 the	constructs	by	DNA	sequencing,	 they	were	 transfected	 into	
FreeStyle™	 293-F	 cells	 and	 His-tag	 purified,	 resulting	 in	 strong	 expression	 for	 the	
sequence-optimized	 (SO)	WT	 and	 all	 of	 the	 mouse/human	 chimeras	 created	 (Fig.	
29B).	
	
	
	
Figure	 29:	 Activity	 of	 recombinant	 mOSM	 and	 production	 of	 mOSM-based	
chimeras.	 (A)	 Western	 blot	 of	 NIH3T3	 cell	 samples	 subjected	 to	 a	 10-minute	
stimulation	 with	 mOSM	 shows	 comparable	 biological	 activity	 for	 the	 bacterial-
derived	(commercial)	and	mammalian-derived	cytokine.	(B)	Western	blot	of	purified	
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mOSM,	comparing	native	 (Nat)	and	sequence-optimized	 (SO)	expression	 in	 the	WT	
and	confirming	expression	of	all	the	constructed	chimeras.	
	
	
4.2.2.	Murine	Oncostatin	M-based	 chimeric	 proteins	 identify	 a	 critical	 region	 for	
species-specific	receptor	complex	activation	
	
Once	purified,	the	ability	of	the	murine-based	OSM	chimeras	to	activate	the	human	
receptor	complexes	was	tested	first	in	a	short-term	stimulation	assay.	Interestingly,	
even	 the	 shortest	 exchange	 in	 the	 AB	 loop	 of	 mOSM	 proved	 sufficient	 to	 enable	
hOSMR	activation,	reinforcing	the	 importance	of	this	region	for	hOSMR	interaction	
(Fig.	30A).	hLIFR	activation	was	also	clearly	within	the	ability	of	the	AB	loop	chimeras,	
and	very	low	levels	were	also	observed	for	the	N-terminal	helix	D	chimeras	(Fig	30B-
C).	As	expected,	WT	mOSM	showed	a	complete	 lack	of	activation	 for	either	of	 the	
human	receptors.	
	
	
	
Figure	 30:	 Short-term	 receptor	 activation	 ability	 of	 mOSM-based	 chimeric	
cytokines	 identifies	 the	 AB	 loop	 as	 a	 differential	 feature	 between	 human	 and	
murine	OSM.	 (A)	Western	blot	of	A375	cell	 samples	after	a	10-minute	stimulation	
with	25	ng/mL	of	WT	mOSM,	WT	hOSM,	WT	hLIF	and	the	four	mOSM-based	chimeric	
cytokines	 created.	 STAT3	 phosphorylation	 reflects	 hOSMR	 activation,	 while	 total	
STAT3	and	pan-Actin	serve	as	loading	controls.	(B)	Western	blot	of	JAR	cell	samples	
after	a	10-minute	stimulation	with	25	ng/mL	of	 the	detailed	cytokines.	 In	 this	case	
STAT3	 phosphorylation	 reflects	 hLIFR	 activation,	 while	 total	 STAT3	 and	 pan-Actin	
serve	 as	 loading	 controls.	 (C)	Quantitative	 analysis	 of	 hOSMR	and	hLIFR	 activation	
levels	after	a	10-minute	stimulation	treatment	with	the	indicated	cytokines,	relative	
to	 the	 observed	 activation	 for	 WT	 hOSM.	 Values	 were	 normalized	 against	 total	
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STAT3	 levels	 and	 presented	 as	 mean	 ±	 s.e.m.	 (n=5).	 Statistical	 significance	 was	
determined	by	Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
The	 same	 activation	 pattern	was	 observed	 after	 24-hour	 stimulation	 experiments.	
Expression	 levels	 of	 hOSMR	 and	 hLIFR	 target	 genes	 confirm	 the	 affinity	 of	 the	 AB	
loop	mOSM-based	 chimeras	 for	 both	 receptor	 complexes,	 as	 well	 as	 an	 apparent	
low-level	 binding	 of	 the	D	helix	 chimeras	 to	 the	 hLIFR	 complex	 (Fig.	 31A-C).	 Long-
term	activation	of	 the	hOSMR/gp130	complex	was	 further	assessed	with	 the	same	
results:	only	stimulation	with	the	WT	hOSM	or	the	murine	AB	loop	chimeras	led	to	
hOSMR-mediated	inhibition	of	cell	proliferation	in	A375	cells	after	5	days	(Fig.	31D).	
	
	
	
Figure	31:	Long-term	receptor	activation	ability	of	mOSM-based	chimeric	cytokines	
confirms	 AB	 loop	 importance.	 (A)	 Western	 blot	 of	 HepG2	 cell	 samples	 after	
stimulation	for	24	hours	with	25	ng/mL	of	WT	mOSM,	WT	hOSM,	WT	hLIF	and	the	
different	mOSM-based	chimeras.	TIMP1	expression	reflects	hOSMR	activation,	while	
pan-Actin	levels	serve	as	loading	control.	(B)	Western	blot	of	JAR	cell	samples	after	a	
24-hour	stimulation	with	25	ng/mL	of	 the	 indicated	cytokines	created.	Total	STAT3	
levels	 reflect	 hLIFR	 activation,	 while	 pan-Actin	 serves	 as	 loading	 control.	 (C)	
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Quantitative	 analysis	 of	 hOSMR	 and	 hLIFR	 activation	 levels	 after	 a	 24-hour	
stimulation	treatment	with	the	detailed	chimeric	cytokines,	relative	to	the	observed	
activation	 for	 WT	 hOSM.	 Values	 were	 normalized	 against	 pan-Actin	 levels	 and	
presented	 as	 mean	 ±	 s.e.m.	 (n=5).	 (D)	 A375	 proliferation	 levels	 5	 days	 after	
stimulation	with	10	ng/mL	of	the	indicated	cytokines,	relative	to	the	proliferation	of	
the	 control	 group.	 Values	 are	 given	 as	mean	 ±	 s.e.m.	 (n=3).	 Statistical	 significance	
was	determined	by	Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
4.2.3.	 Site-directed	 mutagenesis	 of	 murine	 Oncostatin	 M	 pinpoints	 specific	
residues	responsible	for	species-specific	receptor	activation	
	
Since	the	AB	loop	in	mOSM	had	been	found	to	be	a	differentiating	factor	in	respect	
to	 the	 human	 cytokine,	 site-directed	mutagenesis	was	 employed	 to	 clarify	 exactly	
which	substitutions	within	the	AB	loop	were	responsible	to	enable	human	receptor	
activation.	
	
The	AB1	mOSM	chimera	was	selected	as	the	starting	point	for	this	approach,	since	
the	region	replaced	in	this	construct	is	limited	to	just	twelve	amino	acids	(Fig.	27A).	
Five	of	them	(Q36,	L38,	P41,	L43	and	R44	in	mOSM)	are	conserved	in	both	cytokines,	
which	 left	 seven	 candidate	 residues.	 Given	 that	 the	 alanine	 scanning	 experiment	
described	in	section	4.1.6	showed	no	effects	of	the	hOSM	mutants	E47A	and	H48A	
on	their	 receptor	activation	ability,	 the	analogous	A45	and	A46	residues	on	mOSM	
were	 judged	 unlikely	 to	 impact	 hOSMR	 activation	 and	 the	 five	 remaining	
substitutions	became	the	focus	of	this	study.	
	
Thus	 the	mOSM	mutant	 containing	 these	 five	mutations	 (L35I,	 N37G,	N39D,	 T40V	
and	D42K),	as	well	as	all	single,	double,	triple	and	quadruple	mutant	combinations,	
were	created	by	assembly	PCR	and	cloned	through	PacI	and	AscI	restriction	sites	into	
the	pCAGGS	mammalian	expression	vector.	
	
In	first	place	the	quintuple	mutant,	plus	the	five	different	quadruple	mutants,	were	
expressed	 in	 FreeStyle™	 293-F	 cells	 and	 His-tag	 purified.	 Subsequent	 10-minute	
stimulation	experiments	revealed	that	the	presence	of	the	selected	five	mutations	in	
mOSM	is	sufficient	to	enable	both	hOSMR	and	hLIFR	activation	by	the	cytokine	(Fig.	
32A-C).	
	
Quadruple	 mutants	 were	 able	 to	 supplement	 additional	 information	 on	 the	
individual	impact	of	these	five	substitutions.	The	loss	of	activity	of	the	variant	lacking	
the	 N37G	 replacement,	 and	 to	 a	 lesser	 extent	 of	 T40V	 and	 D42K,	 indicated	 the	
importance	of	these	three	mutations	to	enable	human	receptor	activation,	while	the	
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L35I	and	N39D	substitutions	had	very	little	effect	on	downstream	signaling	through	
the	human	receptors	(Fig.	32A-C).	
	
	
	
Figure	32:	Short-term	receptor	activation	ability	of	mOSM	point	mutants	suggests	
residues	 determining	 species	 specificity	 within	 the	 AB	 loop.	 (A)	Western	 blot	 of	
A375	 cell	 samples	after	 a	10-minute	 stimulation	with	25	ng/mL	of	WT	mOSM,	WT	
hOSM,	WT	 hLIF	 and	 the	 quadruple	 and	 quintuple	 mOSM	 point	 mutants	 detailed.	
STAT3	phosphorylation	 reflects	hOSMR	activation,	while	 total	STAT3	and	pan-Actin	
serve	 as	 loading	 controls.	 (B)	Western	 blot	 of	 JAR	 cell	 samples	 after	 a	 10-minute	
stimulation	 with	 25	 ng/mL	 of	 the	 indicated	 cytokines.	 In	 this	 case	 STAT3	
phosphorylation	reflects	hLIFR	activation,	while	 total	STAT3	and	pan-Actin	serve	as	
loading	controls.	(C)	Quantitative	analysis	of	hOSMR	and	hLIFR	activation	levels	after	
0.0
0.2
0.4
0.6
0.8
1.0
1.2
P
-S
TA
T3
 in
te
ns
ity
 re
la
tiv
e 
to
 W
T 
hO
S
M
 
0.0 
0.4 
0.6 
1.0 
0.2 
0.8 
1.2 
hOSMR Activation 
hLIFR Activation 
C	
** 
** 
mOSM 
WT 
mOSM point mutants 
L35I 
N37G 
N39D 
T40V 
L35I 
N37G 
N39D 
 
D42K 
L35I 
N37G 
 
T40V 
D42K 
L35I 
 
N39D 
T40V 
D42K 
 
N37G 
N39D 
T40V 
D42K 
L35I 
N37G 
N39D 
T40V 
D42K 
hLIF 
WT 
** 
mOSM point mutants 
L35I 
N37G 
N39D 
T40V 
L35I 
N37G 
N39D 
 
D42K 
L35I 
N37G 
 
T40V 
D42K 
L35I 
N39D 
T40V 
D42K 
 
N37G 
N39D 
T40V 
D42K 
L35I 
N37G 
N39D 
T40V 
D42K 
P-STAT3 
Pan-Actin 
Ctrl 
STAT3 
m
O
S
M
 W
T 
hO
S
M
 W
T 
hL
IF
 W
T 
A	
hOSMR		
(A375,	10’)	
mOSM point mutants 
L35I 
N37G 
N39D 
T40V 
L35I 
N37G 
N39D 
 
D42K 
L35I 
N37G 
 
T40V 
D42K 
L35I 
N39D 
T40V 
D42K 
 
N37G 
N39D 
T40V 
D42K 
L35I 
N37G 
N39D 
T40V 
D42K 
Ctrl m
O
S
M
 W
T 
hO
S
M
 W
T 
hL
IF
 
W
T 
P-STAT3 
Pan-Actin 
STAT3 
B	
hLIFR		
(JAR,	10’)	
	 85	
treatment	with	the	detailed	cytokines,	relative	to	WT	hOSM.	Values	were	normalized	
against	 total	 STAT3	 levels	 and	 presented	 as	 mean	 ±	 s.e.m.	 (n=5).	 Statistical	
significance	was	determined	by	Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
Findings	from	the	10-minute	experiments	were	confirmed	by	a	24-hour	stimulation	
experiment	in	HepG2	and	JAR	cells	(Fig.	33A-C),	and	in	the	case	of	hOSMR	activation	
by	the	inhibition	of	A375	cell	proliferation	after	5	days	(Fig.	33D).	
	
	
0.0
0.2
0.4
0.6
0.8
1.0
1.2
TI
M
P
1/
S
TA
T3
 in
te
ns
ity
 re
la
tiv
e 
to
 W
T 
hO
S
M
 
0.0 
0.4 
0.6 
1.0 
0.2 
0.8 
1.2 
hOSMR Activation 
hLIFR Activation 
C	
** 
** 
mOSM 
WT 
mOSM point mutants 
L35I 
N37G 
N39D 
T40V 
L35I 
N37G 
N39D 
 
D42K 
L35I 
N37G 
 
T40V 
D42K 
L35I 
 
N39D 
T40V 
D42K 
 
N37G 
N39D 
T40V 
D42K 
L35I 
N37G 
N39D 
T40V 
D42K 
hLIF 
WT 
** 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
A
37
5 
ce
ll 
pr
ol
ife
ra
tio
n 
(5
 d
ay
s)
 
0.0 
0.4 
0.6 
1.0 
0.2 
0.8 
1.2 
D	
* 
** 
mOSM 
WT 
mOSM point mutants 
L35I 
N37G 
N39D 
T40V 
L35I 
N37G 
N39D 
 
D42K 
L35I 
N37G 
 
T40V 
D42K 
L35I 
 
N39D 
T40V 
D42K 
 
N37G 
N39D 
T40V 
D42K 
L35I 
N37G 
N39D 
T40V 
D42K 
hLIF 
WT 
** 
hOSM 
WT 
* 
** 
* 
mOSM point mutants 
L35I 
N37G 
N39D 
T40V 
L35I 
N37G 
N39D 
 
D42K 
L35I 
N37G 
 
T40V 
D42K 
L35I 
N39D 
T40V 
D42K 
 
N37G 
N39D 
T40V 
D42K 
L35I 
N37G 
N39D 
T40V 
D42K 
Ctrl 
m
O
S
M
 W
T 
hO
S
M
 W
T 
hL
IF
 W
T 
A	
TIMP1 
Pan-Actin 
hOSMR		
(HepG2,	24h)	
mOSM point mutants 
L35I 
N37G 
N39D 
T40V 
L35I 
N37G 
N39D 
 
D42K 
L35I 
N37G 
 
T40V 
D42K 
L35I 
N39D 
T40V 
D42K 
 
N37G 
N39D 
T40V 
D42K 
L35I 
N37G 
N39D 
T40V 
D42K 
Ctrl m
O
S
M
 W
T 
hO
S
M
 W
T 
hL
IF
 W
T 
STAT3 
Pan-Actin 
B	
hLIFR		
(JAR,	24h)	
	 86	
	
Figure	33:	Long-term	receptor	activation	ability	of	mOSM	point	mutants	suggests	
residues	 determining	 species	 specificity	 within	 the	 AB	 loop.	 (A)	Western	 blot	 of	
HepG2	 cell	 samples	 after	 a	 24-hour	 stimulation	with	 25	 ng/mL	 of	WT	mOSM,	WT	
hOSM,	WT	hLIF	and	the	quadruple	and	quintuple	mOSM	point	mutants.	TIMP1	levels	
reflect	 hOSMR	activation,	while	 total	 pan-Actin	 levels	 serve	 as	 loading	 control.	 (B)	
Western	 blot	 of	 JAR	 cell	 samples	 after	 a	 24-hour	 stimulation	 with	 the	 indicated	
cytokines.	 In	 this	case	STAT3	 levels	 reflect	hLIFR	activation,	while	pan-Actin	 level	 is	
used	as	a	 loading	control.	 (C)	Quantitative	analysis	of	hOSMR	and	hLIFR	activation	
levels	 after	 the	 24-hour	 stimulation	 treatment,	 relative	 to	 the	 observed	 activation	
for	WT	 hOSM.	 Values	 were	 normalized	 against	 pan-Actin	 levels	 and	 presented	 as	
mean	±	 s.e.m.	 (n=5).	 (D)	A375	proliferation	 levels	5	days	after	 stimulation	with	10	
ng/mL	of	the	 indicated	cytokines,	relative	to	the	proliferation	of	the	control	group.	
Values	are	given	as	mean	±	s.e.m.	(n=3).	Statistical	significance	was	determined	by	a	
Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
Short-term	stimulation	experiments	employing	the	single	mutant	constructs,	as	well	
as	 the	 double	 and	 triple	 mutants	 for	 the	 relevant	 residues	 identified	 by	 the	
quadruple	mutants	(N37G,	T40V	and	D42K),	were	then	carried	out	to	provide	further	
evidence	of	the	role	of	these	three	substitutions	in	enabling	mOSM	signaling	through	
the	human	receptor	complexes	(Fig.	34A-C).	
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Figure	34:	Short-term	receptor	activation	ability	of	mOSM	point	mutants	identifies	
residues	 determining	 species	 specificity	 within	 the	 AB	 loop.	 (A)	Western	 blot	 of	
A375	 cell	 samples	after	 a	10-minute	 stimulation	with	25	ng/mL	of	WT	mOSM,	WT	
hOSM,	 WT	 hLIF	 and	 the	 mOSM	 point	 mutants	 detailed.	 STAT3	 phosphorylation	
reflects	hOSMR	activation,	while	total	STAT3	and	pan-Actin	serve	as	loading	controls.	
(B)	Western	blot	of	JAR	cell	samples	after	a	10-minute	stimulation	with	25	ng/mL	of	
the	detailed	cytokines.	 In	this	case	STAT3	phosphorylation	reflects	hLIFR	activation,	
while	total	STAT3	and	pan-Actin	serve	as	 loading	controls.	(C)	Quantitative	analysis	
of	hOSMR	and	hLIFR	activation	levels	after	a	10-minute	stimulation	treatment	with	
the	 indicated	 cytokines,	 relative	 to	 the	 observed	 activation	 for	WT	 hOSM.	 Values	
were	normalized	against	 total	 STAT3	 levels	 and	presented	as	mean	±	 s.e.m.	 (n=5).	
Statistical	 significance	 was	 determined	 by	 Welch's	 T-test,	 with	 (**)	 indicating	 p-
values	<	0.01.	
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These	results	point	 to	two	substitutions	 in	particular,	N37G	and	D42K,	as	playing	a	
pivotal	 role	 in	 permitting	 hOSMR	 activation.	 The	 24-hour	 and	 5-day	 stimulation	
experiments	 reproduced	 the	 pattern	 observed	 in	 the	 10-minute	 readout	 system,	
reinforcing	this	conclusion	(Fig.	35A-D).	
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Figure	35:	Long-term	receptor	activation	ability	of	mOSM	point	mutants	confirms	
residues	 determining	 species	 specificity	 within	 the	 AB	 loop.	 (A)	Western	 blot	 of	
HepG2	 cell	 samples	 after	 a	 24-hour	 stimulation	with	 25	 ng/mL	 of	WT	mOSM,	WT	
hOSM,	WT	hLIF	and	the	mOSM	point	mutants	detailed.	TIMP1	levels	reflect	hOSMR	
activation,	while	total	pan-Actin	levels	serve	as	loading	control.	(B)	Western	blot	of	
JAR	cell	samples	after	a	24-hour	stimulation	with	the	indicated	cytokines.	In	this	case	
STAT3	 levels	 reflect	 hLIFR	 activation,	 while	 pan-Actin	 level	 is	 used	 as	 a	 loading	
control.	(C)	Quantitative	analysis	of	hOSMR	and	hLIFR	activation	levels	after	the	24-
hour	stimulation	treatment,	relative	to	the	observed	activation	for	WT	hOSM.	Values	
were	normalized	against	pan-Actin	levels	and	presented	as	mean	±	s.e.m.	(n=5).	(D)	
A375	 proliferation	 levels	 5	 days	 after	 stimulation	 with	 10	 ng/mL	 of	 the	 indicated	
cytokines,	relative	to	the	proliferation	of	the	control	group.	Values	are	given	as	mean	
±	 s.e.m.	 (n=3).	 Statistical	 significance	was	 determined	 by	Welch's	 T-test,	with	 (**)	
indicating	p-values	<	0.01.	
	
	
4.2.4.	Mutations	in	the	residues	defining	species	specificity	in	murine	Oncostatin	M	
result	in	promiscuous	mouse	receptor	activation	
	
After	examining	 the	ability	of	 the	 created	mutant	mOSM	cytokines	 to	activate	 the	
human	receptor,	 the	next	 logical	 step	was	 to	examine	whether	human	and	mouse	
OSMR	 are	 mutually	 exclusive	 by	 assessing	 the	 mOSMR	 activation	 ability	 of	 these	
variants.	 To	 this	 end,	 a	 suitable	 readout	 system	 had	 first	 to	 be	 developed	 to	
investigate	the	activation	of	the	different	murine	receptors.	
	
In	 contrast	 to	 the	 human	 situation,	 the	 available	 information	 regarding	 specific	
mLIFR-	 or	mOSMR-expressing	murine	 cell	 lines	 is	 very	 limited:	 the	NIH3T3	murine	
fibroblast	cell	line	had	been	reported	in	the	past	to	be	responsive	to	mOSM	but	not	
hOSM	 or	 hLIF,	 which	 would	 indicate	 lack	 of	 mLIFR	 expression,	 although	 later	
publications	appear	to	contradict	this	observation.	(Ichihara	et	al.	1997)	(Gyotoku	et	
al.	2001)	
	
To	 ascertain	whether	NIH3T3	 cells	 could	be	used	 as	 a	 suitable	 readout	 system	 for	
mOSMR	 activation,	we	 first	 compared	 downstream	 STAT3	 phosphorylation	 after	 a	
10-minute	stimulation	with	both	mLIFR-	and	mOSMR-activating	cytokines	(Fig.	36A).	
The	presence	of	both	receptor	types	was	quite	apparent,	so	to	obtain	a	more	specific	
readout	 NIH3T3	 cells	 were	 stably	 transfected	 with	 an	 shRNA	 construct	 directed	
against	 mLIFR	 (Fig.	 36B).	 By	 comparing	 the	 phosphorylation	 pattern	 of	 these	
knockdown	 cells	 against	NIH3T3	 cells	 stably	 transfected	with	 an	 empty	 plasmid,	 it	
can	then	be	determined	whether	a	cytokine	in	question	signals	through	the	mLIFR.	
	
	 90	
	
	
Figure	 36:	 STAT3	 phosphorylation	 after	 10	 minutes	 can	 be	 used	 to	 distinguish	
mOSMR	and	mLIFR	activation	 in	stably	transfected	NIH3T3	cells.	(A)	Western	blot	
of	STAT3	phosphorylation	 levels	 in	NIH3T3	cells	 stimulated	 for	10	minutes	with	25	
ng/mL	of	hLIF,	hOSM	and	mOSM.	Total	STAT3	and	pan-Actin	levels	serve	as	loading	
controls.	 (B)	Western	 blot	 showing	 STAT3	 phosphorylation	 levels	 in	 NIH3T3	 cells	
stably	transfected	with	shRNA	directed	against	mLIFR	after	a	10-minute	stimulation	
with	 25	 ng/mL	 of	 hLIF,	 hOSM	 and	 mOSM.	 Total	 STAT3	 and	 pan-Actin	 expression	
levels	were	used	as	loading	controls.	
	
	
Efforts	 were	 also	 made	 to	 establish	 a	 second	 readout	 system	 to	 reliably	 confirm	
murine	 receptor	 activation.	 In	 the	 case	 of	 mOSMR,	 Richards	 and	 colleagues	 had	
reported	murine	TIMP1	(mTIMP1)	transcript	levels	to	be	upregulated	in	NIH3T3	cells	
in	 response	 to	 mOSMR	 activity,	 but	 not	 mLIFR.	 (Richards	 et	 al.	 1993)	 This	
observation	was	confirmed	at	the	protein	level	after	24	hours	of	stimulation,	with	a	
Western	blot	against	mTIMP1	reflecting	the	expected	receptor	activation	profile	for	
mOSM,	hOSM	and	hLIF	(Fig.	37A).	
	
Regarding	mLIFR	activation,	murine	hematopoietic	cell	lines	had	been	claimed	to	be	
responsive	to	mLIF	but	not	mOSM,	which	would	hint	at	exclusive	expression	of	the	
mLIFR.	 (Ichihara	et	al.	1997)	Given	that	hematopoietic	stem	cells	give	rise	to	every	
type	of	blood	cell	(reviewed	in	(Schroeder	2010)),	it	appeared	possible	that	some	of	
these	descendant	cell	lineages	might	also	share	the	same	mOSMR/mLIFR	expression	
traits.	 Indeed,	 when	 the	 murine	 monocyte	 cell	 line	 MH-S	 was	 tested	 for	
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responsiveness	 to	mOSMR-	 and	mLIFR-activating	 cytokines,	 after	 10	minutes	 only	
those	 signaling	 through	 the	 mLIFR	 evidenced	 strong	 STAT3	 phosphorylation	 (Fig.	
37B).	 In	 this	 manner,	 10-minute	 stimulation	 experiments	 in	 MH-S	 cells	 proved	
suitable	as	specific	readouts	for	mLIFR	activation	in	subsequent	experiments.	
	
	
Figure	37:	TIMP1	expression	after	24	hours	indicates	mOSMR	activation	in	NIH3T3	
cells,	 while	 STAT3	 phosphorylation	 reflects	 mLIFR	 activation	 in	 MH-S	 cells.	 (A)	
Western	 blot	 reflecting	 TIMP1	 expression	 levels	 in	 NIH3T3	 cells	 stimulated	 for	 24	
hours	with	25	ng/mL	of	hLIF,	hOSM	and	mOSM.	Pan-Actin	levels	serve	as	a	 loading	
control.	 (B)	Western	blot	showing	STAT3	phosphorylation	levels	in	MH-S	after	a	10-
minute	 stimulation	 with	 hLIF,	 hOSM	 and	 mOSM.	 Total	 STAT3	 and	 pan-Actin	
expression	levels	were	used	as	loading	controls.	
	
	
Once	the	appropriate	readout	systems	had	been	established,	the	mOSMR	activation	
ability	of	the	quadruple	and	quintuple	mOSM	mutants,	as	well	as	the	AB	loop	and	N-
terminal	 D-helix	 chimeras,	 could	 be	 assessed.	 In	 first	 place,	 the	 STAT3	
phosphorylation	 pattern	 in	 shRNA-mediated	 mLIFR	 knockdown	 (KD)	 NIH3T3	 cells	
was	unchanged	 in	 respect	 to	 the	control	 cell	 line,	 suggesting	 that	even	 the	mOSM	
variants	 with	 the	 largest	 replacements	 retain	 the	 ability	 to	 signal	 through	 the	
mOSMR	(Fig.	38A-C).	
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Figure	 38:	 Short-term	 stimulations	 with	 mOSM	 chimeras	 point	 at	 preserved	
mOSMR	 activation	 abilities.	 (A)	 Western	 blot	 of	 NIH3T3	 cell	 samples	 stably	
transfected	with	an	empty	vector	and	stimulated	 for	10	minutes	with	25	ng/mL	of	
the	 indicated	 cytokines.	 STAT3	 phosphorylation	 reflects	 mOSMR	 and/or	 mLIFR	
activation,	with	 total	STAT3	and	pan-Actin	serving	as	 loading	controls.	 (B)	Western	
blot	of	NIH3T3	cell	samples	stably	transfected	with	shRNA	against	mLIFR,	harvested	
after	a	10-minute	stimulation	with	25	ng/mL	of	the	indicated	cytokines.	In	this	case	
STAT3	phosphorylation	mainly	reflects	mOSMR	activation,	with	total	STAT3	and	pan-
Actin	serving	as	loading	controls.		(C)	Quantitative	analysis	of	STAT3	phosphorylation	
levels	for	the	mutants	tested,	relative	to	WT	mOSM.	Values	were	normalized	against	
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total	STAT3	levels	and	presented	as	mean	±	s.e.m.	(n=5).	Statistical	significance	was	
determined	by	Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
This	observation	was	complemented	by	employing	the	two	specific	readout	systems	
for	 mOSMR	 and	 mLIFR,	 which	 confirmed	 the	 existence	 of	 receptor-mediated	
signaling	in	these	variants	(Fig.	39A-C).	
	
	
	
Figure	39:	Specific	readout	system	confirms	different	mOSM	chimeras	are	able	to	
activate	the	mLIFR.	(A)	Western	blot	of	NIH3T3	cell	samples	stimulated	for	24	hours	
with	 25	 ng/mL	 of	 the	 indicated	 cytokines.	 mTIMP1	 expression	 reflects	 mOSMR	
activation,	with	pan-Actin	being	used	as	a	loading	control.	(B)	Western	blot	of	MH-S	
cell	samples	harvested	after	a	10-minute	stimulation	with	25	ng/mL	of	the	indicated	
cytokines.	 In	 this	 case	 STAT3	 phosphorylation	 reflects	mLIFR	 activation,	 with	 total	
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STAT3	 and	 pan-Actin	 serving	 as	 loading	 controls.	 	 (C)	 Quantitative	 analysis	 of	
mOSMR	and	mLIFR	activation	 levels	 for	the	mutants	tested,	relative	to	WT	mOSM.	
Values	were	normalized	against	pan-Actin	levels	(for	mTIMP1)	or	total	STAT3	levels	
(for	P-STAT3)	and	presented	as	mean	±	s.e.m.	(n=5).	
	
	
As	 could	 be	 expected	 this	 finding	 was	 extensible	 to	 the	 single,	 double	 and	 triple	
mOSM	mutants:	their	signaling	remained	unaffected	after	knockdown	of	the	mLIFR	
(Fig.	40A-C).	
	
	
	
Figure	 40:	 Short-term	 stimulations	with	mOSM	 point	mutants	 hint	 at	 conserved	
mOSMR	 activation	 abilities.	 (A)	 Western	 blot	 of	 NIH3T3	 cell	 samples	 stably	
transfected	with	an	empty	vector	and	stimulated	 for	10	minutes	with	25	ng/mL	of	
the	 indicated	 cytokines.	 STAT3	 phosphorylation	 reflects	 mOSMR	 and/or	 mLIFR	
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
P
-S
TA
T3
 in
te
ns
ity
 re
la
tiv
e 
to
 W
T 
m
O
S
M
 
0.0 
0.4 
0.6 
1.0 
0.2 
0.8 
1.2 
C	
hOSM 
WT 
hLIF 
WT 
mOSM point mutants 
L35I N37G N39D T40V D42K N37G 
T40V 
N37G 
D42K 
T40V 
D42K 
N37G 
T40V 
D42K 
Empty 
mLIFR KD 
** 
** 
mOSM point mutants 
L35I N37G N39D T40V D42K 
N37G 
T40V 
P-STAT3 
Pan-Actin 
Ctrl 
STAT3 
mOSM 
WT 
hOSM 
WT 
hLIF 
WT 
N37G 
D42K 
T40V 
D42K 
N37G 
T40V 
D42K 
A	
mOSMR+mLIFR	
(NIH3T3	+	empty		
vector,	10’)	
B	 mOSM point mutants 
L35I N37G N39D T40V D42K 
N37G 
T40V 
P-STAT3 
Pan-Actin 
Ctrl 
STAT3 
mOSM 
WT 
hOSM 
WT 
hLIF 
WT 
N37G 
D42K 
T40V 
D42K 
N37G 
T40V 
D42K 
mOSMR		
(NIH3T3	+	mLIFR		
shRNA,	10’)	
	 95	
activation,	with	 total	STAT3	and	pan-Actin	serving	as	 loading	controls.	 (B)	Western	
blot	of	NIH3T3	cell	samples	stably	transfected	with	shRNA	against	mLIFR,	harvested	
after	a	10-minute	stimulation	with	25	ng/mL	of	 the	detailed	cytokines.	 In	 this	case	
STAT3	phosphorylation	reflects	mainly	mOSMR	activation,	with	total	STAT3	and	pan-
Actin	serving	as	loading	controls.		(C)	Quantitative	analysis	of	STAT3	phosphorylation	
levels	for	the	mutants	tested,	relative	to	WT	mOSM.	Values	were	normalized	against	
total	STAT3	levels	and	presented	as	mean	±	s.e.m.	(n=5).	Statistical	significance	was	
determined	by	Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
Specific	 readouts	 confirmed	 that	 these	 variants	 show	 uneven	 mLIFR	 activation	
ability,	 closely	 reflecting	 their	 human	 receptor	 activation	 abilities,	 but	 all	 of	 them	
without	exception	were	still	capable	of	signaling	through	the	mOSMR	to	drive	TIMP1	
production	 in	 NIH3T3	 cells	 (Fig.	 41A-C).	 Taken	 together,	 these	 experiments	
demonstrate	 that	 mutations	 in	 the	 AB	 loop	 of	 mOSM	 confer	 the	 ability	 to	 signal	
through	the	mLIFR	and	both	human	receptor	complexes	without	impacting	mOSMR	
interaction.	
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Figure	41:	Specific	readout	system	confirms	murine	receptor	promiscuity	of	various	
mOSM	 point	mutants.	 (A)	Western	blot	 of	NIH3T3	 cell	 samples	 stimulated	 for	 24	
hours	with	25	ng/mL	of	the	indicated	cytokines.	mTIMP1	expression	reflects	mOSMR	
activation,	with	pan-Actin	being	used	as	a	loading	control.	(B)	Western	blot	of	MH-S	
cell	samples	harvested	after	a	10-minute	stimulation	with	25	ng/mL	of	the	indicated	
cytokines.	 In	 this	 case	 STAT3	 phosphorylation	 reflects	mLIFR	 activation,	 with	 total	
STAT3	 and	 pan-Actin	 serving	 as	 loading	 controls.	 	 (C)	 Quantitative	 analysis	 of	
mOSMR	and	mLIFR	activation	 levels	 for	the	mutants	tested,	relative	to	WT	mOSM.	
Values	were	normalized	against	pan-Actin	levels	(for	mTIMP1)	or	total	STAT3	levels	
(for	P-STAT3)	and	presented	as	mean	±	s.e.m.	(n=5).	
	
	
4.2.5.	 Substitutions	 in	 the	 residues	 involved	 in	 species	 specificity	 in	 human	
Oncostatin	M	enable	murine	OSMR	activation	
	
The	 lack	 of	 effect	 of	 any	 AB	 loop	 substitution	 in	 the	 activation	 of	 the	mOSMR	 by	
mOSM	greatly	contrasts	with	the	prior	observations	in	the	human	system,	and	might	
reflect	the	existence	of	a	different	binding	interface	not	involving	the	AB	loop	in	the	
mouse	 complex.	 To	 investigate	 this	 point	 in	 more	 detail,	 hOSM	 point	 mutants	
carrying	 the	 mouse	 residues	 in	 the	 pivotal	 positions	 identified	 for	 mOSM	 (G39N,	
V42T	and	K44D),	as	well	as	a	chimera	with	the	full	N-terminal	AB	loop	replaced	by	its	
murine	 equivalent,	 were	 created	 by	 overlapping	 PCR,	 expressed	 and	 purified	
following	the	previously	established	protocols.	
	
As	could	be	expected,	given	that	the	glycine	in	position	39	of	hOSM	had	previously	
proved	 critical	 for	 hOSMR	 activation	 in	 the	 alanine	 scanning	 experiment,	 every	
cytokine	 variant	 incorporating	 the	 mutation	 G39N	 was	 no	 longer	 able	 to	 signal	
through	the	hOSMR	(Fig.	42A-C).	
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Figure	42:	Short-term	receptor	activation	ability	of	hOSM	point	mutants	reinforces	
the	importance	of	G39	for	hOSMR	signaling.	(A)	Western	blot	of	A375	cell	samples	
after	a	10-minute	stimulation	with	25	ng/mL	of	WT	mOSM,	WT	hOSM,	WT	hLIF	and	
the	point	mutants	detailed.	STAT3	phosphorylation	reflects	hOSMR	activation,	while	
total	 STAT3	 and	 pan-Actin	 serve	 as	 loading	 controls.	 (B)	 Western	 blot	 of	 JAR	 cell	
samples	after	a	10-minute	stimulation	with	25	ng/mL	of	the	 indicated	cytokines.	 In	
this	case	STAT3	phosphorylation	reflects	hLIFR	activation,	while	total	STAT3	and	pan-
Actin	 serve	 as	 loading	 controls.	 (C)	 Quantitative	 analysis	 of	 hOSMR	 and	 hLIFR	
activation	 levels	 after	 the	 10-minute	 stimulation	 experiments,	 relative	 to	 the	
observed	activation	for	WT	hOSM.	Values	were	normalized	against	total	STAT3	levels	
and	presented	as	mean	±	s.e.m.	(n=5).	
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This	 observation	 could	 be	 confirmed	 through	 the	 longer-term	 readout	 systems:	
while	hLIFR	 signaling	 is	 still	 preserved	 to	 some	extent	 for	 all	 the	mutants	 assayed,	
hOSMR	signaling	is	abrogated	in	the	absence	of	G39	(Fig.	43A-D).	
	
	
	
Figure	43:	 Long-term	 receptor	activation	ability	of	hOSM	point	mutants	 confirms	
G39	as	critical	to	initiate	hOSMR	signaling.	(A)	Western	blot	of	HepG2	cell	samples	
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after	a	24-hour	stimulation	with	25	ng/mL	of	WT	mOSM,	WT	hOSM,	WT	hLIF	and	the	
point	 mutants	 indicated.	 TIMP1	 levels	 reflect	 hOSMR	 activation,	 while	 total	 pan-
Actin	levels	serve	as	loading	control.	(B)	Western	blot	of	JAR	cell	samples	after	a	24-
hour	stimulation	with	the	detailed	cytokines.	 In	this	case	STAT3	levels	reflect	hLIFR	
activation,	while	pan-Actin	level	is	used	as	a	loading	control.	(C)	Quantitative	analysis	
of	 hOSMR	 and	 hLIFR	 activation	 levels	 after	 the	 24-hour	 stimulation	 experiments,	
relative	 to	 the	 observed	 activation	 for	WT	 hOSM.	Values	were	 normalized	 against	
pan-Actin	levels	and	presented	as	mean	±	s.e.m.	(n=5).	(D)	A375	proliferation	levels	
5	 days	 after	 stimulation	with	 10	 ng/mL	 of	 the	 indicated	 cytokines,	 relative	 to	 the	
proliferation	of	the	control	group.	Values	are	given	as	mean	±	s.e.m.	(n=3).	Statistical	
significance	was	determined	by	Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
Surprisingly,	when	the	cell	stimulation	experiments	in	murine	cells	were	carried	out,	
replacing	the	lysine	in	position	44	by	aspartic	acid	appeared	sufficient	to	confer	the	
mutants	with	mOSMR	signaling	ability	(Fig.	44A-C).	
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Figure	 44:	 Short-term	 stimulations	 with	 hOSM-based	mutants	 indicate	 apparent	
mOSMR	 activation	 abilities.	 (A)	 Western	 blot	 of	 NIH3T3	 cell	 samples	 stably	
transfected	with	an	empty	vector	and	stimulated	 for	10	minutes	with	25	ng/mL	of	
the	 indicated	 cytokines.	 STAT3	 phosphorylation	 reflects	 mOSMR	 and/or	 mLIFR	
activation,	with	 total	STAT3	and	pan-Actin	serving	as	 loading	controls.	 (B)	Western	
blot	of	NIH3T3	cell	samples	stably	transfected	with	shRNA	against	mLIFR,	harvested	
after	a	10-minute	stimulation	with	25	ng/mL	of	the	indicated	cytokines.	In	this	case	
STAT3	phosphorylation	reflects	mainly	mOSMR	activation,	with	total	STAT3	and	pan-
Actin	serving	as	loading	controls.		(C)	Quantitative	analysis	of	STAT3	phosphorylation	
levels	for	the	mutants	tested,	relative	to	WT	mOSM.	Values	were	normalized	against	
total	STAT3	levels	and	presented	as	mean	±	s.e.m.	(n=5).	Statistical	significance	was	
determined	by	Welch's	T-test,	with	(**)	indicating	p-values	<	0.01.	
	
	
Confirmatory	 experiments	 employing	 specific	 readouts	 left	 no	 doubt	 that	 K44	 is	
responsible	 for	 the	 lack	of	 cross-species	 reactivity	 of	 hOSM	with	 the	mOSMR,	 and	
that	its	substitution	by	aspartic	acid	is	sufficient	for	the	mutant	cytokine	to	display	a	
signaling	 ability	 in	 murine	 cells	 that	 mirrors	 the	 human	 situation	 (Fig.	 45A-C).	
Furthermore,	these	mutants	 indicate	that	the	AB	loop	of	the	cytokine	does	play	an	
important	 role	 in	 mOSMR	 activation,	 as	 was	 the	 case	 for	 the	 N-terminal	 D-helix	
region	in	the	human	receptor,	despite	the	fact	that	the	native	murine	cytokine	can	
withstand	modifications	in	this	region	without	affecting	OSMR	signaling.	
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Figure	 45:	 Specific	 readout	 system	 confirms	 acquisition	 of	mOSMR	 activation	 by	
hOSM	 variants.	 (A)	Western	 blot	 of	 NIH3T3	 cell	 samples	 stimulated	 for	 24	 hours	
with	 25	 ng/mL	 of	 the	 indicated	 cytokines.	 mTIMP1	 expression	 reflects	 mOSMR	
activation,	with	pan-Actin	being	used	as	a	loading	control.	(B)	Western	blot	of	MH-S	
cell	samples	harvested	after	a	10-minute	stimulation	with	25	ng/mL	of	the	indicated	
cytokines.	 In	 this	 case	 STAT3	 phosphorylation	 reflects	mLIFR	 activation,	 with	 total	
STAT3	 and	 pan-Actin	 serving	 as	 loading	 controls.	 	 (C)	 Quantitative	 analysis	 of	
mOSMR	and	mLIFR	activation	 levels	 for	the	mutants	tested,	relative	to	WT	mOSM.	
Values	were	normalized	against	pan-Actin	levels	(for	mTIMP1)	or	total	STAT3	levels	
(for	P-STAT3)	and	presented	as	mean	±	s.e.m.	(n=5).	
	
	
As	 a	 summary	of	 the	 results	 comprising	 this	 thesis,	 the	 signaling	properties	of	 the	
main	mutant	variants	used	in	this	work	have	been	collected	in	figure	46.	
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Figure	 46:	 Signaling	 properties	 of	 the	 main	 mutant	 variants	 created.	 (A)	 The	
substitution	of	the	AB	loop	region	of	hOSM	by	its	equivalent	hLIF	sequence	disrupted	
STAT3	phosphorylation	through	the	hOSMR,	while	a	replacement	of	the	N-terminal	
helix	D	region	only	had	a	small	impact.	Conversely,	substitutions	of	both	AB	loop	and	
N-terminal	 helix	 D	 sequences	 in	 hLIF	 by	 their	 corresponding	 hOSM	 sequence	was	
required	 for	 the	 chimeric	 cytokine	 to	 signal	 through	 the	 hOSMR	 complex.	 (B)	
Replacement	of	 the	AB	 loop	of	mOSM	by	the	human	 loop	enabled	the	cytokine	to	
signal	 through	 the	hOSMR	while	maintaining	 affinity	 for	 the	murine	 receptor.	 This	
change	in	affinity	is	determined	by	just	three	amino	acid	substitutions,	as	evidenced	
by	the	mOSM	triple	mutant.	In	contrast,	exchanging	the	AB	loop	of	hOSM	by	the	one	
in	mOSM	leads	to	a	switch	in	receptor	signaling.	
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5.	Discussion	
	
The	 availability	 of	 detailed	 data	 on	 cytokine-receptor	 interactions	 for	 potential	
immunotherapeutic	cytokines	is	critical,	as	it	has	led	to	the	development	of	a	whole	
new	approach	 to	 protein	 engineering:	 by	 employing	 this	 information	 as	 a	 basis	 to	
manipulate	 signaling,	 striking	 improvements	 can	 be	 achieved	 in	 terms	 of	 potency,	
affinity	and	specificity.	(Spangler	et	al.	2015)	
	
In	this	regard,	the	interaction	of	IL-6	with	its	receptors	has	been	well	characterized:	
the	 crystal	 structure	 of	 the	 complex	 between	 IL-6,	 the	 IL6R	 and	 the	 extracellular	
region	of	gp130	provided	detailed	information	on	the	interacting	residues	between	
these	molecules.	(Boulanger,	Chow,	et	al.	2003)	The	same	holds	true	for	many	of	the	
other	 IL-6	 family	 members:	 crystallization	 experiments	 have	 provided	 valuable	
insight	 into	 the	 binding	 between	 LIF	 and	 gp130,	 LIF	 and	 LIFR,	 and	 CNTF	 and	 the	
LIFR/CNTFR/gp130	complex.	(Boulanger,	Bankovich,	et	al.	2003)	(Huyton	et	al.	2007)		
(Skiniotis	et	al.	2008)	
	
In	 contrast,	 despite	 the	 fact	 that	 OSM	 possesses	 the	 broadest	 signaling	 abilities	
within	 the	 IL-6	 class	 and	 thus	 the	 widest	 range	 of	 possible	 applications,	 little	
evidence	 regarding	 the	 interaction	 between	 OSM	 and	 its	 receptor	 complexes	 is	
available	to	date.	(Hermanns	2015)	 In	order	to	address	this	 lack	of	 information	the	
present	 work	 employs	 molecular	 biology	 tools	 such	 as	 the	 creation	 of	 chimeric	
proteins,	 successfully	 used	 in	 the	 past	 to	 examine	 differences	 in	 binding	 and	
downstream	 signaling	 in	 a	 variety	 of	 receptor	 systems	 including	 OSMR,	 LIFR	 and	
gp130.	(Kallen	et	al.	1999)	(Hermanns	et	al.	1999)	
	
By	these	means	the	particular	 features	of	hOSM	that	enable	 it	 to	activate	multiple	
receptors	 could	 be	 identified,	 and	 variants	 with	 a	 modified	 receptor	 activation	
profile	 in	respect	 to	the	native	human	cytokine	could	be	obtained.	 In	addition,	 the	
same	 techniques	 were	 applied	 to	 locate	 the	 molecular	 determinants	 causing	 the	
well-described	difference	 in	 receptor	 specificity	between	hOSM	and	mOSM,	which	
hinders	the	translation	of	results	obtained	in	murine	models	to	the	human	situation.	
(Ichihara	 et	 al.	 1997)	 This	 research	 is	 expected	 to	 have	 immediate	 practical	
applications,	as	some	of	the	OSM	variants	created	show	the	potential	to	improve	the	
translatability	of	future	OSM	studies	in	mouse	models.	
	
Finally,	 the	data	collected	 in	 this	work	supports	 the	possibility	 that	OSM	may	have	
adopted	an	evolutionary	path	so	far	unreported	for	other	cytokines,	attaining	a	new	
function	 through	 the	evolution	of	 a	 promiscuous	 intermediate	which	would	 finally	
derive	 into	 a	 new	 specific	molecule.	 This	 process,	widely	 accepted	 in	 enzymology,	
will	be	discussed	in	depth	in	section	5.5.	(Khersonsky	&	Tawfik	2010)	
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5.1.	Novel	recombinant	OSM	production	and	receptor	activation	readout	systems	
	
The	 experiments	 comprising	 this	 work	 relied	 on	 the	 ability	 to	 express	 and	 purify	
several	 wild-type	 cytokines	 (hOSM,	 hLIF	 and	 mOSM),	 as	 well	 as	 different	 point	
mutants	 and	 chimeric	 proteins.	 This	 is	 generally	 a	 laborious	 and	 time-consuming	
process:	 these	 particular	 proteins	 tend	 to	 aggregate	 and	 form	 insoluble	 inclusion	
bodies	 when	 overexpressed	 in	 a	 prokaryotic	 system,	 requiring	 additional	 steps	 in	
order	to	be	refolded	into	their	native	secondary	structure.	(Sporeno	et	al.	1994)	An	
alternative	approach	consists	of	the	fusion	of	the	cytokine	to	a	solubility	tag	such	as	
GST,	which	avoids	the	aggregation	of	the	protein	into	inclusion	bodies	but	implies	an	
additional	step	to	remove	the	tag	after	expression.	(Deller	et	al.	2000)	
	
To	 improve	 on	 the	 reported	methods,	 two	 different	 solutions	were	 developed:	 at	
first,	 soluble	 prokaryotic	 expression	was	 achieved	 by	 employing	 a	modified	E.	 coli	
strain	 expressing	 a	 chaperone/disulfide	 bond	 isomerase.	 This	 method	 led	 to	 the	
production	 and	 direct	 recovery	 of	 wild	 type	 and	 point	 mutant	 cytokines	 without	
additional	steps,	confirming	that	the	observed	recombinant	cytokine	aggregation	in	
the	common	bacterial	strains	is	consequence	of	a	lack	of	disulfide	bond	formation	in	
the	prokaryotic	cytoplasm.	(Baneyx	&	Mujacic	2004)	
	
However,	expression	of	soluble	chimeric	proteins	could	not	be	achieved	in	bacteria,	
perhaps	 due	 to	 the	 substantial	modifications	 in	 their	 native	 amino	 acid	 sequence.	
This	 led	 to	 a	mammalian	 expression	 system	 being	 established:	 human	 FreeStyle™	
293-F	 cells	 proved	 able	 to	 produce	 recombinant	 proteins,	 including	 the	 chimeric	
variants,	in	sufficient	amounts	for	later	use	in	stimulation	experiments.	The	fact	that	
these	cells	are	adapted	to	serum-free	medium	facilitated	downstream	recovery	and	
purification	 of	 the	 recombinant	 proteins.	 In	 both	 prokaryotic	 and	 mammalian	
expression	 systems	 the	 presence	 of	 a	 C-terminal	His-tag	 enabled	 the	 recombinant	
proteins	to	be	purified	using	Ni-NTA	affinity	resins.	(Schmitt	et	al.	1993)	
	
In	 respect	 to	monitoring	 receptor	 activation	 in	 response	 to	 the	 array	 of	 cytokines	
created,	 the	 short-term	 indicator	 selected	 was	 downstream	 phosphorylation	 of	
STAT3.	As	discussed	in	section	1.3,	this	signaling	component	is	shared	by	all	the	IL-6	
family	receptors	and	plays	a	crucial	role	after	their	activation:	OSM	is	no	exception,	
as	 STAT3	 mediates	 most	 of	 its	 biological	 effects	 including	 hematopoiesis,	
cardioprotection	and	liver	regeneration.	(Takizawa	et	al.	2003)	(Hilfiker-Kleiner	et	al.	
2004)	 (Lörchner	 et	 al.	 2015)	 (Li	 et	 al.	 2002)	 (Nakamura	 et	 al.	 2004)	 By	 taking	
advantage	of	well-characterized	cell	lines	exclusively	expressing	hOSMR	or	hLIFR,	as	
well	 as	 novel	 mOSMR	 or	 mLIFR-specific	 cell	 types	 in	 the	 murine	 situation,	 STAT3	
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phosphorylation	 became	 the	 main	 readout	 for	 receptor	 activity	 in	 most	 of	 the	
experiments	contained	in	this	work.	(Auguste	et	al.	1997)	
	
Additional	readout	systems	at	 later	time	points	were	employed	in	order	to	confirm	
the	 initial	 observations	 derived	 from	 the	 measurement	 of	 STAT3	 phosphorylation	
levels	 after	 a	 10-minute	 stimulation.	 In	 the	 case	 of	 OSMR	 activation,	 TIMP1	 was	
selected	as	a	known	specific	target	of	this	receptor	in	contrast	to	the	LIFR:	24	hours	
of	stimulation	are	sufficient	 for	TIMP1	expression	 levels	 to	 increase	dramatically	 in	
both	 human	 and	 murine	 systems.	 (Richards	 et	 al.	 1993)	 (Bugno	 et	 al.	 1995)	 In	
addition,	 given	 that	 hOSM	 was	 first	 identified	 as	 a	 proliferation	 inhibitor	 in	 a	
melanoma	 cell	 line,	 its	 ability	 to	 perform	 this	 activity	 was	 also	 leveraged	 as	 a	
measure	of	hOSMR	activation.	(Zarling	et	al.	1986)	
	
Finding	specific	LIFR	targets	that	were	not	shared	with	the	OSMR	proved	to	be	more	
of	a	challenge,	so	in	the	end	the	decision	was	made	to	employ	an	hLIFR-specific	cell	
line	and	monitor	 total	 STAT3	 levels	after	24	hours	as	a	 reflection	of	hLIFR	activity.	
(Bugno	 et	 al.	 1995)	 In	 all	 these	 cases,	 longer-term	 stimulation	 results	 agreed	with	
those	obtained	in	the	initial	STAT3	phosphorylation	readouts.	
	
5.2.	The	AB	loop	of	Oncostatin	M	influences	activation	of	the	human	OSMR	
	
The	key	role	of	the	N	terminus	of	helix	D	is	well	documented:	it	has	been	described	
in	 the	past	 that	 the	hOSM	residues	F160	and	K163	are	critical	 for	hOSMR	binding.	
(Deller	 et	 al.	 2000)	As	 a	 consequence,	when	 the	phenylalanine	and/or	 lysine	were	
replaced	 by	 alanine,	 the	 mutant	 cytokines	 became	 unable	 to	 elicit	 any	 biological	
activity	or	initiate	hOSMR/hLIFR	signaling.	(Deller	et	al.	2000)	
	
The	FXXK	motif	formed	by	these	two	amino	acids	is	a	conserved	feature	in	all	LIFR-
binding	cytokines,	such	as	LIF,	CNTF	and	CT-1.	(Di	Marco	et	al.	1996)		(Plun-Favreau	
et	al.	2003)	The	positive	region	constituted	by	this	motif	appears	to	interact	with	a	
negative	core	formed	by	an	aspartic	acid	residue	in	the	immunoglobin-like	domain	of	
the	LIFR,	as	site-directed	mutagenesis	of	this	domain	resulted	in	a	mutant	receptor	
with	impaired	cytokine	binding	ability.	(Plun-Favreau	et	al.	2003)	
	
However,	since	hOSM	is	the	only	one	of	these	cytokines	able	to	activate	the	hOSMR	
in	addition	to	the	hLIFR,	it	stands	to	reason	that	this	conserved	FXXK	motif	cannot	be	
the	 only	 structural	 feature	 involved	 in	 hOSMR	 recognition.	 Structural	 comparisons	
between	the	IL-6	class	members	suggested	the	 lengthened	BC	 loop	 in	hOSM	might	
act	as	a	possible	hOSMR-specific	recognition	site,	since	it	forms	part	of	the	general	
binding	region	for	both	receptors.	(Chollangi	et	al.	2012)	However,	the	importance	of	
this	 loop	for	hOSMR	specificity	was	disproved	by	the	production	of	hOSM	mutants	
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with	a	 shortened	BC	 loop	 region,	which	were	 still	 able	 to	activate	 the	hOSMR	and	
displayed	higher	affinity	for	both	receptor	types.	(Chollangi	et	al.	2012)	
	
The	work	presented	here	took	advantage	of	the	similarities	between	hOSM	and	hLIF	
to	create	a	series	of	chimeric	cytokines	based	on	hOSM,	in	which	different	regions	of	
binding	site	III	were	exchanged	by	their	hLIF	equivalents.	By	these	means	it	could	be	
proved	that	the	main	region	of	hOSM	enabling	specific	human	hOSMR	activation	is	
neither	 the	 longer	 BC	 loop	 nor	 the	N-terminal	 helix	 D	 region	 containing	 the	 FXXK	
motif,	since	replacing	them	barely	had	any	impact	on	cytokine	signaling.	
	
It	was	instead	the	AB	loop	of	hOSM	that	proved	to	be	crucial	for	hOSMR	activation:	
replacements	 of	 as	 little	 as	 10	 amino	 acids	 by	 their	 corresponding	 hLIF	 residues	
resulted	 in	 chimeric	 cytokines	 that	were	unable	 to	 initiate	hOSMR	 signaling,	while	
still	 displaying	normal	 function	 through	 the	hLIFR.	After	 this	 initial	 finding,	 alanine	
mutants	of	all	 individual	positions	within	the	AB	loop	of	human	OSM	led	to	a	more	
detailed	 assessment	 of	 the	 relative	 importance	 of	 each	 amino	 acid	 in	 receptor	
binding.	
	
Interestingly,	a	mutation	in	L40	resulted	in	complete	abrogation	of	signaling	through	
hOSMR	and	hLIFR,	which	could	reflect	either	a	crucial	role	in	the	activation	of	both	
receptors	 or	 an	 improper	 structural	 organization	 of	 the	 L40A	mutant.	 This	 second	
supposition	appears	more	likely,	since	amino	acids	with	aliphatic	side	chains	such	as	
leucine	 are	 very	 non-reactive:	 they	 tend	 to	 be	 buried	 in	 the	 protein	 interior,	
particularly	 in	 alpha	 helices,	 seldom	 being	 directly	 involved	 in	 protein	 function.	
(Betts	&	Russell	2003)	Disruption	of	the	secondary	structure	of	hOSM	also	explains	
the	 lack	 of	 signaling	 by	 the	 C49	 mutant,	 as	 this	 residue	 is	 part	 of	 an	 essential	
disulfide	bond	between	C49	and	C167.	 (Kallestad	et	 al.	 1991)	 The	presence	of	 the	
disulfide	 bond	 likely	 ensures	 that	 all	 regions	 of	 binding	 site	 III	 are	 in	 the	 correct	
orientation	and	distance	to	interact	with	the	receptor.	
	
Additionally,	 the	 alanine	 scanning	 analysis	 performed	 uncovered	 four	 different	
residues	 in	the	AB	loop	that	seem	to	be	exclusively	required	for	hOSMR	activation.	
Stimulation	 with	 Q38,	 G39	 and	 L45	 mutants	 led	 to	 normal	 hLIFR	 activation	 but	
complete	 absence	 of	 hOSMR-dependent	 signaling,	 while	 Y34	 resulted	 in	 partial	
impairment	of	hOSMR	activation.	
	
As	stated	above,	the	 leucine	 in	position	45	 is	probably	not	directly	 interacting	with	
the	hOSMR	due	to	its	hydrophobicity,	but	could	instead	be	required	to	maintain	the	
α-helical	structure	in	this	region	of	the	cytokine.	The	glutamine	at	position	38,	on	the	
other	hand,	is	a	polar	residue	frequently	found	in	the	protein	surface:	glutamines	are	
often	involved	in	protein	binding	sites,	interacting	with	other	amino	acids	with	polar	
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side	 chains	 or	 charged	 atoms.	 (Betts	 &	 Russell	 2003)	 An	 example	 of	 one	 such	
interaction	 is	 the	 bovine	 papillomavirus	 type	 1	 E5	 oncoprotein,	 in	 which	 a	 single	
glutamine	 residue	 is	 responsible	 for	 its	 association	 with	 a	 transmembrane	
component	in	the	vacuole.	(Goldstein	et	al.	1992)	Therefore,	it	seems	reasonable	to	
assume	that	in	the	case	of	hOSM	the	direct	binding	of	Q38	to	a	polar	residue	in	the	
hOSMR	is	necessary	for	receptor	recognition.	
	
The	 glycine	 in	 position	 39	 is	 perhaps	 the	 most	 intriguing	 of	 the	 four	 identified	
residues,	given	the	influence	it	also	has	in	species-specific	OSMR	activation.	Glycine	
is	 the	 amino	 acid	 with	 the	 smallest	 side	 chain,	 containing	 only	 a	 hydrogen	 atom	
without	any	carbons:	this	 leads	to	a	much	higher	conformational	 flexibility,	so	that	
glycine	can	be	found	in	structures,	such	as	tight	turns,	in	which	no	other	amino	acid	
can	 reside.	 (Betts	&	 Russell	 2003)	 This	 particularity	 also	 allows	 glycine	 to	 perform	
unique	 functional	 roles,	 such	 as	 binding	phosphates	 through	 its	 backbone	without	
employing	 a	 side	 chain,	 which	 makes	 them	 particularly	 important	 for	 kinase	
proteins.	(Schulze-Gahmen	et	al.	1996)	(Betts	&	Russell	2003)	
	
In	the	case	of	hOSM,	however,	G39	is	located	exactly	in	the	turn	between	the	end	of	
helix	A	and	the	AB	loop,	which	suggests	that	its	importance	is	more	likely	structural.	
In	this	way,	the	presence	of	a	glycine	in	that	position	would	enable	the	AB	loop	and	
D-helix	 regions	of	 the	molecule	 to	be	placed	at	 the	exact	distance	and	orientation	
required	to	enable	hOSMR	recognition	and	activation.	
	
The	last	relevant	residue	for	hOSMR	binding,	albeit	to	a	lesser	degree	than	Q38,	G39	
or	 L45,	 is	 the	 tyrosine	 in	 position	 34.	 This	 partially	 hydrophobic	 amino	 acid	 is	
regularly	found	buried	in	protein	cores,	but	unlike	leucine	the	side	chain	of	tyrosine	
contains	an	aromatic	ring	with	a	reactive	hydroxyl	group,	which	makes	it	more	likely	
to	 interact	 with	 atoms	 other	 than	 carbon.	 (Betts	 &	 Russell	 2003)	 In	 particular,	
aromatic	amino	acids	have	been	proposed	to	be	able	to	stack	on	top	of	each	other,	
with	 their	 aligned	 aromatic	 rings	 creating	 an	 electrostatic	 interaction	 between	
proteins.	(Hunter	et	al.	1991)	
	
If	 this	 were	 the	 case,	 Y34	 of	 hOSM	 would	 be	 interacting	 with	 a	 phenylalanine,	
tryptophan,	 histidine	 or	 another	 tyrosine	 in	 the	 binding	 interface	 of	 the	 hOSMR.	
However,	this	possible	interaction	would	not	be	essential	for	hOSMR	binding	and/or	
activation,	 since	 alanine	 replacement	 of	 Y34	 only	 causes	 a	 partial	 impairment	 of	
signaling.	
	
While	 the	 importance	 of	 the	 AB	 loop	 in	 terms	 of	 hOSMR	 activation	 appears	 clear	
based	 on	 the	 data	 presented,	 the	 exact	 mechanism	 behind	 the	 observed	 loss	 of	
signaling	has	yet	to	be	determined.	Taking	 into	account	the	nature	of	the	common	
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activation	 mechanism	 for	 type	 I	 cytokine	 receptor	 complexes,	 which	 undergo	
conformational	 changes	 that	 lead	 to	 transphosphorylation	 in	 their	 cytoplasmatic	
regions,	there	seem	to	be	two	main	possibilities	to	explain	this	lack	of	activation.	
	
Perhaps	the	most	 intuitive	hypothesis	 is	that	the	mutant	cytokine	completely	 loses	
its	ability	 to	bind	the	hOSMR	due	to	changes	 in	 its	AB	 loop.	However,	 it	cannot	be	
ruled	 out	 that	 this	 AB	 loop	 modification	 would	 result	 in	 a	 molecule	 that	 still	
maintains	 affinity	 for	 the	 hOSMR,	 but	 is	 no	 longer	 able	 to	 induce	 the	 required	
conformational	changes	to	initiate	intracellular	signaling	after	ligand	binding.	
	
To	 conclusively	 answer	 this	 question,	 direct	measurements	 of	 the	 binding	 affinity	
between	the	different	cytokine	variants	and	the	OSMR	would	have	to	be	performed.	
Assays	such	as	isothermal	titration	calorimetry	(ITC)	and	surface	plasmon	resonance	
(SPR)	are	nowadays	widely	used	to	this	end,	due	to	the	small	amount	of	unlabeled	
sample	 required	and	 the	 speed	and	 reliability	of	 its	 results.	 (Besenicar	et	al.	2006)	
(Pierce	 et	 al.	 1999)	 However,	 applying	 these	 techniques	 to	 study	 the	 binding	 of	
hOSM	to	the	hOSMR/gp130	complex	has	proved	challenging:	both	ITC	and	SPR	rely	
on	 reconstituting	 the	 ligand-receptor	 system	 outside	 the	 cellular	 environment,	 in	
solution	for	ITC	and	in	a	sensor	chip	for	SPR.	Unfortunately,	the	lack	of	direct	OSM	-	
OSMR	 interaction	 has	 so	 far	 prevented	 SPR	 measurements	 for	 hOSMR	 to	 be	
performed	successfully,	(Chollangi	et	al.	2012)	while	the	binding	affinity	of	cytokine-
receptor	interactions	might	be	below	the	lower	limit	of	1	nM	in	ITC.	(Rajarathnam	&	
Rösgen	2014)	
	
For	these	reasons,	the	method	of	choice	to	analyze	the	interaction	of	hOSM-derived	
variants	to	the	hOSMR	would	appear	to	be	radioligand	binding.	By	radiolabeling	the	
cytokines	 with	 iodine	 125	 and	 measuring	 binding	 of	 increasing	 amounts	 of	 the	
cytokine	 to	a	monolayer	of	A375	cells,	a	Scatchard	analysis	could	be	performed	to	
determine	its	affinity	constants.	(Linsley	et	al.	1989)	In	this	manner,	WT	hOSM	could	
be	compared	to	 the	mutants	of	 interest	 to	determine	whether	 replacement	of	 the	
AB	 loop	 has	 a	 direct	 effect	 on	 receptor	 binding	 ability,	 or	 only	 affects	 the	
conformational	changes	required	for	signaling	initiation	after	binding.	
	
5.3.	 Differences	 between	 human	 Oncostatin	 M	 and	 human	 Leukemia	 Inhibitory	
Factor	influencing	receptor	complex	activation	
	
Intuitively,	the	central	role	that	the	hOSM	AB	loop	region	plays	in	hOSMR	activation	
would	 suggest	 the	 existence	 of	major	 differences	 in	 this	 region	 between	 hLIF	 and	
hOSM.	However,	a	close	examination	of	the	aligned	loop	regions	reveals	this	not	to	
be	 the	 case:	 in	 fact,	 the	 four	 key	 hOSM	 amino	 acids	 (Y34,	 Q38,	 G39	 and	 L45)	
specifically	 influencing	 hOSMR	 activation	 are	 also	 present	 in	 hLIF	 (Fig.	 15A).	 This	
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indicates	a	high	degree	of	conservation	in	the	region,	which	is	perhaps	unexpected	in	
the	case	of	hLIF	since	a	detailed	site-directed	mutagenesis	study	did	not	identify	any	
of	 the	 individual	 residues	 in	 its	 AB	 loop	 region	 to	 play	 a	 major	 role	 in	 receptor	
binding.	(Hudson	et	al.	1996)	
	
One	relevant	difference	between	these	cytokines	seems	to	be	the	residue	right	after	
the	conserved	QG	sequence,	with	leucine	40	of	hOSM	being	replaced	by	glutamate	
in	hLIF.	Unlike	leucine,	glutamate	is	a	negatively	charged	polar	amino	acid	that	tends	
to	 be	 exposed	 in	 the	 protein	 surface,	 and	 can	 form	 salt	 bridges	 with	 positively	
charged	 residues	 to	 contribute	 to	 protein	 stability	 or	 protein-protein	 interactions.	
(Betts	 &	 Russell	 2003)	 But	 while	 mutations	 in	 L40	 of	 hOSM	 result	 in	 an	 inactive	
cytokine,	hLIF	is	still	able	to	bind	to	the	hLIFR	despite	this	replacement:	this	may	be	a	
reflection	of	the	slightly	different	interaction	mechanism	for	both	cytokines	in	terms	
of	hLIFR	activation,	 for	which	experimental	evidence	had	already	been	provided	 in	
the	past.	(Plun-Favreau	et	al.	2003)	
	
However,	 the	 main	 differential	 feature	 between	 the	 AB	 loops	 of	 hOSM	 and	 hLIF	
seems	to	be	the	presence	of	an	additional	amino	acid	in	the	hLIF	sequence	(Fig.	15A).	
Taking	into	account	that	the	nearby	cysteine	has	a	fixed	spatial	position	due	to	the	
disulfide	 bond	 it	 forms	 with	 helix	 D	 in	 both	 cytokines,	 the	 presence	 of	 an	 extra	
residue	 in	 the	 hLIF	 AB	 loop	 results	 in	 the	 spatial	 rearrangement	 of	 most	 of	 the	
residues	forming	this	region.	In	this	way,	even	if	nearly	all	the	amino	acids	necessary	
for	 hOSMR	 activation	 in	 hOSM	 are	 conserved	 in	 hLIF,	 their	 orientation	 relative	 to	
helix	D	would	make	hOSMR	recognition	and/or	binding	impossible	(Fig.	47).	
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Figure	47:	Spatial	organization	of	binding	site	III	in	human	OSM	and	human	LIF.	The	
residues	in	the	N-terminal	AB	loop	and	N-terminal	helix	D	regions	of	hOSM	(left)	and	
hLIF	(right)	are	depicted,	with	the	critical	residues	for	hOSMR	activation	in	hOSM	and	
its	equivalents	in	hLIF	highlighted.	Note	the	difference	between	the	spatial	location	
of	 L45	 in	 hOSM	 and	 its	 corresponding	 L56	 in	 hLIF,	 due	 to	 the	 presence	 of	 one	
additional	amino	acid	in	this	region	in	the	hLIF	sequence.	
	
	
Many	more	differences	between	these	two	proteins	can	be	 found	 in	other	 regions	
outside	 the	 AB	 loop,	 but	 previous	 reports	 indicated	 that	 in	 the	 case	 of	 hLIFR	
interaction	the	regions	outside	binding	site	 III	 (N-terminal	AB	 loop,	BC	 loop	and	N-
terminal	helix	D)	do	not	appear	to	play	a	major	role.	(Kallen	et	al.	1999)	Thus	when	
the	binding	site	III	regions	of	CNTF	were	transferred	to	another	IL-6	family	member,	
such	 as	 IL-6,	 the	 chimeric	 protein	 acquired	 the	 ability	 to	 initiate	 hLIFR	 signaling	
without	additional	modifications.	(Kallen	et	al.	1999)	
	
To	determine	whether	 this	was	also	 the	 case	 for	 the	hOSMR,	hLIF-based	chimeras	
incorporating	 hOSM	 site	 III	 regions	were	 employed.	 These	 experiments	 evidenced	
that	 a	 combined	 replacement	 of	 the	N-terminal	AB	 loop	 and	N-terminal	D	 helix	 is	
sufficient	 to	enable	hOSMR	signaling	by	hLIF,	 confirming	binding	 site	 III	 as	 the	key	
region	modulating	 recognition	 of	 the	 different	 gp130	 co-receptors	 within	 the	 IL-6	
family.	 It	should	be	stressed,	however,	 that	other	regions	 in	hOSM	outside	binding	
site	III	also	impact	hOSMR	interaction,	as	the	AB	loop	and	D-helix	regions	only	confer	
limited	 hOSMR	 activation	 abilities	 when	 placed	 into	 hLIF.	 This	 would	 also	 explain	
why	the	N-terminal	D-helix	regions	of	hOSM	and	hLIF	appear	to	be	exchangeable	for	
the	hOSM-based	chimeras,	but	in	contrast	only	transferring	the	AB	loop	into	hLIF	is	
insufficient	to	initiate	hOSMR	signaling.	
	
5.4.	Molecular	determinants	of	Oncostatin	M	species	specificity	
	
The	existence	of	species-specific	differences	in	receptor	activation	abilities	between	
the	 human	 and	 murine	 OSM	 orthologs	 was	 originally	 described	 20	 years	 ago.	
(Ichihara	 et	 al.	 1997)	 (Lindberg	 et	 al.	 1998)	While	 some	 recent	 evidence	 suggests	
that	mOSM	may	act	through	the	mLIFR	complex	in	particular	situations,	(Walker	et	
al.	2016)	classical	mOSM	signaling	via	phosphorylation	of	mediator	proteins	such	as	
STATs	is	generally	only	apparent	upon	mOSMR	activation	and	does	not	take	place	if	
only	the	mLIFR	is	present.	(Ichihara	et	al.	1997)	
	
Despite	 this	 being	 a	well-known	phenomenon,	 the	 underlying	mechanisms	 behind	
these	 species-dependent	 modes	 of	 action	 had	 never	 been	 addressed	 until	 now.	
Through	the	generation	of	human/mouse	OSM	chimeric	cytokines,	this	work	proves	
that	 differences	 in	 the	 AB	 loop	 of	 the	 orthologs	 can	 explain	 the	 lack	 of	 cross-
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reactivity	of	the	human	and	mouse	ligands:	exchanging	even	a	small	12	amino	acid	
region	of	mOSM	by	 its	human	equivalent	was	sufficient	 to	enable	human	receptor	
activation,	initiating	both	hOSMR	and	hLIFR	signaling.	
	
Following	up	on	 this	 initial	 result,	 the	creation	of	different	combinations	of	mOSM	
point	mutants	within	the	identified	region	resulted	in	a	more	accurate	identification	
of	 the	 structural	 features	 involved	 in	 determining	 species	 specificity	 of	 mOSM.	
Surprisingly,	only	two/three	modifications	in	the	murine	cytokine	were	sufficient	to	
ensure	signaling	through	the	human	receptors	(Fig.	48).	
	
	
	
Figure	48:	Mutations	in	the	N-terminal	AB	loop	of	mouse	OSM	influencing	species-
specific	receptor	activation.	The	residues	in	the	N-terminal	AB	loop	and	N-terminal	
helix	 D	 regions	 of	 hOSM	 (left)	 and	mOSM	 (middle)	 are	 depicted,	 with	 the	 critical	
residues	differentiating	both	cytokines	highlighted	in	red.	A	mOSM	variant	with	the	
substitutions	 N37G,	 T40V	 and	 D42K	 acquires	 the	 ability	 to	 activate	 the	 mLIFR,	 in	
addition	to	the	mOSMR.	
	
	
The	most	critical	alteration	appears	to	be	the	replacement	of	a	glycine	residue	at	the	
start	of	the	mOSM	AB	loop	by	asparagine.	As	discussed	in	section	5.1,	this	glycine	at	
position	39	in	the	human	cytokine	is	required	for	hOSMR	activation.	Thus	 it	should	
come	 as	 no	 surprise	 that	 only	 mOSM	 mutant	 proteins	 incorporating	 the	 N37G	
replacement	became	capable	of	activating	the	hOSMR.	However,	while	the	presence	
of	 this	 modification	 was	 clearly	 necessary,	 the	 single	 N37G	 point	 mutant	 only	
evidenced	residual	human	receptor	activation	abilities,	indicating	that	other	residues	
in	the	AB	loop	must	also	be	contributing	towards	the	lack	of	affinity	between	mOSM	
and	hOSMR.	
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The	main	additional	difference	between	the	human	and	mouse	orthologs	proved	to	
be	the	presence	of	an	aspartate	 instead	of	a	 lysine	 in	position	42	of	mOSM.	Unlike	
the	glycine	involved	in	the	first	substitution,	this	lysine	(K44	in	hOSM)	had	not	been	
identified	as	critical	in	the	prior	alanine	scanning	experiments.	This	fact	suggests	that	
the	relevance	of	this	amino	acid	replacement	is	most	likely	related	to	the	nature	of	
the	 substituting	 residue,	 and	 not	 of	 the	 lysine	 itself:	 while	 both	 are	 polar	 amino	
acids,	 lysine	 is	 positively	 charged	 and	 aspartate	 is	 negatively	 charged.	 (Betts	 &	
Russell	2003)	
	
In	this	way,	while	the	presence	of	a	positively	charged	residue	in	that	position	of	the	
AB	 loop	 may	 not	 be	 a	 strict	 requirement	 for	 hOSMR	 binding,	 it	 appears	 that	 a	
negatively	 charged	 amino	 acid	 in	 the	 same	 position	 can	 hinder	 human	 receptor	
activation.	The	opposite	applies	 for	the	mouse	receptor,	since	the	presence	of	K44	
appears	to	be	the	main	factor	impeding	mOSMR	activation	by	the	human	cytokine:	
the	 hOSM	 point	 mutants	 carrying	 a	 K44D	 substitution	 became	 able	 to	 initiate	
mOSMR	signaling,	although	always	at	the	expense	of	lower	hOSMR	signaling	ability	
when	compared	to	WT	hOSM.	
	
In	 addition	 to	 N37G	 and	 D42K,	 the	 replacement	 of	 threonine	 40	 by	 the	
corresponding	valine	 in	hOSM	resulted	 in	 further	enhancement	of	human	receptor	
signaling.	In	this	case	there	is	no	drastic	difference	in	side	chain	properties	between	
these	residues,	both	being	C-beta	branched	and	hydrophobic,	so	the	preference	for	
valine	over	threonine	is	likely	based	on	slight	differences	in	the	spatial	conformation	
of	the	binding	interface	of	mOSM.	(Betts	&	Russell	2003)	
	
However,	none	of	these	modifications	in	the	AB	loop	of	mOSM	affected	its	ability	to	
activate	 the	 mOSMR:	 this	 could	 be	 explained	 by	 the	 influence	 of	 other	 regions	
outside	binding	site	III	in	OSMR	interaction,	as	first	discussed	in	section	5.1.	Although	
the	AB	 loop	clearly	plays	an	 important	 role	 in	mOSMR	activation,	mOSM	has	 likely	
incorporated	 additional	 modifications	 in	 other	 regions	 of	 the	 protein	 favoring	
receptor	 interaction,	 which	 would	 allow	 for	 a	 certain	 degree	 of	 flexibility	 in	 the	
residue	 composition	 of	 the	 loop.	 In	 contrast	 hOSM,	 lacking	 these	 extra	
modifications,	is	forced	to	meet	more	stringent	requirements	in	terms	of	its	AB	loop	
sequence	to	initiate	mOSMR	signaling.	
	
5.5.	Evolutionary	implications	
	
It	has	been	reported	in	the	past	that	genes	of	the	immune	system	are	subjected	to	
directional	 selection,	 defined	 as	 a	 selection	 process	 favoring	 change:	 as	 a	 result	
these	 genes	 evolve	 rapidly,	 most	 likely	 in	 order	 to	 enhance	 the	 ability	 of	 the	
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organism	 to	 respond	 against	 new	pathogens.	 (Hurst	&	 Smith	 1999)	 In	 light	 of	 this	
fact,	 it	 should	 come	 as	 no	 surprise	 that	 cytokines	 are	 among	 the	 most	 rapidly	
evolving	genes	in	vertebrates.	(Scapigliati	et	al.	2006)	
	
Additionally,	 it	 is	clear	 that	gene	duplication	processes	have	played	a	major	role	 in	
the	 diversification	 of	 both	 cytokines	 and	 its	 receptors:	 only	 two	 type	 I	 cytokine	
receptors,	one	of	which	is	homologous	to	gp130,	were	identified	in	an	urochordate	
(sea	 squid,	Ciona	 intestinalis),	which	diverged	 from	vertebrates	 approximately	 794	
million	 years	 ago.	 (Liongue	&	Ward	 2007)	 In	 contrast	 27	 core	 receptors,	 including	
members	of	all	5	structural	groups	present	in	mammals,	could	be	traced	to	the	last	
common	 ancestor	 between	 teleosts	 and	 mammals,	 which	 separated	 around	 476	
million	years	ago.	(Liongue	&	Ward	2007)	
	
IL-6	 family	 cytokines	 and	 its	 receptors	 are	 no	 exception,	 showing	 clear	 signs	 of	 a	
common	 origin	 through	 gene	 duplication:	 this	 is	 most	 evident	 for	 LIF	 and	 OSM,	
which	are	linked	in	tandem	in	human	chromosome	22q12.	(Rose	et	al.	1993)	(Jeffery	
et	 al.	 1993)	 (Giovannini	 et	 al.	 1993)	 LIFR	 and	 OSMR	 are	 also	 thought	 to	 have	
originated	 after	 duplication	 of	 a	 common	 ancestral	 receptor,	 as	 they	 are	 found	
within	a	cluster	of	cytokine	 receptor	 loci	 in	 the	chromosome	5p12-p13	 in	humans.	
(Gearing	et	al.	1993)	 (Arita	et	al.	2008)	Moreover,	 there	 is	by	now	ample	evidence	
that	ligands	and	receptors	co-evolve	to	attain	specific	interaction,	but	little	is	known	
about	how	specificity	evolves	 in	natural	proteins.	(Moyle	et	al.	1994)	(Richter	et	al.	
1995)	(Eick	et	al.	2012)	
	
This	 work	 offers	 detailed	 molecular	 insight	 on	 a	 possible	 mechanism	 for	 the	
evolution	 of	 new	 cytokines.	 Human	 and	murine	 LIF	 sport	 around	 80%	 amino	 acid	
identity,	 compared	 to	 the	approximately	50%	observed	 for	OSM,	 implying	 that	 LIF	
has	a	 slower	 rate	of	evolution	and	should	 thus	be	closer	 to	 the	common	ancestral	
cytokine.	 (Layton	et	al.	1994)	The	experiments	performed	 illustrate	how	a	reduced	
number	of	modifications	in	the	AB	loop	and	N-terminal	D-helix	regions	are	sufficient	
to	confer	a	new	function	to	LIF,	offering	a	clear	molecular	path	to	explain	how	the	
ancestral	cytokine	may	have	developed	the	additional	ability	 to	activate	the	OSMR	
(and	thus	become	promiscuous)	after	the	initial	gene	duplication	event	took	place.	
	
Protein	promiscuity	has	gradually	come	to	the	forefront	as	a	relevant	mechanism	in	
molecular	evolution	since	it	was	first	proposed	as	a	driving	force	for	the	acquisition	
of	new	enzymatic	functions.	(Jensen	1976)	(Khersonsky	&	Tawfik	2010)	According	to	
this	 theory,	 the	 most	 evolutionarily	 favorable	 path	 for	 the	 evolution	 of	 a	 new	
function	 is	 the	appearance	of	 a	promiscuous	 variant	of	 the	original	 protein,	which	
would	still	preserve	its	original	function	while	simultaneously	displaying	a	new	one.	
(Aharoni	et	al.	2005)	
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In	 this	 way	 protein	 evolution	 would	 take	 place	 gradually,	 with	 very	 unspecific	
primitive	 enzymes	 steadily	 giving	way	 to	more	 specialized	 ones	 by	means	 of	 gene	
duplication	 and	 divergence	 processes,	 resulting	 in	 increased	 metabolic	 efficiency.	
(Khersonsky	et	al.	2006)	It	has	also	been	shown	that	a	small	number	of	modifications	
in	 the	 amino	 acid	 sequence	 of	 an	 enzyme	 can	 lead	 to	 drastic	 changes	 in	 their	
substrate	affinity:	as	an	example,	the	replacement	of	a	single	residue	in	a	bacterial	
endopeptidase	 was	 sufficient	 for	 it	 to	 specifically	 cleave	 alanine-arginine	 bonds	
instead	 of	 the	 arginine-arginine	 sequences	 preferred	 by	 the	 WT	 enzyme.	
(Varadarajan	et	al.	2005)	
	
Originally	described	in	enzymes,	the	evolutionary	role	of	promiscuity	has	been	since	
extended	to	protein-protein	interactions,	with	the	first	such	report	studying	bacterial	
toxin-antitoxin	 systems:	 many	 bacteria	 express	 both	 toxins	 capable	 of	 inhibiting	
growth	and	specific	antitoxins	capable	of	sequestering	it,	similar	to	apoptotic	genes	
in	higher	organisms.	(Yamaguchi	et	al.	2011)	Site-directed	mutagenesis	experiments	
showed	that	the	apparition	of	a	promiscuous	toxin	led	first	to	the	mutations	in	the	
antitoxin	to	specifically	recognize	it,	followed	by	the	toxin	finally	shedding	its	original	
affinity	to	become	specific	for	the	new	antitoxin.	(Aakre	et	al.	2015)	
	
The	 acquisition	 of	 specificity	 can	 be	 attributed	 to	 the	 well-described	 evolutionary	
pressures	favoring	specificity	 in	complex	biological	 interaction	networks	 in	order	to	
minimize	 crosstalk.	 (Capra	 et	 al.	 2012)	 Thus,	 proteins	 participating	 in	 signaling	
pathways	that	are	derived	from	a	common	origin	have	often	incorporated	mutations	
conferring	 specificity:	 such	 proved	 to	 be	 the	 case	 for	 SH3,	 a	 protein-interaction	
domain	with	multiple	variants	in	the	yeast	genome.	(Zarrinpar	et	al.	2003)	
	
Taken	together,	this	final	stage	in	the	evolution	of	a	new	protein	is	consistent	with	
the	situation	observed	for	OSM	in	the	murine	system,	in	which	it	has	lost	the	original	
function	of	its	ancestral	protein	and	can	no	longer	interact	with	the	LIFR.	The	present	
work	 indicates	 that	 this	 step	 would	 have	 involved	 the	 development	 of	 additional	
interactions	between	mOSM	and	the	mOSMR,	enabling	the	cytokine	to	modify	its	N-
terminal	 AB	 loop	 in	 such	 a	 way	 as	 to	 inhibit	 mLIFR	 activation	 while	 maintaining	
mOSMR	activity.	Phylogenetic	analyses	 for	OSM	and	the	OSMR	are	consistent	with	
this	 hypothesis,	 identifying	 the	 murine	 orthologs	 (Mus	 musculus)	 as	 the	 most	
evolutionarily	distant	to	the	common	ancestor	in	both	cases	(Fig.	26).	
	
Additional	evidence	supporting	the	evolutionary	divergence	of	the	murine	receptor	
along	 with	 its	 ligand	 can	 be	 found	 in	 the	 fact	 that	 IL-31,	 which	 is	 the	 only	 other	
known	cytokine	signaling	through	a	complex	including	the	OSMR,	displays	the	same	
species	specificity	as	OSM:	human	IL-31	 is	only	able	to	activate	the	hOSMR/IL31RA	
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complex,	while	mouse	IL-31	can	only	act	through	mOSMR/IL31RA.	(Broxmeyer	et	al.	
2007)	
	
Despite	 the	 amount	 of	 circumstantial	 evidence	 available,	 conclusive	 proof	 of	 this	
hypothesis	would	most	likely	require	the	identification	of	the	ligand-receptor	binding	
interfaces	 in	both	human	and	mouse	 systems,	which	 remain	unknown	 so	 far.	 This	
could	 be	 achieved	 by	 cross-linking	 techniques	 coupled	 with	 mass	 spectrometry,	
(Rappsilber	 et	 al.	 2000)	 which	 would	 allow	 the	 identification	 and	 comparison	 of	
particular	regions	of	the	different	human	and	murine	receptors	in	direct	contact	with	
OSM.	
	
5.6.	Consequences	for	future	studies	on	Oncostatin	M	
	
Protein-based	 therapies	 constitute	 a	 particularly	 promising	 approach	 in	 the	 search	
for	 new	 medical	 treatments,	 since	 they	 are	 generally	 more	 specific	 and	 better	
tolerated	 by	 the	 body	 than	 small-molecule	 drugs.	 (Leader	 et	 al.	 2008)	 These	
compounds	achieve	their	therapeutic	goals	by	activating	specific	molecular	pathways	
in	a	wide	array	of	ailments,	including	cardiovascular	diseases.	(Ichiki	&	Burnett	2012)	
	
Within	 this	 frame,	 interest	 in	 the	 therapeutic	 applications	 of	 external	 OSM	
administration	 has	 steadily	 increased	 since	 the	 initial	 description	 of	 its	 beneficial	
effects	 in	 a	 murine	model	 of	 myocardial	 infarction	 (MI).	 (Kubin	 et	 al.	 2011)	 OSM	
cardioprotection	 is	mediated	by	different	mechanisms:	 the	 first	of	 these	 is	a	direct	
effect	 on	 cardiomyocytes,	 promoting	 their	 dedifferentiation	 and	 enabling	 them	 to	
better	survive	the	hypoxic	conditions	characteristic	of	a	MI	injury.	(Pöling	et	al.	2012)	
Additionally,	OSM	is	able	to	modulate	the	response	of	the	immune	system	after	MI,	
regulating	 macrophage	 accumulation	 in	 the	 heart	 through	 the	 induction	 of	 Reg	
protein	production	to	drive	cardiac	healing.	(Lörchner	et	al.	2015)	
	
Other	studies	have	since	confirmed	the	protective	effects	of	OSM	in	the	heart	after	
infarction	in	otherwise	healthy	animals,	linking	it	to	an	increase	in	angiogenesis	and	
autophagy	 in	order	 to	 limit	cardiac	 remodeling	after	 infarction.	 (Zhang	et	al.	2015)	
(Hu	 et	 al.	 2017)	 OSM	 also	 proved	 able	 to	 alleviate	 cardiac	 injury	 in	 diabetic	mice	
through	the	inhibition	of	apoptotic	processes.	(Sun	et	al.	2015)	In	addition	to	acute	
heart	 disease,	 potential	 therapeutic	 usage	 of	 OSM	 has	 also	 been	 extended	 to	
cerebral	 ischemic	 stroke	 and	 spinal	 cord	 injury	 in	 other	 works.	 (Guo	 et	 al.	 2015)	
(Slaets	et	al.	2014)	
	
However,	 since	 all	 these	 studies	 were	 carried	 out	 in	 murine	 models,	 their	
translatability	to	the	human	situation	 is	 jeopardized	by	the	receptor	promiscuity	of	
human	OSM.	It	 is	possible	that	additional	activation	of	the	LIFR	would	enhance	the	
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protective	effects	observed	in	mice	after	infarction,	since	LIF	has	been	described	to	
promote	 cardiomyocyte	 survival	 and	 stimulate	 regeneration	 after	 MI.	 (Zou	 et	 al.	
2003)	 (Kanda	et	al.	2016)	 In	addition,	 LIF	administration	outside	 the	context	of	MI	
seemed	 to	 have	 modest	 positive	 effects	 on	 cardiac	 function	 without	 evidence	 of	
harmful	effects	on	cardiomyocytes.	(Zgheib	et	al.	2012)	
	
Nevertheless,	LIFR	activation	has	also	been	linked	to	potentially	harmful	side	effects	
such	as	hematologic	alterations	or	cachexia,	which	could	compromise	its	usefulness	
in	a	clinical	setting.	(Wallace	et	al.	1995)	(Juan	et	al.	2009)	Particularly	worrying	is	the	
reported	 increase	 in	 platelet	 numbers,	 which	 was	 significantly	 higher	 for	 LIFR-
activating	cytokines	in	a	comparative	study.	(Juan	et	al.	2009)	This	is	due	to	the	link	
between	 a	 higher	 platelet	 count	 and	 higher	 blood/plasma	 viscosity,	 as	 this	 last	
parameter	has	been	positively	associated	with	increased	mortality	rates	in	different	
patient	cohorts	in	a	variety	of	studies.	(Ho	2004)	(Keatinge	et	al.	1986)	(Patterson	et	
al.	2015)	(Peters	et	al.	2017)	
	
The	human-like	murine	cytokines	created	 in	this	work	are	expected	to	constitute	a	
very	useful	tool	in	order	to	address	this	issue.	Showing	the	ability	to	simultaneously	
activate	mOSMR	and	mLIFR,	these	OSM	variants	can	improve	the	human	relevance	
of	preclinical	studies	carried	out	in	mice	by	mimicking	the	receptor	activation	profile	
that	would	take	place	in	humans.	
	
Along	 this	 line,	 future	 research	 plans	 are	 focused	 on	 assessing	 the	 impact	 of	 this	
human-like	mouse	OSM	 in	 vivo	 in	 terms	of	 survival	 and	 functional	 recovery	of	 the	
heart	 after	 MI,	 and	 comparing	 its	 beneficial	 effects	 to	 those	 evidenced	 by	 the	
unmodified	 mouse	 LIF	 and	 mouse	 OSM.	 Additionally,	 these	 cytokines	 will	 be	
administered	to	mice	with	no	cardiac	injury,	monitoring	their	changes	in	weight	and	
comparing	their	blood	profiles	to	examine	the	existence	of	possible	side	effects.	
	
In	 case	 the	 harmful	 side	 effects	 of	 LIFR	 activation	were	 to	 outweigh	 its	 beneficial	
effects	 in	these	experiments,	some	of	the	mutant	cytokines	generated	evidenced	a	
certain	preference	towards	hOSMR	activation	when	compared	to	WT	hOSM.	These	
variants	could	thus	become	therapeutically	relevant	in	the	human	situation,	leading	
to	a	decrease	in	concomitant	hLIFR	activity	due	to	hOSM	treatment.	
	
Finally,	 the	 generation	 of	 a	 transgenic	 mouse	 strain	 incorporating	 the	 described	
promiscuity-inducing	 substitutions	 into	 the	 endogenous	 mOSM	 sequence	 would	
result	 in	a	humanized	mouse	model	of	OSM	action.	Humanized	models	have	been	
extensively	 used	 in	 the	 field	 of	 human	 hematopoiesis	 and	 immune	 function	 to	
minimize	 the	 significant	 differences	 developed	 between	 the	 murine	 and	 human	
immune	 systems	 after	 65-75	 million	 years	 of	 evolution,	 ranging	 from	 a	 different	
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lymphocyte/neutrophil	 balance	 to	 variations	 in	 cytokines/chemokines	 and	 its	
corresponding	receptors.	(Mestas	&	Hughes	2004)	
	
Thus,	 in	 order	 to	 minimize	 the	 discrepancy	 between	murine	 and	 human	 immune	
system	 biology,	 increasingly	 sophisticated	 humanized	 mouse	 models	 have	 been	
developed	 since	 the	 human	 growth	 hormone	 gene	was	 first	 introduced	 into	mice	
more	than	30	years	ago.	(Brinster	&	Palmiter	1984)	Nowadays	such	models	employ	
genetically	modified	mice	 strains	 carrying	mutations	 leading	 to	 immunodeficiency,	
such	as	 the	severe	combined	 immunodeficiency	 (Scid)	mutation:	 these	animals	are	
then	subjected	to	sublethal	 irradiation	or	chemotherapy	followed	by	transplants	of	
human	hematopoietic	stem/progenitor	cells,	which	are	then	able	to	engraft	and	give	
rise	to	the	different	human	immune	cell	lineages.	(Rongvaux	et	al.	2013)	
	
Complemented	 with	 the	 substitution	 of	 several	 murine	 immunomodulatory	
cytokines	 by	 their	 human	 orthologs,	 the	 degree	 of	 complexity	 achieved	 by	 such	 a	
humanized	mouse	immune	system	can	approach	that	of	the	native	human	system	in	
terms	 of	 subset	 diversity	 and	 numbers.	 (Rongvaux	 et	 al.	 2014)	 The	 use	 of	 these	
humanized	murine	models	has	been	instrumental	in	the	study	of	processes	such	as	
early	human	hematopoietic	development,	the	 initiation	of	acute	myeloid	 leukemia,	
infectious	 diseases	 that	 exclusively	 target	 human	 cells	 such	 as	 the	 human	
immunodeficiency	 virus	 (HIV)	 or	 autoimmune	 diseases,	 among	 many	 others.	
(Doulatov	 et	 al.	 2010)	 	 (Lapidot	 et	 al.	 1994)	 (Rämer	 et	 al.	 2011)	 (Namikawa	 et	 al.	
1988)	(Brehm	et	al.	2010)	
	
In	 case	of	OSM,	 the	 generation	of	 a	 humanized	 animal	model	would	 facilitate	 the	
study	of	its	physiological	actions	in	vivo	in	a	manner	more	easily	translatable	to	the	
human	situation,	while	at	the	same	time	avoiding	the	difficulties	presented	by	other	
animal	models	 closer	 to	humans	 such	as	primates,	 in	which	 research	activities	 are	
restricted	due	to	both	ethical	considerations	and	economic	reasons.	(Rongvaux	et	al.	
2013)	
	
In	 conclusion,	 the	 work	 presented	 offers	 substantial	 insight	 into	 the	 structural	
features	 determining	 OSM	 interaction	 with	 its	 receptors	 in	 both	 the	 human	 and	
murine	 systems.	 This	 knowledge	 has	 important	 evolutionary	 implications	 for	 OSM	
and	cytokines	as	a	whole,	suggesting	a	 likely	evolutionary	path	after	duplication	of	
the	ancestral	protein	 through	promiscuous	 intermediates.	 In	addition,	 some	of	 the	
OSM	 variants	 created	 are	 expected	 to	 have	 promising	 applications	 in	 the	 field,	
improving	 the	 translatability	 of	 preclinical	 research	 studying	 the	 potential	
therapeutic	application	of	OSM	in	murine	models	
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6.	Summary	
	
Oncostatin	M	 (OSM)	 is	 a	 prominent	member	 of	 the	 IL-6	 cytokine	 family.	 It	 signals	
through	 a	 heterodimeric	 OSM	 receptor/gp130	 (OSMR)	 complex,	 specific	 for	 this	
cytokine	 and	 driving	 its	 many	 biological	 effects.	 Especially	 interesting	 are	 its	
potential	 therapeutic	 applications,	 as	 OSM	 has	 been	 beneficial	 in	 several	 murine	
cardiovascular	disease	models.	Unfortunately,	 the	translatability	of	 these	results	 to	
the	human	situation	is	not	assured	due	to	the	different	receptor	activation	abilities	
of	human	and	mouse	OSM	(hOSM/mOSM).	While	mOSM	 is	 specific	 for	 the	OSMR,	
hOSM	 signals	 through	 the	 leukemia	 inhibitory	 factor	 receptor/gp130	 (LIFR)	 in	
addition	 to	 the	 OSMR,	 which	 could	 result	 in	 additional	 effects	 besides	 those	
reflected	in	preclinical	mouse	models.	Taken	together,	there	is	a	clear	need	for	more	
information	 on	 these	 ligand-receptor	 interactions,	 the	 exclusive	 features	 of	 OSM	
governing	OSMR	activation	and	the	divergence	between	hOSM	and	mOSM.	
	
This	thesis	contributes	new	insights	into	these	topics	by	means	of	molecular	biology	
tools:	 in	 the	 first	place,	a	mammalian	expression	system	was	established	to	obtain	
recombinant	hOSM,	mOSM	and	human	leukemia	inhibitory	factor	(hLIF)	as	well	as	an	
array	of	mutant	variants	of	these	cytokines.	Cytokine	stimulation	experiments	were	
then	carried	out	in	cell	lines	with	specific	readouts	for	each	receptor	complex,	such	
as	A375	cells	for	hOSMR,	JAR	cells	for	hLIFR,	NIH3T3	cells	for	mOSMR	or	MH-S	cells	
for	 mLIFR.	 Both	 shorter-	 and	 longer-term	 readouts	 were	 used,	 monitoring	 the	
phosphorylation	of	a	key	downstream	signaling	component	(STAT3)	10	minutes	after	
stimulation	and	measuring	expression	levels	of	well-known	target	genes	(e.g.	TIMP1)	
after	24	hours.		
	
In	a	first	approach,	different	binding	site	regions	in	hOSM	or	hLIF	were	exchanged	to	
create	 hOSM/hLIF	 chimeras.	 Cell-stimulation	 experiments	 using	 these	 chimeric	
variants	pointed	to	the	N-terminal	AB	loop	and	N-terminal	helix	D	regions	of	hOSM	
as	 responsible	 for	 hOSMR	 signaling,	 enabling	 hOSMR	 activation	 by	 a	 hLIF-based	
chimera	 with	 these	 two	 hOSM	 regions.	 Subsequently,	 site-directed	 mutagenesis	
studies	 individually	 targeting	 all	 the	 residues	 within	 these	 regions	 identified	 the	
amino	acids	Y34,	Q38,	G39,	L45	and	P153	as	critical	for	hOSMR	activation.	
	
Similar	methods	were	applied	to	study	the	receptor	specificity	of	mOSM,	which	was	
mapped	 to	 its	 N-terminal	 AB	 loop	 by	 means	 of	 chimeric	 mouse/human	 OSM	
cytokines.	 In	 this	 case,	 point	mutagenesis	 experiments	 revealed	 residues	N37,	 T40	
and	 D42	 of	 the	 murine	 cytokine	 to	 be	 responsible	 for	 mOSMR	 specificity.	 This	
specificity	was	 lost	 upon	 replacing	 these	 amino	acids	by	 their	 hOSM	counterparts,	
resulting	 in	 a	 mOSM	 variant	 able	 to	 activate	 mLIFR	 as	 well	 as	 mOSMR.	 Finally,	
phylogenetic	 analyses	 indicated	 that	 the	 acquisition	of	 specificity	 likely	 constitutes	
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the	 final	 stage	 in	 OSM	 evolution,	 as	 it	 is	 associated	 with	 a	 larger	 evolutionary	
distance	from	the	ancestral	form	of	the	protein.	
	
In	sum,	new	key	features	of	OSM	enabling	human	and	murine	OSMR	signaling	have	
been	identified	and	characterized	in	detail	by	using	a	variety	of	recombinant	mutant	
cytokines.	These	results	illustrate	a	novel	path	for	cytokine	evolution	within	the	IL-6	
family,	in	which	an	initial	gene	duplication	event	in	the	LIF/OSM	ancestral	gene	was	
followed	first	by	the	acquisition	of	a	new	function	(OSMR	activation)	and	finally	by	
the	 loss	of	 the	ancestral	 function	 (LIFR	activation)	 to	attain	 specificity.	 In	 addition,	
some	of	the	mOSM	mutants	generated	are	expected	to	improve	the	translatability	of	
future	 research	 on	 the	 therapeutic	 applications	 of	 OSM.	 Given	 that	 these	mutant	
variants	 possess	 a	 human-like	 receptor	 signaling	 profile,	 their	 use	 in	 murine	
preclinical	disease	models	will	more	closely	 reflect	 the	potential	effect	of	hOSM	 in	
the	human	situation,	with	LIFR	being	activated	along	with	the	OSMR.	
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7.	Zusammenfassung	
	
Oncostatin	 M	 (OSM)	 ist	 ein	 Zytokin	 der	 Interleukin-6	 Familie.	 Die	 vielfältigen	
biologischen	 Funktionen	 von	 OSM	 werden	 auf	 molekularer	 Ebene	 durch	 die	
Aktivierung	 eines	 spezifischen	 heterodimeren	 Rezeptorkomplexes,	 bestehend	 aus	
OSM	 Rezeptor	 (OSMR)	 und	 gp130,	 vermittelt.	 Dabei	 implizieren	 insbesondere	 die	
aus	murinen	 Tiermodellen	 gewonnenen	 Erkenntnisse	 eine	 protektive	Wirkung	 von	
OSM	 in	 der	 Progression	 diverser	 kardiovaskulärer	 Erkrankungen.	 Eine	 direkte	
Ableitung	 für	 den	Mensch	 und	 Fortführung	 translationaler	 Studien	wird	 allerdings	
durch	 speziesspezifische	 Unterschiede	 in	 der	 Aktivierung	 unterschiedlicher	
Rezeptordimere	 erschwert.	 So	 vermittelt	 murines	 OSM	 (mOSM)	 seine	 Effekte	
exklusiv	 durch	 den	 OSMR/gp130	 Komplex,	 wohingegen	 humanes	 OSM	 (hOSM)	
zusätzlich	den	 leukemia	 inhibitory	 factor	 receptor	 (LIFR)/gp130	Komplex	aktivieren	
kann.	 Insbesondere	 vor	 dem	 Hintergrund	 einer	 potentiell	 therapeutischen	
Bedeutung	 bedarf	 es	 weiterführende	 Untersuchungen,	 die	 jene	 Ligand-Rezeptor-
Interkationen,	sowie	die	Divergenz	von	mOSM	und	hOSM	analysieren.	
	
Die	 hier	 vorgelegte	 Studie	 adressiert	 jene	 Fragestellungen	 mittels	 folgender	
molekularbiologischer	Methoden:	 	 Etablierung	eines	Säugertier-Expressionssystems	
zur	Generierung	von	rekombinanten,	unmodifizierten	als	auch	mutierten	Varianten	
von	hOSM,	mOSM	und	hLIF;	gefolgt	von	Zytokinstimulationsstudien	in	Zelllinien,	die	
exklusiv	 den	 hOSMR	 (A375),	 hLIFR	 (JAR),	 mOSMR	 (NIH3T3)	 und	 mLIFR	 (MH-S)	
exprimieren.	Ferner	wurden	Kurzzeit-	 sowie	Langzeitstimulationen	durchgeführt,	 in	
der	die	Phosphorylierung	des	 Signalmoleküls	 STAT3	nach	10	Minuten,	 als	 auch	die	
vermehrte	 Expression	 von	 bekannten	 Zielgenen	 (u.a.	 TIMP-1)	 nach	 24	 Stunden	
bestimmt	und	so	als	distinkte	Parameter	zur	Aktivierung	des	OSMR	genutzt	wurden.	
	
Zur	 Identifikation	 zytokinspezifischer	 Bindungsstellen	 von	 OSM	 und	 LIF	 wurden	
anfänglich	 chimäre	 hOSM/hLIF	 Varianten	 generiert,	 in	 dem	 unterschiedliche	
Bindungsstellen	 von	 hOSM	 und	 hLIF	 wechselseitig	 ausgetauscht	 wurden.	
Nachfolgende	 Stimulationsstudien	 mit	 chimären	 hOSM	 und	 hLIF	 charakterisierten	
dabei	 die	 N-terminale	 AB-Schleife,	 sowie	 die	 N-terminale	 helikale	 D-Region	 als	
hauptverantwortliche	Regionen	für	die	Aktivierung	des	OSMR,	indem	die	Aktivierung	
des	 hOSMR	 durch	 eine	 chimäre	 hLIF	 Variante	 mit	 beiden	 Regionen	 reproduziert	
werden	 konnte.	 Durch	 die	 systematische	 Generierung	 von	 Punktmutationen	 in	
beiden	Regionen	konnten	ferner	die	Aminosäurenreste	Y34,	Q38,	G39,	L45	and	P153	
als	 kritische	 Komponenten	 für	 die	 spezifische	 Aktivierung	 des	 OSMR	 durch	 OSM	
identifiziert	werden.	
	
Vergleichbare	 Methoden	 und	 Analysen	 wurden	 zur	 Charakterisierung	 der	
Bindungsspezifizität	von	mOSM	an	den	mOSMR	genutzt.	Hier	konnte	die	N-terminale	
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AB-Schleife	 und	die	 darin	 befindlichen	Aminosäurenreste	N37,	 T40	und	D42	durch	
die	 Generierung	 von	 chimären	 mOSM	 und	 hOSM	 Proteinen	 und	 nachfolgender	
Punktmutationen	als	entscheidende	Größen	für	die	Spezifität	von	mOSM	identifiziert	
werden.	Zusätzlich	konnte	durch	die	simultane	Substitution	dieser	drei	Aminosäuren	
eine	murine	OSM	Variante	 generiert	werden,	die	den	mLIFR	als	 auch	den	mOSMR	
aktiviert.	Mit	Hilfe	von	phylogenetischen	Modellen	konnte	gezeigt	werden,	dass	die	
hier	 identifizierten	 unterschiedlichen	 Bindungsspezifitäten	 von	 humanen	 und	
murinen	 OSM	 einen	 evolutionären	 Prozess	 reflektiert,	 deren	 Ursprung	 auf	 einem	
gemeinsamen		Vorläufer-Gen	begründet	ist.		
	
Insgesamt	 charakterisiert	 und	 identifiziert	 die	 vorgelegte	 Studie	 molekulare		
Unterschiede,	die	zur	speziesspezifischen	Aktivierung	des	OSMR	durch	humanes	und	
murines	OSM	führen.	Die	durchgeführten	Analysen	liefern	somit	einen	molekularen	
Erklärungsansatz	für	den	Entwicklungsprozess	und	die	dadurch	erworbene	Spezifität	
der	 IL-6	 Zytokinfamilie,	 d.h.	 dass	 die	 Duplikation	 des	 Vorläufergens	 zunächst	 zur	
Akquisition	 neuer	 (Aktivierung	 des	 OSMR)	 und	 anschließend	 zum	 Verlust	
ursprünglicher	 Funktionen	 (Inaktivierung	 des	 LIFR)	 führte.	 Schließlich	 ergeben	 sich	
durch	die	Generierung	von	murinen	OSM	Varianten,	die	sich	 in	der	Aktivierung	der	
Rezeptorensysteme	äquivalent	zu	hOSM	verhalten,	neue	Anwendungsmöglichkeiten	
in	präklinischen,	murinen	Tiermodellen,	um	die	Aktivität	von	humanem	OSM	unter	
(patho-)physiologischen	Bedingungen	zu	studieren.	
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8.	List	of	Abbreviations	
	
BSA	 Bovine	serum	albumin	
cDNA	 Complementary	DNA	
CLC	 Cardiotrophin-like	cytokine	
CNTF	 Ciliary	neurotrophic	factor	
CNTFR	 Ciliary	neurotrophic	factor	receptor	
CT-1	 Cardiotrophin-1	
DMEM	 Dulbecco's	modified	Eagle	medium	
DMSO	 Dimethyl	sulfoxide	
EBI-3	 Epstein-Barr	virus	induced	3	
EDTA	 Ethylenediaminetetraacetic	acid	
FBS	 Fetal	bovine	serum	
gp130	 Glycoprotein	130	
h	(prefix)	 Human	
His-tag	 Hexahistidine	tag	
HIV	 Human	immunodeficiency	virus	
IL-6	 Interleukin-6	
IL-6R	 Interleukin-6	receptor	
IL-11	 Interleukin-11	
IL-11RA	 Interleukin-11	receptor	alpha	
IL-27	 Interleukin-27	
IL-27RA	 Interleukin-27	receptor	subunit	alpha	
IL-31	 Interleukin-31	
IL-31RA	 Interleukin-31	receptor	alpha	
IPTG	 Isopropyl	β-D-1-thiogalactopyranoside	
ITC	 Isothermal	titration	calorimetry	
JAK	 Janus	kinase	family	
JNK	 c-Jun	N-terminal	kinase	
KD	 Knockdown	
LB	 Lysogeny	broth	
LDL	 Low-density	lipoprotein	
LIF	 Leukemia	inhibitory	factor	
LIFR	 Leukemia	inhibitory	factor	receptor	
m	(prefix)	 Mouse	
MAPK	 Mitogen-activated	protein	kinases	
metaGA	 Metapopulation	genetic	algorithm	
MI	 Myocardial	infarction	
MS	 Mass	spectrometry	
Ni-NTA	 Nickel-nitrilotriacetic	acid	
NMR	 Nuclear	magnetic	resonance	
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NP	 Neuropoietin	
OSM	 Oncostatin	M	
OSMR	 Oncostatin	M	receptor	
PCR	 Polymerase	chain	reaction	
PEG-6000	 Polyethylene	Glycol	6000	
PI3K/Akt	 Phosphoinositide	3-kinase/protein	kinase	B	
PMSF	 Phenylmethylsulfonylfluorid	
RefSeq	 Reference	Sequence	database	
RPMI	 Roswell	Park	Memorial	Institute	
RT	 Room	temperature	
Scid	 Severe	combined	immunodeficiency	
SDS	 Sodium	dodecyl	sulfate	
SDS-PAGE	 SDS-polyacrylamide	gel	electrophoresis	
SO	 Sequence-optimized	
SPR	 Surface	plasmon	resonance	
STAT	 Signal	transducer	and	activator	of	transcription	
TAE	 Tris-acetate-EDTA	
TBS-T	 Tris-buffered	saline	+	Tween	20	
TE	 Tris-EDTA	
TEMED	 Tetramethylethylenediamine	
TIMP1	 Tissue	inhibitor	of	metalloproteinase	1	
WT	 Wild-type	
	
	
	 124	
9.	List	of	Figures	
	
Figure	1:	Cytokine-receptor	interactions	within	the	IL-6	cytokine	family.	
Figure	2:	Main	biological	activities	of	OSM.	
Figure	3:	Secondary	structure	and	receptor	binding	site	locations	of	OSM	and	LIF.	
Figure	4:	Main	signaling	pathways	activated	by	OSM.	
Figure	5:	OSM	displays	species-specific	receptor	activation	abilities.	
Figure	6:	STAT3	phosphorylation	reflects	hOSMR	activation	in	A375	cells,	and	hLIFR	
activation	in	JAR	cells	
Figure	7:	TIMP1	expression	after	24	hours	reflects	hOSMR	activation	in	HepG2	cells,	
while	STAT3	upregulation	is	a	consequence	of	hLIFR	activation	in	JAR	cells.	
Figure	8:	A375	cell	line	proliferation	reflects	hOSMR	activation	after	5	days.	
Figure	 9:	 The	 presence	 of	 DsbC,	 a	 chaperone/disulfide	 bond	 isomerase,	 enables	
soluble	recombinant	hOSM	expression	in	E.	coli.	
Figure	 10:	 Effective	 recovery	 of	 recombinant	 His-tagged	 hOSM	 by	 Ni-NTA	
purification.	
Figure	11:	Recovered	recombinant	His-tagged	hOSM	is	highly	pure.	
Figure	12:	Recombinant	His-tagged	hOSM	displays	biological	activity	comparable	to	
the	commercially	available	cytokine.	
Figure	13:	Optimization	of	recombinant	protein	expression	in	mammalian	cells.	
Figure	14:	Recombinant	protein	expression	in	mammalian	cells	results	in	highly	pure,	
active	cytokines.	
Figure	15:	Design	of	human	OSM/LIF	chimeric	cytokines.	
Figure	16:	Short-term	receptor	activation	ability	of	hOSM-based	chimeric	cytokines	
identifies	the	AB	loop	as	critical	for	hOSMR	activation.	
Figure	17:	 Long-term	 receptor	 activation	 ability	 of	 hOSM-based	 chimeric	 cytokines	
confirms	the	importance	of	the	AB	loop	in	hOSMR	activation.	
Figure	18:	Design	of	human	LIF/OSM	chimeric	cytokines.	
Figure	 19:	 Short-term	 receptor	 activation	 ability	 of	 hLIF-based	 chimeric	 cytokines	
indicates	the	importance	of	site	III	regions	in	receptor	interaction.	
Figure	 20:	 Long-term	 receptor	 activation	 ability	 of	 hLIF-based	 chimeric	 cytokines	
confirms	the	importance	of	binding	site	III	region	for	hOSMR	interaction.	
Figure	 21:	 Short-term	 receptor	 activation	 ability	 of	 hOSM	 AB	 loop	 point	 mutants	
identifies	critical	amino	acids	for	receptor	activation.	
Figure	 22:	 Long-term	 receptor	 activation	 ability	 of	 human	 OSM	 AB	 loop	 point	
mutants	validates	critical	cytokine	residues.	
Figure	23:	Critical	AB	loop	residues	are	conserved	in	mammalians.	
Figure	 24:	 Short-term	 receptor	 activation	 ability	 of	 hOSM	N-terminal	 helix	D	point	
mutants	assesses	individual	residue	involvement.	
Figure	 25:	 Long-term	 receptor	 activation	 ability	 of	 hOSM	N-terminal	 helix	 D	 point	
mutants	confirms	critical	amino	acids	in	the	region.	
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Figure	 26:	Murine	OSM	and	OSMR	orthologs	 are	more	 evolutionarily	 distant	 from	
the	ancestral	state	
Figure	27:	Design	of	human/mouse	OSM	chimeric	cytokines.	
Figure	28:	Expression	of	recombinant	mOSM	in	a	mammalian	system.	
Figure	29:	Activity	of	recombinant	mOSM	and	production	of	mOSM-based	chimeras	
Figure	30:	Short-term	receptor	activation	ability	of	mOSM-based	chimeric	cytokines	
identifies	the	AB	loop	as	a	differential	feature	between	human	and	murine	OSM.	
Figure	31:	Long-term	receptor	activation	ability	of	mOSM-based	chimeric	cytokines	
confirms	AB	loop	importance.	
Figure	 32:	 Short-term	 receptor	 activation	 ability	 of	mOSM	point	mutants	 suggests	
residues	determining	species	specificity	within	the	AB	loop.	
Figure	 33:	 Long-term	 receptor	 activation	 ability	 of	 mOSM	 point	 mutants	 suggests	
residues	determining	species	specificity	within	the	AB	loop.	
Figure	34:	Short-term	receptor	activation	ability	of	mOSM	point	mutants	 identifies	
residues	determining	species	specificity	within	the	AB	loop.	
Figure	 35:	 Long-term	 receptor	 activation	 ability	 of	mOSM	 point	mutants	 confirms	
residues	determining	species	specificity	within	the	AB	loop.	
Figure	 36:	 STAT3	 phosphorylation	 after	 10	 minutes	 can	 be	 used	 to	 distinguish	
mOSMR	and	mLIFR	activation	in	stably	transfected	NIH3T3	cells.	
Figure	37:	TIMP1	expression	after	24	hours	 indicates	mOSMR	activation	 in	NIH3T3	
cells,	while	STAT3	phosphorylation	reflects	mLIFR	activation	in	MH-S	cells.	
Figure	38:	Short-term	stimulations	with	mOSM	chimeras	point	at	preserved	mOSMR	
activation	abilities.	
Figure	 39:	 Specific	 readout	 system	 confirms	 different	mOSM	 chimeras	 are	 able	 to	
activate	the	mLIFR.	
Figure	 40:	 Short-term	 stimulations	 with	 mOSM	 point	 mutants	 hint	 at	 conserved	
mOSMR	activation	abilities.	
Figure	41:	Specific	readout	system	confirms	murine	receptor	promiscuity	of	various	
mOSM	point	mutants.	
Figure	42:	Short-term	receptor	activation	ability	of	hOSM	point	mutants	 reinforces	
the	importance	of	G39	for	hOSMR	signaling.	
Figure	 43:	 Long-term	 receptor	 activation	 ability	 of	 hOSM	 point	 mutants	 confirms	
G39	as	critical	to	initiate	hOSMR	signaling.	
Figure	 44:	 Short-term	 stimulations	 with	 hOSM-based	 mutants	 indicate	 apparent	
mOSMR	activation	abilities.	
Figure	 45:	 Specific	 readout	 system	 confirms	 acquisition	 of	 mOSMR	 activation	 by	
hOSM	variants.	
Figure	46:	Signaling	properties	of	the	main	mutant	variants	created.	
Figure	47:	Spatial	organization	of	binding	site	III	in	human	OSM	and	human	LIF.	
Figure	48:	Mutations	 in	the	N-terminal	AB	 loop	of	mouse	OSM	influencing	species-
specific	receptor	activation	
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